Nektar Therapeutics Annual Report 2009

Plain-text annual report

Annual Report 2009 Dear Shareholders, 2009 was a year of tremendous accomplishment for Nektar Therapeutics. We obtained clinical validation for our advanced polymer conjugation technology platform with small molecules, forged a major agreement with AstraZeneca, advanced two anti-cancer drug candidates, and expanded our early-stage product pipeline. Our advancing pipeline of mid and late stage drug candidates combined with a proprietary platform technology that can be applied to both large and small mole- cules positions Nektar as one of the most exciting biopharmaceutical companies in our industry. Nektar Pipeline of Product Candidates PRODUCT / INDICATION PARTNER RESEARCH & PRECLINICAL PHASE 1 PHASE 2 PREPARING FOR PHASE 3 PHASE OF CLINICAL DEVELOPMENT NKTR-061 Oral NKTR-118 NKTR-102 NKTR-102 NKTR-102 NKTR-105 Oral NKTR-119 NKTR-181 NKTR-194 NKTR-171 NKTR-140 NKTR-125 RNAi Polymer Conjugates (Amikacin Inhale-BAY41-6551) / Gram Negative Pneumonia Opioid-Induced Constipation Platinum-Resistant Ovarian Cancer Metastatic Breast Cancer Metastatic Colorectal Cancer Patients with KRAS mutation Solid Tumors (Opioid Combo Products) / Analgesic Abuse deterrent analgesic Peripherally-acting opioid Neuropathic Pain (Protease Inhibitor) / HIV Antihistamine Multiple Indications Nektar Therapeutics has developed an extensive pipeline of promising drug candidates developed using our advanced polymer conjugate technology platform. Nektar is addressing unmet medical needs by leveraging and expanding our technology platform to improve known molecules across multiple therapeutic areas. Key therapeutic areas of opportunity include oncology drug candidates and pain compounds. A key milestone Nektar achieved in the past year was the completion of our Phase 2 study for oral NKTR-118 signiﬁ cantly ahead of schedule. The resulting impressive data led to a groundbreaking $1.5 billion partnership with AstraZeneca in September 2009. Howard W. Robin President and Chief Executive Ofﬁ cer This partnership provided Nektar with validation of our technology with small molecules. NKTR-118 is a novel peripheral opioid an- tagonist that demonstrates how our technology can be leveraged to exclude drugs from the central nervous system and it repre- sents a breakthrough for our platform. Our partner, AstraZeneca, is currently preparing for Phase 3 development of the compound for patients with opioid-induced constipation. Opioid-induced constipation is a large and underserved patient population that currently has no approved oral therapies to treat the problem. With our Phase 2 data, we demonstrated that NKTR-118 restored near normal bowel function in patients on chronic opioid therapy experiencing severe constipation. Importantly, the drug candidate did not diminish pain relief, indicating that the drug works as we designed it to work – acting peripherally and preserving centrally- mediated analgesia. The agreement with AstraZeneca also includes the development of oral NKTR-119, a program that combines various opioid can- didates with NKTR-118 designed to provide pain relief without NEKTAR // Annual Report 2009 1 the side effects of constipation typically associated with opioids. AstraZeneca is the ideal development and commercial partner for NKTR-118 and NKTR-119, with a strong track record of suc- cessfully launching new products and establishing blockbuster commercial franchises. The signiﬁ cant economics for the new AstraZeneca agreement is an example of how Nektar can leverage its proprietary tech- nology platform to create shareholder value. It highlights our commitment and ability to retain considerable economic interest in our proprietary programs. We received a $125 million upfront payment and have the potential to receive milestone payments of up to $1.5 billion, in addition to signiﬁ cant double-digit royal- ties from the ﬁ rst dollar of sales for NKTR-118 and NKTR-119. NKTR-118 is the ﬁ rst oral small molecule compound that was designed using our technology and represents the ﬁ rst success- ful PEGylation of an oral drug. The understanding of how our proprietary technology platform can be used to modulate entry into the central nervous system has generated three new excit- ing drug candidates that give Nektar the opportunity to address the over $10 billion global pain market. NKTR-181 is a poten- tially safer opioid with reduced side effects and lower potential for abuse, NKTR-171 is designed to treat neuropathic pain, and NKTR-194 is a peripherally-acting analgesic designed to target the NSAID and COX-2 inhibitor markets. Each of these unique research candidates represents a major commercial opportunity and demonstrates the ﬂ exibility of our technology platform to engineer desired pharmaceutical prop- erties into known molecules. NKTR-181 is an excellent example of how we can use our proprietary polymer conjugation approach to regulate the rate of entry into the CNS. This novel analgesic candidate is engineered to reduce the euphoria, sedation and respiratory death associated with opioids, and, by design, can’t be converted easily into an abusable form. Early preclinical stud- ies of NKTR-181 in efﬁ cacy, sedation and abuse liability models have shown excellent results. Our plan is to advance NKTR-181 to IND stage over the coming year. We are also using our technology platform to dramatically improve the pharmacokinetics and pharmacodynamics of chemothera- peutic agents. Over the past year, we made important progress in advancing two promising anti-cancer drugs, NKTR-102 and NKTR-105, through the clinic. NKTR-102 is a novel cytotoxic candidate that combines our proprietary multi-arm polymer “The signiﬁ cant economics for the new AstraZeneca agreement is an example of how Nektar can leverage its proprietary technology platform to create shareholder value.” 2 Annual Report 2009 // NEKTAR Leveraging Nektar’s Versatile Technology Platform To Broadly Address Pain Market NUMEROUS NEW PRODUCT OPPORTUNITIES IN PAIN NKTR-171 Neuropathic pain NKTR-181 Abuse deterrent, safer opioid NKTR-194 Non-scheduled opioid Product concept Peripherally-acting tricyclic anti-depressant (No CNS entry) Opioid (Regulated CNS entry) Peripherally-acting opioid (No CNS entry) Target product market Anticonvulsants Antidepressants Opioids Potential product advantages Commercial potential No sedation No dizziness No seizures No arrhythmia Reduced respiratory death Less euphoria, less dependence Abuse deterrent >$1.5 Billion >$1.5 Billion >$2 Billion NSAIDs COX-2 inhibitors No CNS effects No GI bleeding risk No CV risk No withdrawal The clinical validation of Nektar’s stable polymer conjugation approach with NKTR-118, partnered with AstraZeneca, demonstrates the ability of our technology to regulate penetration of oral small molecule drugs into the central nervous system (CNS). This has created numerous Nektar product opportunities in the area of pain where controlling the rate and level of entry into the CNS can greatly increase the desired pharmacologic properties of oral small molecule drugs. NKTR-181: DRAMATICALLY REDUCED ABUSE LIABILITY IN VALIDATED MODEL r o i v a h e B e v i t c i d d A i g n w o h S % 100% 80% 60% 40% 20% 0% At 100-fold higher dose, NKTR-181 shows less abuse potential than oxycodone 0% 0 25% 0.003 25% 0.01 100% 0.03 0% 0.1 0% 0.3 25% 50% 1 3 Unit Dose (mg/kg/injection) Oxycodone NKTR-181 Source: Jack Bergman, Ph.D., Harvard Medical School’s McLean Hospital, 2009. NKTR-181 has demonstrated promising efﬁ cacy and safety results in preclinical studies. With NKTR-181, regulating CNS entry of the opioid could eliminate the euphoria and risk of respiratory death associated with traditional opi- oids. Eliminating euphoria could signiﬁ cantly reduce or eliminate the physiological basis for addictive behavior. In a standard abuse liability model for NKTR-181, results showed that NKTR-181 demonstrated less abuse potential than oxycodone. Leveraging Nektar’s Technology to Develop Novel Chemotherapeutic Agents PARENT MOLECULE NKTR-102 Standard irinotecan dosing provides limited exposure of active metabolite to tumors A superior pharmacokinetic profile compared to irinotecan ) l m / g n ( c n o C e t i l o b a t e M e v i t c A a m s a P l Tumor cells have no exposure to active drug and are constantly dividing 20 10 1 0.1 0 3 6 9 12 ) l m / g n ( c n o C e t i l o b a t e M e v i t c A a m s a P l blunted Cmax 20 10 1 0.1 0 Continuous exposure of drug to tumor cells 3 6 9 12 Time (weeks) Irinotecan Active Metabolite: T ½ ~ 1 day: Not detectable 5-6 days following dose Time (weeks) NKTR-102 Active Metabolite: T ½ ~ 50 days In a typical irinotecan chemotherapy regimen, therefore, tumors are getting drug exposure for a relatively short time and then 2-3 weeks pass before the next dose, during which time tumor cell division continues. Irinotecan also has a high Cmax which can cause acute toxicity. NKTR-102 was designed with the beneﬁ ts of an optimized pharma- cokinetics proﬁ le, longer half-life and a markedly reduced Cmax that may offer efﬁ cacy and safety advantages. PARENT MOLECULE NKTR-105 Standard docetaxel dosing provides limited exposure of active metabolite to tumors A superior pharmacokinetic profile compared to docetaxel Tumor cells have no exposure to active drug and are constantly dividing blunted Cmax 10,000 1,000 ) l m / g n ( l e x a t e c o D a m s a l P 100 100 10 1 0.1 0.01 0 3 6 9 12 10,000 1,000 ) l m / g n ( l e x a t e c o D a m s a l P 100 100 10 1 0.1 0.01 0 Continuous exposure of drug to tumor cells 3 6 9 12 Time (weeks) Docetaxel Active Metabolite: T ½ ~ ½ day: Not detectable 3-4 days following dose Time (weeks) NKTR-105 Docetaxel: T ½ > 20 days Preliminary Phase 1 pharmacokinetic data for NKTR-105 demonstrated that we successfully applied our technol- ogy to signiﬁ cantly improve the pharmacokinetic proﬁ le of docetaxel. As with NKTR-102, by reducing the peak plasma concentrations and providing continuous exposure of docetaxel using our advanced polymer conjugate technology to create NKTR-105, we hope to achieve improvements in both efﬁ cacy and safety. conjugate technology with a well-understood topoisomerase I- inhibitor, irinotecan. In Phase 1, NKTR-102 demonstrated anti- tumor activity in multiple tumor settings. As a result, in 2009, we began Phase 2 clinical trials for NKTR-102 in platinum-resistant ovarian cancer, metastatic breast cancer and second-line col- orectal cancer. Our study of NKTR-102 in women with platinum-resistant ovar- ian cancer completed enrollment far ahead of schedule. We recently reported highly promising preliminary data from the ﬁ rst stage of this study that shows NKTR-102 could provide a dra- matic clinical beneﬁ t for patients. Ovarian cancer is the ﬁ fth deadliest form of cancer for women. In the U.S. alone, 21,000 new cases of ovarian cancer are diagnosed annually and 15,000 women die from the disease. Once platinum-resistance devel- ops for these women, the patients are generally resistant to all forms of further therapy. Our results from the Phase 2 study of NKTR-102 were recently accepted for an oral podium presenta- tion at the prestigious American Society of Clinical Oncology (ASCO) Meeting in June 2010. We are particularly excited about the recognition that our Phase 2 results for NKTR-102 are re- ceiving within the oncology community. We believe NKTR-102 holds great promise for women with platinum-resistant and refractory ovarian cancer. The studies of NKTR-102 in women with metastatic breast cancer and patients with the KRAS gene mutation with second-line col- orectal cancer are ongoing. In the ﬁ rst part of 2010, we initiated an additional trial evaluating NKTR-102 in combination with 5FU in patients with colorectal cancer. Irinotecan in combination with 5FU is the current standard of care in second-line colon cancer and this study, along with the ongoing 174-patient KRAS study, support our ultimate goal of replacing irinotecan in the colorec- tal setting. Our second oncology candidate, NKTR-105, was created by applying Nektar’s advanced polymer conjugate technology to a cell-cycle inhibitor, docetaxel, which is approved for use in sev- eral solid tumor indications. We initiated a Phase 1 clinical trial of NKTR-105 in 2009. Like NKTR-102, NKTR-105 is designed to signiﬁ cantly improve the pharmacokinetic proﬁ le of docetaxel. Based on the successes of NKTR-102 and NKTR-105, we have expanded our research to identify new chemotherapeutics that could beneﬁ t from the application of our advanced polymer conjugate technology. This area is an important research focus for us in 2010. NEKTAR // Annual Report 2009 5 “Based on the successes of NKTR-102 and NKTR-105, we have expanded our research to identify new chemotherapeutics that could beneﬁ t from the application of our advanced polymer conjugate technology.” Our success to-date with our technology platform in small mol- ecules sets the stage for the future growth of our pipeline across a wide range of therapeutic areas. We have long been a leader in large molecule PEGylation, and we have now demonstrated that Nektar’s advanced polymer conjugate technology applied to small molecules can enable the creation of novel, orally bio- available therapeutics and cytotoxics with highly desirable pharmaceutical properties. Our investment into research and development has allowed us to leverage our advanced polymer conjugate technologies to build a high-value and diversiﬁ ed R&D pipeline. We ended 2009 in a strong ﬁ nancial position with approximately $400 million in cash. Nektar’s portfolio of late-stage partnered assets are progressing through late stage development, as well. If approved, these pro- grams represent signiﬁ cant future economic potential for Nektar. For Amikacin Inhale, our partner Bayer is continuing to prepare for Phase 3 studies and we expect Bayer to initiate these stud- ies in the coming year. Bayer’s Cipro Inhale, which is in Phase 2 development, was recently granted orphan drug designation by the FDA. Our partner, Affymax, recently announced that they completed their four Phase 3 studies for Hematide in renal anemia and they expect to present top-line results from these studies in June 2010. Finally, MAP has indicated that patients in their pivotal trials for their migraine investigational compound, Levadex, are also expected to complete treatment this year. Our signiﬁ cant achievements over this past year are a result of the hard work and efforts of a dedicated and talented team at Nektar. We are highly focused on advancing new drug candidates that could greatly beneﬁ t patients and create value for our share- holders. I’d like to personally extend my thanks to my colleagues at Nektar for their ingenuity and hard work and I’d like to express my appreciation to our shareholders for your continued support of our company and our mission. Sincerely, Howard W. Robin President and Chief Executive Ofﬁ cer “We are highly focused on advancing new drug candidates that could greatly beneﬁ t patients and create value for our shareholders.” 6 Annual Report 2009 // NEKTAR 2009: A Year of Transformation and Achievement for Nektar CLINICAL VALIDATION OF NEKTAR’S TECHNOLOGY PLATFORM WITH SMALL MOLECULES » First successful PEGylation of a small molecule » Achieved ﬁ rst oral bioavailability with a polymer-conjugated drug » Demonstrated capability to modulate drugs crossing the blood- brain barrier » Greatly improved the PK proﬁ les of anti-cancer agents to enhance efﬁ cacy and reduce side effects GROUNDBREAKING AGREEMENT SIGNED WITH ASTRAZENECA » Highlights value of Nektar’s technology platform » AstraZeneca to develop and commercialize NKTR-118 and NKTR-119 » Total of up to $1.5 billion in milestones in addition to signiﬁ cant double-digit royalties ENTERED 2010 IN STRONG FINANCIAL POSITION » Entered 2010 with approximately $400 million in cash and investments Nektar is addressing unmet medical needs by leveraging and expanding our technology platform to improve known molecules. Nektar’s advanced polymer conjugate technology platform has broad applicability to both large and small molecules which enables us to create drug candidates across multiple therapeutic areas. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Í ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. ‘ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2009 or For the transition period from to Commission File Number: 0-24006 NEKTAR THERAPEUTICS (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 94-3134940 (IRS Employer Identification No.) 201 Industrial Road San Carlos, California 94070 (Address of principal executive offices and zip code) 650-631-3100 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Common Stock, $0.0001 par value Name of Each Exchange on Which Registered NASDAQ Global Select Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ‘ No Í Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ‘ No Í Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days) Yes Í No ‘ Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes Í No ‘ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. Í Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer ‘ Non-accelerated filer ‘ Accelerated filer Í Smaller reporting company ‘ (Do not check if a smaller reporting company) Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2) Yes ‘ No Í The approximate aggregate market value of voting stock held by non-affiliates of the registrant, based upon the last sale price of the registrant’s common stock on the last business day of the registrant’s most recently completed second fiscal quarter, June 30, 2009 (based upon the closing sale price of the registrant’s common stock listed as reported on the NASDAQ Global Select Market), was approximately $597,697,691. This calculation excludes approximately 323,230 shares held by directors and executive officers of the registrant. Exclusion of these shares does not constitute a determination that each such person is an affiliate of the registrant. As of February 26, 2010, the number of outstanding shares of the registrant’s common stock was 93,645,805. Portions of registrant’s definitive Proxy Statement to be filed for its 2010 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K. DOCUMENTS INCORPORATED BY REFERENCE 1 NEKTAR THERAPEUTICS 2009 ANNUAL REPORT ON FORM 10-K TABLE OF CONTENTS PART I Item 1. Business Item 1A. Risk Factors Item 1B. Unresolved Staff Comments Item 2. Properties Item 3. Legal Proceedings Item 4. Submission of Matters to a Vote of Security Holders PART II Item 5. Market for Registrant’s Common Equity Related Stockholder Matters and Issuer Purchases of Equity Securities Item 6. Selected Financial Data Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations Item 7A. Quantitative and Qualitative Disclosures About Market Risk Item 8. Financial Statements and Supplementary Data Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure Item 9A. Controls and Procedures Item 9B. Other Information PART III Item 10. Directors, Executive Officers and Corporate Governance Item 11. Executive Compensation Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters Item 13. Certain Relationships and Related Transactions and Director Independence Item 14. Principal Accounting Fees and Services PART IV Item 15. Exhibits, Financial Statement Schedules Signatures Page 4 4 25 37 37 37 37 38 38 40 41 52 54 87 87 88 89 89 89 89 89 89 90 90 95 2 Forward-Looking Statements This report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical fact are “forward-looking statements” for purposes of this annual report on Form 10-K, including any projections of earnings, revenue or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, pre-clinical development, clinical trials and manufacturing), any statements concerning proposed drug candidates or other new products or services, any statements regarding future economic conditions or performance, any statements regarding expected benefits from the closing of the sale of pulmonary assets to Novartis on December 31, 2008, any statements regarded the timing of the move of our corporate headquarters to, and the estimated costs of, the facility subject to the sublease with Pfizer, Inc. dated September 30, 2009, any statements regarding the success of our collaborations including in relation to the license agreement with AstraZeneca AB dated September 20, 2009, and though not a 2009 agreement, any statement regarding our plans and objective for our collaboration with Bayer Healthcare LLC entered into in August 2007 for BAY41-6551 (NKTR-061 or Amikacin Inhale), and plans and objectives to initiate Phase 3 clinical trials, any statements regarding the plans and timing for a potential collaboration transaction for NKTR-102, and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “estimates,” “potential” or “continue,” or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, such expectations or any of the forward- looking statements may prove to be incorrect and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not limited to, the risk factors set forth in Part I, Item 1A “Risk Factors” below and for the reasons described elsewhere in this annual report on Form 10-K. All forward-looking statements and reasons why results may differ included in this report are made as of the date hereof and we do not intend to update any forward-looking statements except as required by law or applicable regulations. Except where the context otherwise requires, in this annual report on Form 10-K, the “Company,” “Nektar,” “we,” “us,” and “our” refer to Nektar Therapeutics, a Delaware corporation, and, where appropriate, its subsidiaries. Trademarks The Nektar brand and product names, including but not limited to Nektar®, contained in this document are trademarks, registered trademarks or service marks of Nektar Therapeutics in the United States (U.S.) and certain other countries. This document also contains references to trademarks and service marks of other companies that are the property of their respective owners. 3 Item 1. Business PART I We are a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize our PEGylation and advanced polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Our current proprietary product pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti- infectives, anti-viral and immunology. Our research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. We create our innovative drug candidates by using our proprietary chemistry platform to modify the chemical structure of drugs by applying our proprietary advanced polymer conjugate technologies and expertise. Polymer chemistry is a science focused on the synthesis or bonding of polymer architectures with drug molecules to alter the properties of the molecule when it is bonded with polymers. Additionally, we may utilize established pharmacologic targets to engineer a new drug candidate relying on a combination of the known properties of these targets and our proprietary polymer chemistry technology and expertise. Our drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Our objective is to apply our advanced polymer conjugate technology platform to create new drugs in multiple therapeutic areas. Each of our drug candidates which we are currently developing internally is a proprietary new chemical or biological entity that addresses large potential markets. We are developing drug candidates that can be delivered by either oral or subcutaneous administration. Our most advanced proprietary product candidate, Oral NKTR-118, is a peripheral opioid antagonist that is currently being evaluated for the treatment of opioid-induced constipation. On September 20, 2009, we entered into a license agreement with AstraZeneca AB for the global development and commercialization of Oral NKTR-118 and NKTR-119. NKTR-119 is an early stage research development program that combines various opioids with Oral NKTR-118. Under this agreement, AstraZeneca assumed all responsibility for development and commercialization of NKTR-118 and NKTR-119. Our other lead product candidate, NKTR-102, a topoisomerase I inhibitor-polymer conjugate, is currently being evaluated in three separate Phase 2 clinical trials for ovarian, breast and colorectal cancers. In addition, in 2009 we commenced a Phase 1 clinical trial for NKTR-105 (PEGylated docetaxel) for patients with refractory solid tumors. We also have a number of early stage programs in research and preclinical development. In addition to our proprietary product candidate pipeline, we have a number of collaborations and license, manufacturing and supply agreements for our technology with leading biotechnology and pharmaceutical companies, including Affymax, Amgen Baxter, Roche, Merck (formerly Schering Plough), Pfizer and UCB Pharma. A total of seven products using our PEGylation technology platform have received regulatory approval in the U.S. or Europe, and are currently marketed by our partners. There are also a number of other products in clinical development that use our technology platform. We currently anticipate that these collaborations, and the amortization of the $125.0 million upfront payment from AstraZeneca, will represent the majority of our revenue in 2010. We anticipate that our 2010 revenue will be comprised of a combination of upfront payments, contract research fees, milestone payments, manufacturing product sales and product royalties. We also have a collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic. We originally developed the liquid aerosol inhalation platform and product and entered into a collaboration agreement with Bayer Healthcare LLC in August 2007 for its further development and commercialization. BAY41-6551 completed Phase 2 development and we and Bayer are currently preparing for the start of a Phase 3 clinical study. Bayer and Nektar have been working together to prepare for the pivotal studies of BAY41-6551 following the consummation of the collaboration in August 2007. The program is behind schedule. The reason for this is that Bayer and Nektar decided to finalize the design of the device for commercial manufacturing prior to initiating Phase 3 clinical development with the objective of commencing Phase 3 clinical trials as soon as possible following completion of this work. On December 31, 2008, we completed the sale and transfer of certain pulmonary technology rights, certain pulmonary collaboration agreements and approximately 140 of our dedicated pulmonary personnel and operations to Novartis Pharma AG. We retained all of our rights to BAY41-6551 and certain rights to receive royalties on net sales of the Cipro Inhale (also known as Ciprofloxacin Inhaled Powder or CIP) program with Bayer Schering Pharma AG that we transferred to Novartis as part of the transaction. We also retained certain intellectual property rights to patents specific to inhaled insulin. We were incorporated in California in 1990 and reincorporated in Delaware in 1998. We maintain our executive offices at 201 Industrial Road, San Carlos, California 94070, and our main telephone number is (650) 631-3100. 4 Our Technology Platform With our expertise as a leader in the PEGylation field, we have advanced our technology platform to include first-generation PEGylation and new advanced polymer conjugate chemistries that can be tailored in very specific and customized ways with the objective of optimizing and significantly improving the profile of a wide range of molecules and many classes of drugs and disease areas. PEGylation has been a highly effective technology platform for the development of therapeutics with significant commercial success, such as Roche’s PEGASYS® (PEG-interferon alfa-2a) and Amgen’s Neulasta® (pegfilgrastim). All of the PEGylated drugs approved over the last fourteen years were enabled with our PEGylation technology through our collaborations and licensing partnerships with a number of pharmaceutical companies. PEG (polyethylene glycol) is a versatile technology and is a water soluble, amphiphilic, non-toxic, non-immunogenic compound that is safely cleared from the body. Its primary use to date has been in currently approved biologic drugs to favorably alter their pharmacokinetic or pharmacodynamic properties. However, in spite of its widespread success in commercial drugs, there are limitations with the first-generation PEGylation approaches used with biologics. These limitations include the inability of the earlier approaches of PEGylation technology to be used successfully with small molecule drugs, antibody fragments and peptides, all of which could potentially benefit from the application of the technology. Other limitations of the early approaches of PEGylation technology include resulting sub-optimal bioavailability and bioactivity, and its limited ability to be used to fine-tune properties of the drug, as well as its inability to be used to create oral drugs. With our expertise and proprietary technology in PEGylation, we have created a next-generation of PEGylation technology. Our advanced polymer conjugate technology platform is designed to overcome the limitations of the first generation of the technology platform and allow the platform to be utilized with a broader range of molecules across many therapeutic areas. Both our PEGylation and advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits: (cid:129) (cid:129) (cid:129) (cid:129) (cid:129) (cid:129) (cid:129) (cid:129) improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug; improve targeting or binding affinity of a drug to its target receptors with the potential to improve efficacy and reduce toxicity or drug resistance; improve solubility of a drug; enable oral administration of parenterally-administered drugs, or drugs that must be administered intravenously or subcutaneously, and increase oral bioavailability of small molecules; prevent drugs from crossing the blood-brain barrier and limiting undesirable central nervous system effects; reduce first-pass metabolism effects of certain drug classes with the potential to improve efficacy, which could reduce the need for other medicines and reduce toxicity; reduce rate of drug absorption and of elimination or metabolism by improving stability of the drug in the body and providing it with more time to act on its target; and reduce immune response to certain macromolecules with the potential to prolong their effectiveness with repeated doses. We have a broad range of approaches that we may use when designing our own drug candidates, some of which are outlined below: Small Molecule Stable Polymer Conjugates Our customized approaches for small molecule polymer conjugates allows for the fine-tuning of the physicochemical and pharmacological properties of small molecule oral drugs to potentially increase their therapeutic benefit. In addition, this approach can enable oral administration of subcutaneously or intravenously delivered small molecule drugs that may have shown low bioavailability when delivered orally. The benefits of this approach can also include: improved potency, increased oral bioavailability, 5 modified biodistribution with enhanced pharmacodynamics, and reduced transport across specific membrane barriers in the body, such as the blood-brain barrier. A primary example of the application of membrane transport inhibition, specifically reducing transport across the blood-brain barrier is Oral NKTR-118, a novel peripheral opioid antagonist that completed Phase 2 clinical development in 2009. An example of a drug candidate that uses this approach to avoid first-pass metabolism is NKTR-140, a protease inhibitor in the early stages of discovery research. Small Molecule Pro-Drug Releasable Polymer Conjugates The pro-drug polymer conjugation approach can be used to optimize the pharmacokinetics and pharmacodynamics of a small molecule drug to substantially increase both its efficacy and side effect profile. We are currently using this platform with oncolytics, which typically have sub-optimal half-lives that can limit their therapeutic efficacy. With our technology platform, we believe that these drugs can be modulated for programmed release within the body, optimized bioactivity and increased sustained exposure of active drug to tumor cells in the body. We are using this approach with the two oncolytic candidates in our pipeline, NKTR-102, a topoisomerase I inhibitor-polymer conjugate currently in Phase 2 clinical development, and NKTR-105, a polymer conjugate form of docetaxel that is currently in Phase 1 clinical development. Large Molecule Polymer Conjugates (Proteins and Peptides) Our customized approaches with large molecule polymer conjugates have enabled numerous successful PEGylated biologics on the market today. We are using our advanced polymer conjugation technology-based approach to enable peptides, which are much smaller in size than other biologics, such as proteins and antibody fragments. We are in the early stages of discovery research with a number of peptides that utilize this proprietary approach. Peptides are important in modulating many physiological processes in the body. Some of the benefits of working with peptides are: they are small, more easily optimized, and can be rapidly investigated for therapeutic potential. However, peptide drug discovery has been slowed by the extremely short half-life and limited bioavailability of these molecules. Based on our knowledge of the technology and biologics, our scientists have designed a novel hydrolyzable linker that can be used to optimize the bioactivity of a peptide. Through rational drug design and the use of our approach, a peptide’s pharmacokinetics and pharmacodynamics can be substantially improved and its half-life can be significantly extended. The approach can also be used with proteins and larger molecules, as well. Antibody Fragment Polymer Conjugates This approach uses a large molecular weight polyethylene glycol (PEG) conjugated to antibody fragments in order to potentially improve their toxicity profile, extend their half-life and allow for ease of synthesis with the antibody. The specially designed PEG then becomes part of the antibody fragment Fc. Since the antibody fragment is more like a biologic, this conjugation has a branched architecture with either stable or degradable linkage. This approach can be used to reduce antigenicity, reduce glomerular filtration rate, enhance uptake by inflamed tissues, and retain antigen-binding affinity and recognition. There is currently one approved product on the market that utilizes our technology with an antibody fragment, CIMZIA™ (certoluzimab pegol), which was developed by our partner UCB Pharma and is approved for the treatment of Crohn’s Disease in the U.S. and Rheumatoid Arthritis in the U.S. and Europe. Our Strategy The key elements of our business strategy are described below: Advance Our Internal Clinical Pipeline of Drug Candidates that Leverage Our PEGylation and Advanced Polymer Conjugate Chemistry Platform Our objective is to create value by advancing our lead drug candidates through early to mid-stage clinical development. To support this strategy, over the past two years we have significantly expanded and added expertise to our internal clinical development and regulatory departments. We decide on a product-by-product basis whether to continue development into Phase 3 pivotal clinical trials and commercialize products on our own, or seek a partner, or pursue a combination of these approaches. To date, we have partnered our proprietary drug development programs prior to Phase 3 clinical development. 6 A key component of our development strategy is to potentially reduce the risks and time associated with drug development by capitalizing on the known safety and efficacy of approved drugs as well as established pharmacologic targets and drugs directed to those targets. For many of our novel drug candidates, we may seek approval in indications for which the parent drugs have not been studied or approved. We believe that the improved characteristics of our drug candidates will provide meaningful benefit to patients compared to the existing therapies, and allow for approval to provide new treatments for patients for which the parent drugs are not currently approved. Ensure Future Growth of our Pipeline through Internal Research Efforts and Advancement of our Preclinical Drug Candidates into Clinical Trials We believe it is important to maintain a diverse pipeline of new drug candidates to continue to build on the value of our business. Our discovery research organization is identifying new drug candidates by applying our technology platform to a wide range of molecule classes, including small molecules and large proteins, peptides and antibodies, across multiple therapeutic areas. We continue to advance our most promising early research drug candidates into preclinical development with the objective to advance these early stage research programs to human clinical studies over the next several years. Enter into Strategic and High-Value Partnerships to Bring Our Drugs to Market Our partnering strategy is to enter into collaborations with larger pharmaceutical and biotechnology companies at appropriate stages in our drug candidate development process to fund further clinical development, manage the global regulatory filing process, and market and sell drugs when and if they are approved. The options for future collaboration arrangements range from comprehensive licensing arrangements to co-promotion and co-development agreements with the structure of the collaboration depending on factors such as the cost and complexity of development, marketing and commercialization needs and therapeutic area. Continue to Build a Leading Intellectual Property Estate in the Field of PEGylation and Polymer Conjugate Chemistry across Therapeutic Modalities We are committed to continuing to build on our intellectual property position in the field of PEGylation and polymer conjugate chemistry. To that end, we have a comprehensive patent strategy with the objective of developing a patent estate covering a wide range of novel inventions including among others, polymer materials, conjugates, formulations, synthesis, therapeutic areas and methods of treatment. Nektar Proprietary Internal Drug Candidates in Clinical Development The following table summarizes our proprietary product candidate pipeline and Nektar-discovered drug candidates that are being developed in partnerships with pharmaceutical companies. The table includes the type of molecule or drug, the target indications for the product or product candidate, and the clinical trial status of the program. Drug Candidate/Program Target Indications Status (1) Oral NKTR-118 (oral PEG-naloxol) Opioid-induced constipation Phase 2 (Partnered with AstraZeneca AB) BAY41-6551 (NKTR-061, Amikacin Inhale) Gram-negative pneumonias Phase 2 (Partnered with Bayer Healthcare LLC)* NKTR-102 (topoisomerase I inhibitor-polymer conjugate) NKTR-102 NKTR-102 Second-line colorectal cancer in patients with the KRAS gene mutation Phase 2 Metastatic breast cancer Phase 2 Platinum-resistant/refractory ovarian cancer Phase 2 NKTR-105 (PEGylated docetaxel) Solid tumors Phase 1 NKTR-119 (Opioid/NKTR-118 combinations) Pain NKTR-181 (abuse deterrent, tamper-resistant Pain opioid) NKTR-194 (non-scheduled opioid) Mild to moderate pain NKTR-171 (tricyclic antidepressant) Neuropathic pain NKTR-140 (protease inhibitor candidate) HIV Research/Preclinical (Partnered with AstraZeneca AB) Research/Preclinical Research/Preclinical Research/Preclinical Research/Preclinical 7 (1) Status definitions are: Phase 3 or Pivotal—product in large-scale clinical trials conducted to obtain regulatory approval to market and sell the drug (these trials are typically initiated following encouraging Phase 2 trial results). Phase 2—product in clinical trials to establish dosing and efficacy in patients. Phase 1—product in clinical trials, typically in healthy subjects, to test safety. In the case of oncology drug candidates, Phase 1 clinical trials are typically conducted in cancer patients. Research/preclinical—product is being studied in research by way of vitro studies and/or animal studies * This product candidate uses a liquid aerosol technology platform that was transferred to Novartis in the pulmonary asset sale transaction that was completed on December 31, 2008. As part of that transaction, we retained an exclusive license to this technology for the development and commercialization of this drug candidate originally developed by us. Approved Drugs and Drug Candidates Enabled By Our Technology through Licensing Collaborations The following table outlines our collaborations with a number of pharmaceutical companies that license our technology, including Amgen, Merck (formerly Schering-Plough), Baxter, UCB Pharma and F. Hoffmann-La Roche. A total of seven products using our PEGylation technology have received regulatory approval in the U.S. or Europe. There are also a number of other candidates that have been filed for approval or are in various stages of clinical development. These collaborations generally contain one or more elements including license rights to our proprietary technology, manufacturing and supply agreements under which we may receive manufacturing revenue, milestone payments, and/or product royalties on commercial sales. Drug Primary or Target Indications Licensing Partner and Drug Marketer Status (1) Neulasta® (pegfilgrastim) PEGASYS® (peginterferon alfa-2a) Somavert® (pegvisomant) PEG-INTRON® (peginterferon alfa-2b) Neutropenia Hepatitis-C Acromegaly Hepatitis-C Macugen® (pegaptanib sodium injection) Age-related macular degeneration Amgen Inc. Approved F. Hoffmann-La Roche Ltd Approved Pfizer Inc. Merck (formerly Schering- Plough Corporation) Eyetech Inc. Approved Approved Approved CIMZIA™ (certolizumab pegol) Crohn’s disease UCB Pharma MIRCERA® (C.E.R.A.) (Continuous Erythropoietin Receptor Activator) Anemia associated with chronic kidney disease in patients on dialysis and patients not on dialysis CIMZIA™ (certolizumab pegol) Rheumatoid arthritis Hematide™ (synthetic peptide- based, erythropoiesis- stimulating agent) Anemia F. Hoffmann-La Roche Ltd Approved in U.S. and Switzerland Approved in U.S. and EU (Launched only in the EU)* UCB Pharma Affymax, Inc. Approved in U.S. and EU Phase 3 Levadex™ Cipro Inhale Migraine MAP Pharmaceuticals Phase 3 Cystic fibrosis lung infections Bayer Schering Pharma AG Phase 2** CIMZIA ™ (certoluzimab pegol) Psoriasis Longer-acting Factor VIII and other blood clotting proteins Hemophilia UCB Pharma Baxter Phase 2 Research/preclinical 8 (1) Status definitions are: Approved—regulatory approval to market and sell product obtained in the U.S., EU and other countries. Filed —Products for which a New Drug Application (NDA) or Biologics License Application (BLA) has been filed. Phase 3 or Pivotal—product in large-scale clinical trials conducted to obtain regulatory approval to market and sell the drug (these trials are typically initiated following encouraging Phase 2 trial results). Phase 2—product in clinical trials to establish dosing and efficacy in patients. Phase 1—product in clinical trials, typically in healthy subjects, to test safety. In the case of oncology drug candidates, Phase 1 clinical trials are typically conducted in cancer patients. Research/preclinical—product is being studied in research by way of vitro studies and/or animal studies. * Amgen Inc. prevailed in a patent lawsuit against F. Hoffmann-La Roche Ltd and as a result of this legal ruling Roche is currently prevented from marketing MIRCERA® in the U.S until July 2014. ** This product candidate was developed using our proprietary pulmonary delivery technology that was transferred to Novartis in an asset sale transaction that closed on December 31, 2008. As part of the transaction, Novartis assumed our rights and obligations for our Cipro Inhale agreements with Bayer Schering PharmaAG; however, we maintained the rights to receive certain royalties on commercial sales of Cipro Inhale if the product candidate is approved. With respect to all of our collaboration and license agreements with third parties, please refer to Item 1A, Risk Factors, including without limitation, “We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.” Overview of Selected Proprietary Nektar Drug Development Programs and Significant Partnered Drug Development Programs Oral NKTR-118 and NKTR-119, License Agreement with AstraZeneca AB On September 20, 2009, we entered into a license agreement with AstraZeneca AB, in which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell Oral NKTR-118 and NKTR-119. Under the terms of this agreement, AstraZeneca will bear all costs associated with research, development and commercialization for Oral NKTR-118 and NKTR-119 and will be responsible for all development and commercialization activities. AstraZeneca made an upfront payment to us of $125.0 million in the fourth quarter of 2009. We are also entitled to development milestone payments if certain development and regulatory objectives are achieved and sales milestone payments if annual sales targets are achieved, as well as royalties based on annual worldwide net sales of Oral NKTR-118 and NKTR-119 products. AstraZeneca will use commercially reasonable efforts to develop one product based on NKTR-119 and has the right to develop multiple products based on NKTR-119. Oral NKTR-118, which combines our stable polymer conjugate technology with naloxol, a derivative of the opioid-antagonist drug naloxone, completed Phase 2 development in 2009. Results from the Phase 2 clinical study were presented in October 2009 at an oral plenary session of the American College of Gastroenterology 2009 Annual Clinical Meeting. The data presented from the Phase 2 study showed that Oral NKTR-118 achieved the primary endpoint of change from baseline in spontaneous bowel movements in patients taking opiates. The study also showed there was no apparent reversal of opioid-mediated analgesia with any of the Oral NKTR-118 dose groups, as measured by no change in Numeric Rating Scale (NRS) pain scores and no increase in mean daily opiate use. The most commonly reported side effects from this Phase 2 clinical study of Oral NKTR-118 were dose dependent gastrointestinal-related effects. 9 NKTR-119 is an early stage drug development program that is intended to combine Oral NKTR-118 with selected opioids, with the goal of treating pain without the side effect of constipation traditionally associated with opioid therapy. AstraZeneca is responsible for all further research and development activities for NKTR-119. According to the American Pain Society, over 200 million opioid prescriptions are filled in the U.S. annually with worldwide sales of opioids reaching $7.5 billion in 2007. Depending on the population studied and the definitions used, constipation occurs in up to 90% of patients taking opioids. Currently, there are no specific oral drugs approved or specifically indicated to treat opioid induced constipation or opioid bowel dysfunction. BAY41-6551 (NKTR-061, Amikacin Inhale), Agreement with Bayer Healthcare LLC In August 2007, we entered into a co-development, license and co-promotion agreement with Bayer Healthcare LLC (Bayer) to develop a specially-formulated Amikacin (BAY41-6551, NKTR-061, Amikacin Inhale). Under the terms of the agreement, Bayer is responsible for most future clinical development and commercialization costs, all activities to support worldwide regulatory filings, approvals and related activities, further development of formulated Amikacin and final product packaging for BAY41-6551. We are responsible for all future development of the nebulizer device used in BAY41-6551through the completion of Phase 3 clinical trials and for clinical and commercial manufacturing and supply of the nebulizer device. We have engaged third party contract manufacturers to perform our device manufacturing obligations for this program. Under the terms of the agreement, we are entitled to development and sales milestone payments upon achievement of certain annual sales targets. We are also entitled to royalties based on annual worldwide net sales of BAY41-6551. Our right to receive these royalties in any particular country will expire upon the later of ten years after the first commercial sale of the product in that country or the expiration of certain patent rights in that particular country, subject to certain exceptions. The agreement expires in relation to a particular country upon the expiration of all royalty and payment obligations between the parties related to such country. Subject to termination fee payment obligations, Bayer also has the right to terminate the agreement for convenience. In addition, the agreement may also be terminated by either party for certain product safety concerns, the product’s failure to meet certain minimum commercial profile requirements or uncured material breaches by the other party. For certain Bayer terminations, we may have reimbursement obligations to Bayer. BAY41-6551 is in clinical development to treat Gram-negative pneumonias, including Hospital-Acquired (HAP), Healthcare- Associated, and Ventilator-Associated pneumonias. Gram-negative pneumonias are often the result of complications of other patient conditions or surgeries. Gram-negative pneumonia carries a mortality risk that can exceed 50% in mechanically-ventilated patients and accounts for a substantial proportion of the pneumonias in intensive care units today. BAY41-6551 is designed to be an adjunctive therapy to the current antibiotic therapies administered intravenously as standard of care. The targeted aerosol delivery platform in BAY41-6551 delivers the antimicrobial agent directly to the site of infection in the lungs. This product candidate can be integrated with conventional mechanical ventilators or used as a hand-held ‘off-vent’ device for patients no longer requiring breathing assistance. This product candidate has completed Phase 2 clinical development. Bayer and Nektar have been working together to prepare for the pivotal studies of BAY41-6551 following the consummation of the collaboration in August 2007. The program is behind schedule. The reason for this is that Bayer and Nektar decided to finalize the design of the device for commercial manufacturing prior to initiating Phase 3 clinical development with the objective of commencing Phase 3 clinical trials as soon as possible following completion of this work. Please refer to Item 1A, Risk Factors, “If we or our partners are not able to manufacture drugs in quantities and at costs that are commercially feasible, our proprietary and partnered product candidates may experience clinical delays or constrained commercial supply which could significantly harm our business.” NKTR-102 (Topoisomerase I inhibitor-polymer conjugate) We are developing NKTR-102, a novel topoisomerase I inhibitor-polymer conjugate that was designed using our advanced polymer conjugate technology platform. This product candidate is currently in Phase 2 clinical development in multiple cancer indications including breast, colorectal and ovarian. By applying our proprietary pro-drug polymer conjugate technology to irinotecan, NKTR-102 has the potential to be a more effective and tolerable anti-tumor agent. Irinotecan, also known as Camptosar®, is a topoisomerase I inhibitor used for the treatment of solid tumors. Using a proprietary approach that directly conjugates the drug to a multi-arm polymer architecture, NKTR-102 has a unique pharmacokinetic and pharmacodynamic profile that has demonstrated anti- tumor activity in patients in early stage clinical trials. 10 Two separate NKTR-102 Phase 2 studies are ongoing in platinum-resistant ovarian and metastatic breast cancers. These studies are open label, single arm two-stage studies including two treatment regimens (every 14 days or every 21 days). Patients include those with metastatic breast cancer with prior taxane treatment and those with metastatic and platinum-resistant ovarian cancer. These clinical studies are designed to evaluate the overall response rate (ORR) of NKTR-102 monotherapy in each tumor setting, with certain secondary endpoints including progression-free survival. In January 2010, we announced preliminary results from the first stage of the two-stage efficacy and safety trial of single-agent NKTR-102 in women with platinum-resistant ovarian cancer. We expect to announce final results from these Phase 2 clinical development programs in 2010. Ovarian and breast cancers are significant health problems for women worldwide. In 2008, there were an estimated 21,650 new diagnoses and an estimated 15,520 deaths from ovarian cancer in the United States and, historically, less than 40% of women with ovarian cancer are cured. The American Cancer Society estimated that over 184,000 new cases of invasive breast cancer were diagnosed and nearly 41,000 women died of breast cancer in the United States in 2008. A Phase 2 clinical development program for NKTR-102 was initiated in early 2009 to evaluate the efficacy and safety of NKTR-102 monotherapy versus irinotecan in second-line colorectal cancer patients with the KRAS mutant gene. The primary endpoint of the Phase 2 placebo-controlled trial of NKTR-102 in colorectal cancer will be a clinically meaningful improvement in progression-free survival as compared to standard irinotecan monotherapy. According to recent data presented at the American Society of Clinical Oncology in 2008, it is estimated that up to 45% of colorectal cancer cases have this mutation in the KRAS gene and do not respond to EGFR-inhibitors, such as cetuximab. We expect this Phase 2 clinical trial to continue throughout 2010. A Phase 2a study of NKTR-102 was completed in 2009 to evaluate NKTR-102 in combination with cetuximab in 18 patients with refractory solid tumors, primarily gastrointestinal-related cancers, in order to establish the recommended Phase 2 dose. According to the National Comprehensive Clinical Network, colorectal cancer is the most frequently diagnosed cancer in men and women in the United States. In 2008, it is estimated that over 108,000 new cases of colon cancer and approximately 40,780 cases of rectal cancer occurred. During the same year, it is estimated that 49,960 people died from colon and rectal cancer. NKTR-105 (PEGylated docetaxel) NKTR-105 is a PEGylated conjugate form of docetaxel, an anti-neoplastic agent belonging to the taxoid family that acts by disrupting the microtubular network in cells. Docetaxel is a major chemotherapy agent approved for use in five different cancer indications: breast, non-small cell lung, prostate, gastric, and head and neck. Annual sales of docetaxel in 2007 exceeded $2 billion. Anti-cancer agents, such as docetaxel, typically have suboptimal pharmacokinetic profiles which can limit their therapeutic value. Docetaxel frequently causes neutropenia. Patients are advised the treatment with corticosteroids is required in conjunction with docetaxel dosing and some neutropenia patients require pre-treatment with corticosterioids. Our advanced polymer conjugation technology can be used to optimize the bioactivity of these drugs and increase the sustained exposure of active drug to tumor cells in the body. NKTR-105 is currently being evaluated in a Phase 1 clinical trial in cancer patients that began in February 2009. The study will assess the safety, pharmacokinetics, and anti-tumor activity of NKTR-105 in approximately 30 patients with refractory solid tumors who have failed all prior available therapies. We expect to have results from this study in 2010. NKTR-181 (abuse deterrent, tamper-resistant opioid) NKTR-181 is being developed as a safer opioid with reduced potential for abuse engineered using our advanced polymer conjugation technology platform. By regulating entry of the drug into the CNS, this polymer-conjugate opioid drug candidate is designed to have potent analgesia with the potential for fewer side effects associated with sedation, a reduced risk of death due to respiratory depression, and less euphoria associated with administration, resulting in an safer, abuse-deterrent analgesic. The stable opioid-polymer conjugate drug is also designed to be tamper-resistant to reduce the potential for diversion for illicit reprocessing. This program is in the early stages of research and preclinical development. NKTR-194 (non-scheduled opioid) NKTR-194 is an opioid designed using our advanced polymer conjugation technology platform to be nearly totally excluded from the CNS and therefore act only against peripheral pain. This approach has the potential to avoid certain CNS side effects, gastrointestinal bleeding and cardiovascular risks associated with NSAIDs and COX-2 inhibitors currently used to treat moderate peripheral pain. This program is in the early stages of research and preclinical development. 11 NKTR-171 (tricyclic antidepressant-polymer conjugate) NKTR-171 is a drug candidate designed to treat neuropathic pain without the CNS side effects associated with the use of tricyclic antidepressants. The product is being developed using our advanced polymer conjugate technology to near totally preclude the drug from penetrating the CNS. This program is in the early stages of research and preclinical development. NKTR-140 (protease inhibitor-polymer conjugate) NKTR-140 is a protease inhibitor product candidate to treat human immunodeficiency virus (HIV), which can lead to acquired immunodeficiency syndrome or AIDS. The product candidate was developed using our advanced small molecule polymer conjugate technology. This product candidate is designed to have improved potency as compared to leading protease inhibitors used in clinical practice today, and also to eliminate the need for a co-administered protease inhibitor booster, such as ritonavir. This program is in the early stages of research and preclinical development. Overview of Select Technology Licensing Collaborations and Programs Hematide™, Agreement with Affymax, Inc. In April 2004, we entered into a license, manufacturing and supply agreement with Affymax, Inc. (Affymax), under which we granted Affymax a worldwide, non-exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize Hematide. We currently manufacture our proprietary PEGylation materials for Affymax on a fixed price basis subject to annual adjustments. Affymax has an option to convert this manufacturing pricing arrangement to cost plus at any time prior to the date the New Drug Application (NDA) for Hematide is submitted to the Food and Drug Administration (FDA). In addition, Affymax is responsible for all clinical development, regulatory and commercialization expenses and we are entitled to development milestones and royalties on net sales of Hematide. We will share a portion of our future royalty payments with Enzon Pharmaceuticals, Inc. Our right to receive royalties in any particular country will expire upon the later of ten years after the first commercial sale of the product in that country or the expiration of patent rights in that particular country. The agreement expires on a country-by-country basis upon the expiration of Affymax’s royalty obligations. The agreement may also be terminated by either party for the other party’s continued material breach after a cure period or by us in the event that Affymax challenges the validity or enforceability of any patent licensed to them under the agreement. Levadex™, Agreement with MAP Pharmaceuticals In June 2004, we entered into a license agreement with MAP Pharmaceuticals which includes a worldwide, exclusive license, to certain of our patents and other intellectual property rights to develop and commercialize a formulation of dihydroergotamine for administration to patients via the pulmonary or nasal delivery route. Under the terms of the agreement, we have the right to receive certain development milestone payments and royalties based on net sales of Levadex. Our right to receive royalties in any particular country will expire upon the later of (i) ten years after first commercial sale in that country, (ii) the date upon the licensed know-how becomes known to the general public, and (iii) expiration of certain patent claims, each on a country-by-country basis. Either party may terminate the agreement upon a material, uncured default of the other party. Hemophilia Programs, Agreement with Subsidiaries of Baxter International In September 2005, we entered into an exclusive research, development, license and manufacturing and supply agreement with Baxter Healthcare SA and Baxter Healthcare Corporation (Baxter) to develop products with an extended half-life for the treatment and prophylaxis of Hemophilia A patients using our PEGylation technology. In December 2007, we expanded our agreement with Baxter to include the license of our PEGylation technology and proprietary PEGylation methods with the potential to improve the half-life of any future products Baxter may develop for the treatment and prophylaxis of Hemophilia B patients. Under the terms of the agreement, we are entitled to research and development funding, and we manufacture our proprietary PEGylation materials for Baxter on a cost plus basis. Baxter is responsible for all clinical development, regulatory, and commercialization expenses. In relation to Hemophilia A, we are entitled to development milestone payments and royalties on net sales varying by product and country of sale. Our right to receive these royalties in any particular country will expire upon the later of ten years after the first commercial sale of the product in that country or the expiration of patent rights in certain designated countries or in that particular country. In relation 12 to Hemophilia B, we are entitled to development and sales milestone payments and royalties on net sales varying by product and country of sale. Our right to receive these royalties in any particular country will expire upon the later of twelve years after the first commercial sale of the product in that country or the expiration of patent rights in certain designated countries or in that particular country. The agreement expires in relation to a particular product and country upon the expiration of all of Baxter’s royalty obligations related to such product and country. The agreement may also be terminated by either party for the other party’s material breach or insolvency, provided that such other party has been given a chance to cure or remedy such breach or insolvency. Subject to certain limitations as to time, and possible termination fee payment obligations, Baxter also has the right to terminate the agreement for convenience. We have the right to terminate the agreement or convert Baxter’s license from exclusive to non-exclusive in the event Baxter fails to comply with certain diligence obligations. Cipro Inhale, Assigned to Novartis as of December 31, 2008 We were a party to a collaborative research, development and commercialization agreement with Bayer Schering Pharma AG related to the development of an inhaled powder formulation of Ciprofloxacin for the treatment of chronic lung infections caused by Pseudomonas aeruginosa in cystic fibrosis patients. As of December 31, 2008, we assigned the collaborative research, development and commercialization agreement to Novartis Pharma AG in connection with the closing of the asset sale transaction. We maintain the right to receive certain potential royalties in the future based on net product sales if Cipro Inhale receives regulatory approval and is successfully commercialized. Overview of Select Licensing Partnerships for Approved Products All of the approved products today that use our technology platforms are a result of licensing collaborations with partners. We also have a number of product candidates in clinical development by our partners that use our technology or involve rights over which we have patents or other proprietary intellectual property. In a typical collaboration involving our PEGylation technology, we license our proprietary intellectual property related to our PEGylation technology or proprietary conjugated drug molecules in consideration for upfront payments, development milestone payments and royalties from sales of the resulting commercial product as well as sales milestones. We also manufacture and supply our proprietary PEGylation materials to our partners. Neulasta®, Agreement with Amgen, Inc. In July 1995, we entered into a non-exclusive supply and license agreement with Amgen, Inc. (Amgen), pursuant to which we license our proprietary PEGylation technology to be used in the development and manufacture of Neulasta. Neulasta selectively stimulates the production of neutrophils that are depleted by cytotoxic chemotherapy, a condition called neutropenia that makes it more difficult for the body to fight infections. We manufacture and supply our proprietary PEGylation materials for Amgen on a fixed price basis. The term of the agreement is for a fixed duration with a limited number of renewal options. This supply term is scheduled to expire in 2010 unless extended. The parties are currently discussing various extension alternatives. PEGASYS®, Agreement with F. Hoffmann-La Roche Ltd In February 1997, we entered into a license, manufacturing and supply agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche), under which we granted Roche a worldwide, exclusive license to use certain PEGylation materials to manufacture and commercialize a certain class of products, of which PEGASYS is the only product currently commercialized. PEGASYS is approved in the U.S., E.U. and other countries for the treatment of Hepatitis C and is designed to help the patient’s immune system fight the Hepatitis C virus. As a result of Roche exercising a license extension option in December 2009, beginning in 2010 Roche has the right to manufacture all of its requirements for our proprietary PEGylation materials for PEGASYS and we would supply raw materials or perform additional manufacturing, if any, only on an as requested basis. The agreement expires on the later of January 10, 2015 or the expiration of our last relevant patent containing a valid claim. Somavert®, Agreement with Pfizer, Inc. In January 2000, we entered into a license, manufacturing and supply agreement with Sensus Drug Development Corporation (subsequently acquired by Pharmacia Corp. in 2001 and then acquired by Pfizer, Inc. in 2003), for the PEGylation of Somavert (pegvisomant), a human growth hormone receptor antagonist for the treatment of acromegaly. We currently manufacture our 13 proprietary PEGylation reagent for Pfizer on a price per gram basis. The agreement expires on the later of ten years from the grant of first marketing authorization in the designated territory, which occurred in March 2003, or the expiration of our last relevant patent containing a valid claim. In addition, Pfizer may terminate the agreement if marketing authorization is withdrawn or marketing is no longer feasible due to certain circumstances, and either party may terminate for cause if certain conditions are met. PEG-Intron®, Agreement with Merck (formerly Schering-Plough Corporation) In February 2000, we entered into a manufacturing and supply agreement with Schering-Plough Corporation (Schering) for the manufacture and supply of our proprietary PEGylation materials to be used by Schering in production of a pegylated recombinant human interferon-alpha (PEG-Intron). PEG-Intron is a treatment for patients with Hepatitis C. We currently manufacture our proprietary PEGylation materials for Schering on a price per gram basis. The agreement is for a fixed duration with renewal terms conditioned upon mutual agreement. We have sent notice that we do not intend to renew this agreement and under the terms of the agreement it expires in 2011. Macugen®, Agreement with Eyetech Inc. In 2002, we entered into a license, manufacturing and supply agreement with Eyetech Inc. (Eyetech) in 2005, pursuant to which we license our proprietary PEGylation technology for the development and commercialization of Macugen®, a PEGylated anti- vascular endothelial growth factor aptamer currently approved in the U.S. and E.U. for use in treating age-related macular degeneration. We currently manufacture our proprietary PEGylation materials for Eyetech on a price per gram basis. Under the terms of the agreement, we will receive royalties on net product sales in any particular country covered by a valid patent claim for the longer of ten years from the date of the first commercial sale of the product in that country or the manufacture, use or sale of such product in that country. We share a portion of the payments received under this agreement with Enzon. The agreement expires upon the expiration of our last relevant patent containing a valid claim. In addition, Eyetech may terminate the agreement if marketing authorization is withdrawn or marketing is no longer feasible due to certain circumstances, and either party may terminate for cause if certain conditions are met. CIMZIA™, Agreement with UCB Pharma In December 2000, we entered into a license, manufacturing and supply agreement for CIMZIA™ (certolizumab pegol, CDP870) with Celltech Chiroscience Ltd., which was acquired by UCB Pharma (UCB) in 2004. Under the terms of the agreement, UCB is responsible for all clinical development, regulatory, and commercialization expenses. We have the right to receive manufacturing revenue on a cost-plus basis and royalties on net product sales. We are entitled to receive royalties on net sales of the CIMZIA™ product in any particular country for the longer of ten years from the first commercial sale of the product in that country or the expiration of patent rights in that particular country. We share a portion of the payments we receive from UCB with Enzon. CIMZIA™ is currently approved in the treatment of Crohn’s Disease in the U.S and the treatment of rheumatoid arthritis in EMEA. UCB is also conducting Phase 2 clinical trials on CIMZIA™ for psoriasis. The agreement expires upon the expiration of all of UCB’s royalty obligations, provided that the agreement can be extended for successive two year renewal periods upon mutual agreement of the parties. In addition, UCB may terminate the agreement should it cease the development and marketing of CIMZIA™ and either party may terminate for cause under certain conditions. MIRCERA® (C.E.R.A.) (Continuous Erythropoietin Receptor Activator), Agreement with F. Hoffmann-La Roche Ltd In December 2000, we entered into a license, manufacturing and supply agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche), which was amended and restated in its entirety in December 2005. Pursuant to the agreement, we license our proprietary PEGylation materials for use in the development and manufacture of Roche’s MIRCERA product. MIRCERA is a novel continuous erythropoietin receptor activator indicated for the treatment of anemia associated with chronic kidney disease in patients on dialysis and patients not on dialysis. We are entitled to receive royalties on net sales of the MIRCERA product in any particular country for the longer of ten years from the first commercial sale of the product in that country or the expiration of patent rights in that particular country. The agreement expires upon the expiration of all of Roche’s royalty obligations, unless earlier terminated by Roche for convenience or by either party for cause under certain conditions. 14 In May 2007, MIRCERA was approved in the EU and the product was subsequently launched by Roche in the EU in August of 2007. In November 2007, the FDA approved Roche’s Biologics License Application (BLA) for MIRCERA but the product has not been launched in the U.S. as a result of patent-related issues. In October 2008, a federal district court ruled in favor of Amgen Inc. in a patent infringement lawsuit involving MIRCERA and issued a permanent injunction which prevents Roche from marketing or selling MIRCERA in the U.S. even though the FDA approved MIRCERA. In December 2009, the U.S. District Court for the District of Massachusetts entered a final judgment and permanent injunction and Roche and Amgen entered into a settlement and limited license agreement which allows Roche to begin selling MIRCERA in the U.S. in July 2014. Significant Developments in our Business that Occurred in 2008 Exit from the Inhaled Insulin Programs In 1995, we entered into a collaborative development and licensing agreement with Pfizer to develop and market Exubera® and, in 2006 and 2007, we entered into a series of interim letter agreements with Pfizer to develop a next generation form of dry powder inhaled insulin and proprietary inhaler device, also known as NGI. In January 2006, Exubera received marketing approval in the U.S. and EU for the treatment of adults with Type 1 and Type 2 diabetes. Under the collaborative development and licensing agreement, Pfizer had sole responsibility for marketing and selling Exubera. We performed all of the manufacturing of the Exubera dry powder insulin, and we supplied Pfizer with the Exubera inhalers through third party contract manufacturers (Bespak Europe Ltd. and Tech Group, Inc.). Our total revenue from Pfizer was nil, nil and $189.1 million, representing 0%, 0% and 64% of total revenue, for the years ended December 31, 2009, 2008, and 2007, respectively. On October 18, 2007, Pfizer announced that it was exiting the Exubera business and gave notice of termination under our collaborative development and licensing agreement. On November 9, 2007, we entered into a termination agreement and mutual release with Pfizer. Under this agreement we received a one-time payment of $135.0 million in November 2007 from Pfizer in satisfaction of all outstanding contractual obligations under our then-existing agreements relating to Exubera and NGI. All agreements between Pfizer and us related to Exubera and NGI, other than the termination agreement and mutual release and a related interim Exubera manufacturing maintenance letter, terminated on November 9, 2007. In February 2008, we entered into a termination agreement with Bespak and Tech Group pursuant to which we paid an aggregate of $39.9 million in satisfaction of outstanding accounts payable and termination costs and expenses that were due under the Exubera inhaler contract manufacturing agreement. We also entered into a maintenance agreement with both Pfizer and Tech Group to preserve key personnel and manufacturing capacity to support potential future Exubera inhaler manufacturing if we found a new partner for the inhaled insulin program. On April 9, 2008, we announced that we had ceased all negotiations with potential partners for Exubera and NGI as a result of new data analysis from ongoing clinical trials conducted by Pfizer which indicated an increase in the number of new cases of lung cancer in Exubera patients who were former smokers as compared to patients in the control group who were not former smokers. In April 2008, we ceased all spending associated with maintaining Exubera manufacturing capacity and any further NGI development, including, but not limited to, terminating the Exubera manufacturing capacity maintenance arrangements with Pfizer and Tech Group. Asset Sale to Novartis On December 31, 2008, we completed the sale of certain assets related to our pulmonary business, associated technology and intellectual property to Novartis Pharma AG and Novartis Pharmaceuticals Corporation (together referred to as Novartis) for a purchase price of $115.0 million in cash (Novartis Pulmonary Asset Sale). Under the terms of the transaction, we transferred to Novartis certain assets and obligations related to our pulmonary technology, development and manufacturing operations including: (cid:129) (cid:129) dry powder and liquid pulmonary technology platform including but not limited to our pulmonary inhalation devices, formulation technology, manufacturing technology and related intellectual property; capital equipment, information systems and facility lease obligations for our pulmonary development and manufacturing facility in San Carlos, California; (cid:129) manufacturing and associated development services payments for the Cipro Inhale program; 15 (cid:129) manufacturing and royalty rights to the Tobramycin Inhalation Powder (TIP) program through the termination of our collaboration agreement with Novartis; certain other interests that we had in two private companies; and approximately 140 of our personnel primarily dedicated to our pulmonary technology, development programs, and manufacturing operations. (cid:129) (cid:129) In consideration for the transfer of the above described pulmonary assets, we received $115.0 million in cash on December 31, 2008. In addition, we retained all of our rights to BAY41-6551, partnered with Bayer Healthcare LLC, certain royalty rights for the Cipro Inhale development program partnered with Bayer Schering Pharma AG, and certain intellectual property rights specific to inhaled insulin. In connection with the Novartis Pulmonary Asset Sale, we also entered into an Exclusive License Agreement with Novartis Pharma. Pursuant to the Exclusive License Agreement, Novartis Pharma granted back to us an exclusive, irrevocable, perpetual, non-transferable, royalty-free and worldwide license under certain specific patent rights and other related intellectual property rights acquired by Novartis Pharma from Nektar in the transaction, as well as certain improvements or modifications thereto that are made by Novartis Pharma after the closing. Certain of such patent rights and other related intellectual property rights relate to our development program for NKTR-063 or are necessary for us to satisfy certain of our continuing contractual obligations to third parties, including in connection with development, manufacture, sale, and commercialization activities related to BAY41-6551. We also entered into a service agreement pursuant to which we have subcontracted to Novartis certain services to be performed related to our partnered program for BAY41-6551 and a transition services agreement pursuant to which Novartis and we will provide each other with specified services for limited time periods following the closing of the Novartis Pulmonary Asset Sale to facilitate the transition of the acquired assets and business from us to Novartis. Research and Development Our total Research and development expenditures can be disaggregated into the following significant types of expenses (in millions): Salaries and employee benefits Stock compensation expense Facility and equipment Outside services, including Contract Research Organizations Supplies, including clinical trial materials Travel, lodging, and meals Other Research and development Manufacturing and Supply Years ended December 31, 2009 2008 2007 $ $ 29.4 3.6 9.9 38.9 10.4 1.7 1.2 $ 58.4 4.6 25.9 40.2 19.0 3.3 3.0 70.7 6.3 33.9 26.8 10.8 2.2 2.9 $ 95.1 $ 154.4 $ 153.6 We have a manufacturing facility located in Huntsville, Alabama related to our PEGylation and advanced polymer conjugate technologies. This facility is capable of manufacturing PEGylation derivatives and starting materials for active pharmaceutical ingredients (APIs). The facility is also used to produce APIs for clinical development for our proprietary product candidates that utilize our PEGylation and advanced polymer conjugate technology. The facility and associated equipment is designed and operated to be in compliance with the guidelines of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) applicable to APIs (ICH Q7A guidelines). We source drug starting materials for our manufacturing activities from one or more suppliers. If we are responsible for manufacturing activities under a collaboration arrangement, we typically source drug starting materials from the collaboration partner. 16 For the drug starting materials necessary for our proprietary drug candidate development, we have agreements for the supply of such drug components with drug suppliers that we believe have sufficient capacity to meet our demands. However, from time to time, we source critical raw materials from one or a limited number of suppliers and there is a risk that if such supply were interrupted, it would materially harm our business. In addition, we typically order raw materials on a purchase order basis and do not enter into long-term dedicated capacity or minimum supply arrangements. Prior to the closing of the Novartis Pulmonary Asset Sale on December 31, 2008, we operated a drug powder manufacturing and packaging facility in San Carlos, California capable of producing drug powders in quantities sufficient for clinical trials of product candidates utilizing our pulmonary technology. As part of the Novartis Pulmonary Asset Sale, we transferred this manufacturing facility and the related operations, and Novartis hired approximately 140 of the related supporting personnel, as of December 31, 2008. Government Regulation The research and development, clinical testing, manufacture and marketing of products using our technologies are subject to regulation by the FDA and by comparable regulatory agencies in other countries. These national agencies and other federal, state and local entities regulate, among other things, research and development activities and the testing (in vitro, in animals, and in human clinical trials), manufacture, labeling, storage, recordkeeping, approval, marketing, advertising and promotion of our products. The approval process required by the FDA before a product using any of our technologies may be marketed in the U.S. depends on whether the chemical composition of the product has previously been approved for use in other dosage forms. If the product is a new chemical entity that has not been previously approved, the process includes the following: (cid:129) (cid:129) (cid:129) (cid:129) extensive preclinical laboratory and animal testing; submission of an Investigational New Drug application (IND) prior to commencing clinical trials; adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug for the intended indication; and submission to the FDA of an NDA for approval of a drug, a BLA for approval of a biological product or a Premarket Approval Application (PMA) or Premarket Notification 510(k) for a medical device product (a 510(k)). If the active chemical ingredient has been previously approved by the FDA, the approval process is similar, except that certain preclinical tests relating to systemic toxicity normally required for the IND and NDA or BLA may not be necessary if the company has a right of reference to such data or is eligible for approval under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. Preclinical tests include laboratory evaluation of product chemistry and animal studies to assess the safety and efficacy of the product and its chosen formulation. Preclinical safety tests must be conducted by laboratories that comply with FDA good laboratory practices (GLP) regulations. The results of the preclinical tests for drugs, biological products and combination products subject to the primary jurisdiction of the FDA’s Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) are submitted to the FDA as part of the IND and are reviewed by the FDA before clinical trials can begin. Clinical trials may begin 30 days after receipt of the IND by the FDA, unless the FDA raises objections or requires clarification within that period. Clinical trials involve the administration of the drug to healthy volunteers or patients under the supervision of a qualified, identified medical investigator according to a protocol submitted in the IND for FDA review. Drug products to be used in clinical trials must be manufactured according to current good manufacturing practices (cGMP). Clinical trials are conducted in accordance with protocols that detail the objectives of the study and the parameters to be used to monitor participant safety and product efficacy as well as other criteria to be evaluated in the study. Each protocol is submitted to the FDA in the IND. Apart from the IND process described above, each clinical study must be reviewed by an independent Institutional Review Board (IRB) and the IRB must be kept current with respect to the status of the clinical study. The IRB considers, among other things, ethical factors, the potential risks to subjects participating in the trial and the possible liability to the institution where the trial is conducted. The IRB also reviews and approves the informed consent form to be signed by the trial participants and any significant changes in the clinical study. 17 Clinical trials are typically conducted in three sequential phases. Phase 1 involves the initial introduction of the drug into healthy human subjects (in most cases) and the product generally is tested for tolerability, pharmacokinetics, absorption, metabolism and excretion. Phase 2 involves studies in a limited patient population to: (cid:129) (cid:129) (cid:129) determine the preliminary efficacy of the product for specific targeted indications; determine dosage and regimen of administration; and identify possible adverse effects and safety risks. If Phase 2 trials demonstrate that a product appears to be effective and to have an acceptable safety profile, Phase 3 trials are undertaken to evaluate the further clinical efficacy and safety of the drug and formulation within an expanded patient population at geographically dispersed clinical study sites and in large enough trials to provide statistical proof of efficacy and tolerability. The FDA, the clinical trial sponsor, the investigators or the IRB may suspend clinical trials at any time if any one of them believes that study participants are being subjected to an unacceptable health risk. In some cases, the FDA and the drug sponsor may determine that Phase 2 trials are not needed prior to entering Phase 3 trials. Following a series of formal and informal meetings between the drug sponsor and the regulatory agencies, the results of product development, preclinical studies and clinical studies are submitted to the FDA as an NDA or BLA for approval of the marketing and commercial shipment of the drug product. The FDA may deny approval if applicable regulatory criteria are not satisfied or may require additional clinical or pharmaceutical testing or requirements. Even if such data are submitted, the FDA may ultimately decide that the NDA or BLA does not satisfy all of the criteria for approval. Additionally, the approved labeling may narrowly limit the conditions of use of the product, including the intended uses, or impose warnings, precautions or contraindications which could significantly limit the potential market for the product. Further, as a condition of approval, the FDA may impose post-market surveillance, or Phase 4, studies or risk management programs. Product approvals, once obtained, may be withdrawn if compliance with regulatory standards is not maintained or if safety concerns arise after the product reaches the market. The FDA may require additional post-marketing clinical testing and pharmacovigilance programs to monitor the effect of drug products that have been commercialized and has the power to prevent or limit future marketing of the product based on the results of such programs. After approval, there are ongoing reporting obligations concerning adverse reactions associated with the product, including expedited reports for serious and unexpected adverse events. Each manufacturer of drug product for the U.S. market must be registered with the FDA and typically is inspected by the FDA prior to NDA or BLA approval of a drug product manufactured by such establishment. Establishments handling controlled substances must also be licensed by the U.S. Drug Enforcement Administration. Manufacturing establishments of U.S. marketed products are subject to inspections by the FDA for compliance with cGMP and other U.S. regulatory requirements. They are also subject to U.S. federal, state, and local regulations regarding workplace safety, environmental protection and hazardous and controlled substance controls, among others. A number of the drugs we are developing are already approved for marketing by the FDA in another form or using another delivery system. We believe that, when working with drugs approved in other forms, the approval process for products using our alternative drug delivery or formulation technologies may involve less risk and require fewer tests than new chemical entities do. However, we expect that our formulations will often use excipients not currently approved for use. Use of these excipients will require additional toxicological testing that may increase the costs of, or length of time needed to, gain regulatory approval. In addition, as they relate to our products, regulatory procedures may change as regulators gain relevant experience, and any such changes may delay or increase the cost of regulatory approvals. For product candidates currently under development utilizing pulmonary technology, the pulmonary inhaler devices are considered to be part of a drug and device combination for deep lung delivery of each specific molecule. The FDA will make a determination as to the most appropriate center and division within the agency that will assume prime responsibility for the review of the applicable applications, which would consist of an IND and an NDA or BLA where CDER or CBER are determined to have primary jurisdiction or an investigational device exemption application and PMA or 510(k) where the Center for Devices and Radiological Health (CDRH) is determined to have primary jurisdiction. In the case of our product candidates, CDER in consultation with CDRH could be involved in the review. The assessment of jurisdiction within the FDA is based upon the primary mode of action of the drug or the location of the specific expertise in one of the centers. 18 Where CDRH is determined to have primary jurisdiction over a product, 510(k) clearance or PMA approval is required. Medical devices are classified into one of three classes—Class I, Class II, or Class III—depending on the degree of risk associated with each medical device and the extent of control needed to ensure safety and effectiveness. Devices deemed to pose lower risks are placed in either Class I or II, which requires the manufacturer to submit to the FDA a Premarket Notification requesting permission to commercially distribute the device. This process is known as 510(k) clearance. Some low risk devices are exempted from this requirement. Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a previously cleared 510(k) device are placed in Class III, requiring PMA approval. To date, our partners have generally been responsible for clinical and regulatory approval procedures, but we may participate in this process by submitting to the FDA a drug master file developed and maintained by us which contains data concerning the manufacturing processes for the inhaler device or drug. For our proprietary products, we prepare and submit an IND and are responsible for additional clinical and regulatory procedures for product candidates being developed under an IND. The clinical and manufacturing development and regulatory review and approval process generally takes a number of years and requires the expenditure of substantial resources. Our ability to manufacture and market products, whether developed by us or under collaboration agreements, ultimately depends upon the completion of satisfactory clinical trials and success in obtaining marketing approvals from the FDA and equivalent foreign health authorities. Sales of our products outside the U.S. are subject to local regulatory requirements governing clinical trials and marketing approval for drugs. Such requirements vary widely from country to country. In the U.S., under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the U.S. The company that obtains the first FDA approval for a designated orphan drug for a rare disease receives marketing exclusivity for use of that drug for the designated condition for a period of seven years. In addition, the Orphan Drug Act provides for protocol assistance, tax credits, research grants, and exclusions from user fees for sponsors of orphan products. Once a product receives orphan drug exclusivity, a second product that is considered to be the same drug for the same indication may be approved during the exclusivity period only if the second product is shown to be “clinically superior” to the original orphan drug in that it is more effective, safer or otherwise makes a “major contribution to patient care” or the holder of exclusive approval cannot assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. In the U.S., the FDA may grant Fast Track designation to a product candidate, which allows the FDA to expedite the review of new drugs that are intended for serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. An important feature of Fast Track designation is that it emphasizes the critical nature of close, early communication between the FDA and the sponsor company to improve the efficiency of product development. Patents and Proprietary Rights We invest a significant portion of our resources in the creation and development of new drug compounds that serve unmet needs in the treatment of patients. In doing so, we create intellectual property. As part of our strategy to secure our intellectual property created by these efforts, we routinely apply for patents, rely on trade secret protection, and enter into contractual obligations with third parties. When appropriate, we will defend our intellectual property, taking any and all legal remedies available to us, including, for example, asserting patent infringement, trade secret misappropriation and breach of contract claims. As of January 1, 2010, we owned approximately 100 U.S. and 380 foreign patents. Currently, we have over approximately 100 patent applications pending in the U.S. and 480 pending in other countries. A focus area of our current drug creation and development efforts centers on our innovations in and improvements to our PEGylation and advanced polymer conjugate technology platforms. In this area, our patent portfolio contains patents and patent applications that encompass our PEGylation and advanced polymer conjugate technology platforms, some of which we acquired in our acquisition of Shearwater Corporation in June 2001. More specifically, our patents and patent applications cover polymer architecture, drug conjugates, formulations, methods of making polymers and polymer conjugates, and methods of administering polymer conjugates. Our patent strategy is to file patent applications on innovations and improvements to cover a significant majority of the major pharmaceutical markets in the world. Generally, patents have a term of twenty years from the earliest priority date (assuming all maintenance fees are paid). In some instances, patent terms can be increased or decreased, depending on the laws and regulations of the country or jurisdiction that issued that patent. 19 In January 2002, we entered into a Cross-License and Option Agreement with Enzon Pharmaceuticals, Inc., pursuant to which we and Enzon provided certain licenses to selected portions of each party’s PEGylation patent portfolio. In certain cases, we have the option to license certain of Enzon’s PEGylation patents for use in our proprietary products or for sublicenses to third parties in each case in exchange for payments to Enzon based on manufacturing profits, revenue share or royalties on net sales if a designated product candidate is approved in one or more markets. In connection with the Novartis Pulmonary Asset Sale, as of December 31, 2008, we entered into an exclusive license agreement with Novartis Pharma. Pursuant to the exclusive license agreement, Novartis Pharma grants back to us an exclusive, irrevocable, perpetual, royalty-free and worldwide license under certain specific patent rights and other related intellectual property rights acquired by Novartis from us in the Novartis Pulmonary Asset Sale, as well as certain improvements or modifications thereto that are made by Novartis. Certain of such patent rights and other related intellectual property rights relate to our development program for NKTR-063 or are necessary for us to satisfy certain continuing contractual obligations to third parties, including in connection with development, manufacture, sale, and commercialization activities related to BAY41-6551 partnered with Bayer Healthcare LLC. The patent positions of pharmaceutical and biotechnology companies, including ours, involve complex legal and factual issues. There can be no assurance that the patents we apply for will be issued to us or that the patents that are issued to us will be held valid and enforceable in a court of law. Even for patents that are enforceable, we anticipate that any attempt to enforce our patents would be time consuming and costly. Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued. As a consequence, we do not know whether any of our pending patent applications will be granted with broad coverage or whether the claims that eventually issue, or those that have issued, will be circumvented. Since publication of discoveries in scientific or patent literature often lag behind actual discoveries, we cannot be certain that we were the first inventor of inventions covered by our patents or patent applications or that we were the first to file patent applications for such inventions. Moreover, we may have to participate in interference proceedings in the U.S. Patent and Trademark Office, which could result in substantial cost to us, even if the eventual outcome is favorable. An adverse outcome could subject us to significant liabilities to third parties, require disputed rights to be licensed from or to third parties or require us to cease using the technology in dispute. Please refer to Item 1A, Risk Factors, including but not limited to “We may not be able to obtain intellectual property licenses related to the development of our technology on a commercially reasonable basis, if at all,” and “If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.” U.S. and foreign patent rights and other proprietary rights exist that are owned by third parties and relate to pharmaceutical compositions and reagents, medical devices and equipment and methods for preparation, packaging and delivery of pharmaceutical compositions. We cannot predict with any certainty which, if any, of these rights will be considered relevant to our technology by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. We could incur substantial costs in defending ourselves and our partners against any such claims. Furthermore, parties making such claims may be able to obtain injunctive or other equitable relief, which could effectively block our ability to develop or commercialize some or all of our products in the U.S. and abroad and could result in the award of substantial damages. In the event of a claim of infringement, we or our partners may be required to obtain one or more licenses from third parties. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternative technology. The failure to obtain licenses if needed may have a material adverse effect on our business, results of operations and financial condition. We also rely on trade secret protection for our confidential and proprietary information. No assurance can be given that we can meaningfully protect our trade secrets. Others may independently develop substantially equivalent confidential and proprietary information or otherwise gain access to, or disclose, our trade secrets. In certain situations in which we work with drugs covered by one or more patents, our ability to develop and commercialize our technologies may be affected by limitations in our access to these proprietary drugs. Even if we believe we are free to work with a proprietary drug, we cannot guarantee we will not be accused of, or determined to be, infringing a third party’s rights and be prohibited from working with the drug or found liable for damages. Any such restriction on access or liability for damages would have a material adverse effect on our business, results of operations and financial condition. It is our policy to require our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who receive confidential information from us to execute confidentiality agreements upon the commencement of employment or 20 consulting relationships with us. These agreements provide that all confidential information developed or made known to the individual during the course of the individual’s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. The agreements provide that all inventions conceived by an employee shall be our property. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information. Our revenue is derived from our collaboration agreements with partners, under which we may receive contract research payments, milestone payments based on clinical progress, regulatory progress or net sales achievements, royalties or manufacturing revenue. AstraZeneca AB and UCB Pharma represented 35% and 17%, respectively, of our total revenue during the year ended December 31, 2009. No other collaboration partner accounted for more than 10% of our total revenue during the year ended December 31, 2009. If we are unable to continue to develop and protect proprietary intellectual property and license our technologies to partners, our business, results of operations and financial condition could suffer. Backlog In our partnered programs where we manufacture and supply our proprietary drug formulations, inventory is produced and sales are made pursuant to customer purchase orders for delivery. The volume of drug formulation actually purchased by our customers, as well as shipment schedules, are subject to frequent revisions that reflect changes in both the customers’ needs and product availability. In our partnered programs where we provide contract research services, those services are typically provided under a work plan that is subject to frequent revisions that change based on the development needs and status of the program. The backlog at a particular time is affected by a number of factors, including scheduled date of manufacture and delivery and development program status. In light of industry practice and our own experience, we do not believe that backlog as of any particular date is indicative of future results. Competition Competition in the pharmaceutical and biotechnology industry is intense and characterized by aggressive research and development and rapidly-evolving science, technology, and standards of medical care throughout the world. We frequently compete with pharmaceutical companies and other institutions with greater financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies. Science and Technology Competition We believe that our proprietary and partnered products will compete with others in the market on the basis of one or more of the following parameters: efficacy, safety, ease of use and cost. We face intense science and technology competition from a multitude of technologies seeking to enhance the efficacy, safety and ease of use of approved drugs and new drug molecule candidates. A number of the products in our pipeline have direct and indirect competition from large pharmaceutical companies and biopharmaceutical companies. With our PEGylation and advanced polymer conjugate technologies, we believe we have competitive advantages relating to factors such as efficacy, safety, ease of use and cost for certain applications and molecules. We constantly monitor scientific and medical developments in order to improve our current technologies, seek licensing opportunities where appropriate, and determine the best applications for our technology platforms. In the fields of PEGylation and advanced polymer conjugate technologies, our competitors include The Dow Chemical Company, Enzon Pharmaceuticals, Inc., SunBio Corporation, Novo Nordisk A/S (formerly assets held by Neose Technologies, Inc.), Mountain View Pharmaceuticals, Inc., and NOF Corporation. Several other chemical, biotechnology and pharmaceutical companies may also be developing PEGylation technology, advanced polymer conjugate technology or technologies intended to deliver similar scientific and medical benefits. Some of these companies license or provide the technology to other companies, while others develop the technology for internal use. 21 Product and Program Specific Competition Oral NKTR-118 (oral PEGylated naloxol) There are no oral drugs approved specifically for the treatment of opioid-induced constipation (OIC) or opioid bowel dysfunction (OBD). The only approved treatment for OIC is a subcutaneous treatment known as methylnaltrexone bromide marketed by Pfizer (formerly Wyeth). Other current therapies that are utilized to treat OIC and OBD include over-the-counter laxatives and stool softeners, such as docusate sodium, senna, and milk of magnesia. These therapies do not address the underlying cause of constipation as a result of opioid use and are generally viewed as ineffective or only partially effective to treat the symptoms of OID and OBD. There are a number of companies developing potential products which are in various stages of clinical development and are being evaluated for the treatment of OIC and OBD in different patient populations. Potential competitors include Progenics Pharmaceuticals, Inc., Pfizer (formerly Wyeth), Adolor Corporation, GlaxoSmithKline, Mundipharma Int. Limited, Sucampo Pharmaceuticals, Alkermes and Takeda Pharmaceutical Company Limited. NKTR-102 (PEGylated irinotecan) There are a number of chemotherapies and cancer therapies approved today and in various stages of clinical development for ovarian and breast cancers including but not limited to: Avastin® (bevacizumab), Camptosar® (irinotecan), Ellence® (epirubicin), Gemzar® (gemcitabine), Herceptin® (trastuzumab), Hycamtin® (topotecan), Paraplatin® (carboplatin), and Taxol® (paclitaxel). These therapies are only partially effective in treating ovarian, breast or cervical cancers. Major pharmaceutical or biotechnology companies with approved drugs or drugs in development for these cancers include Bristol-Meyers Squibb, Genentech, Inc., GlaxoSmithKline plc, Pfizer, Inc., Eli Lilly & Co., and many others. There are also a number of chemotherapies and cancer therapies approved today and in clinical development for the treatment of colorectal cancer. Approved therapies for the treatment of colorectal cancer include Eloxatin, Camptosar, Avastin, Erbitux, Vectibix, Xeloda, Adrucil, and Wellcovorin. These therapies are only partially effective in treating the disease. There are a number of drugs in various stages of preclinical and clinical development from companies exploring cancer therapies or improved chemotherapeutic agents to potentially treat colorectal cancer. If these drugs are approved, they could be competitive with NKTR-102. These include products in development from Bristol-Myers Squibb Company, Pfizer, Inc., GlaxoSmithKline plc, Antigenics, Inc., F. Hoffman-La Roche Ltd, Novartis AG, Cell Therapeutics, Inc., Neopharm Inc., Meditech Research Ltd, Alchemia Limited, Enzon Pharmaceuticals, Inc., and others. BAY41-6551 (NKTR-061, Amikacin Inhale) There are currently no approved drugs on the market for adjunctive treatment or prevention of Gram-negative pneumonias in mechanically ventilated patients which are also administered via the pulmonary route. The current standard of care includes approved intravenous antibiotics which are partially effective for the treatment of either hospital-acquired pneumonia or ventilator-associated pneumonia in patients on mechanical ventilators. These drugs include drugs that fall into the categories of antipseudomonal cephalosporins, antipseudomonal carbepenems, beta-lactam/beta-lactamase inhibitors, antipseudomonal fluoroquinolones, such as ciprofloxacin or levofloxacin, and aminoglycosides, such as amikacin, gentamycin or tobramycin. Environment As a manufacturer of drug products for the U.S. market, we are subject to inspections by the FDA for compliance with cGMP and other U.S. regulatory requirements, including U.S. federal, state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others. Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time. We have incurred, and may continue to incur, significant expenditures to ensure we are in compliance with these laws and regulations. We would be subject to significant penalties for failure to comply with these laws and regulations. 22 Employees and Consultants As of December 31, 2009, we had 335 employees, of which 239 employees were engaged in research and development, commercial operations and quality activities and 96 employees were engaged in general administration and business development. Of the 335 employees, 279 were located in the United States and 56 were located in India as of December 31, 2009. We have a number of employees who hold advanced degrees, such as Ph.D.s. None of our employees are covered by a collective bargaining agreement, and we have experienced no work stoppages. We believe that we maintain good relations with our employees. To complement our own expert professional staff, we utilize specialists in regulatory affairs, process engineering, manufacturing, quality assurance, clinical development and business development. These individuals include certain of our scientific advisors as well as independent consultants. Available Information Our website address is http://www.nektar.com. The information in, or that can be accessed through, our website is not part of this annual report on Form 10-K. Our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K and amendments to those reports are available, free of charge, on or through our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities Exchange Commission (SEC). The public may read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. Information on the operation of the Public Reference Room can be obtained by calling 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements and other information regarding our filings at www.sec.gov. 23 EXECUTIVE OFFICERS OF THE REGISTRANT The following table sets forth the names, ages and positions of our executive officers as of February 28, 2010: Name Age Position Howard W. Robin John Nicholson Bharatt M. Chowrira, Ph.D., J.D. Lorianne K. Masuoka, M.D. Stephen K. Doberstein, Ph.D. Gil M. Labrucherie, J.D. Jillian B. Thomsen 57 Director, President and Chief Executive Officer 58 44 48 51 38 44 Senior Vice President and Chief Financial Officer Senior Vice President and Chief Operating Officer Senior Vice President and Chief Medical Officer Senior Vice President and Chief Scientific Officer Senior Vice President, General Counsel and Secretary Senior Vice President and Chief Accounting Officer Howard W. Robin has served as our Director, President and Chief Executive Officer since January 2007 and was appointed as a member of our Board of Directors in February 2007. Mr. Robin served as Chief Executive Officer, President and director of Sirna Therapeutics, Inc., a clinical-stage biotechnology company pioneering RNAi-based therapies for serious diseases and conditions, from July 2001 to November 2006 and served as their Chief Operating Officer, President and Director from January 2001 to June 2001. From 1991 to 2001, Mr. Robin was Corporate Vice President and General Manager at Berlex Laboratories, Inc., the U.S. pharmaceutical subsidiary of the German pharmaceutical firm Schering AG, and, from 1987 to 1991, he served as their Vice President of Finance and Business Development and Chief Financial Officer. From 1984 to 1987, Mr. Robin was Director of Business Planning and Development at Berlex and was a Senior Associate with Arthur Andersen LLP prior to joining Berlex. Since February 2006, Mr. Robin has served as a member of the Board of Directors of Acologix, Inc., a biopharmaceutical company focused on therapeutic compounds for the treatment of osteo-renal diseases. He received his B.S. in Accounting and Finance from Fairleigh Dickinson University in 1974. John Nicholson has served as our Senior Vice President and Chief Financial Officer since December 2007. Mr. Nicholson joined the Company as Senior Vice President of Corporate Development and Business Operations in October 2007 and was appointed Senior Vice President and Chief Financial Officer in December 2007. Before joining Nektar, Mr. Nicholson spent 18 years in various executive roles at Schering Berlin, Inc., the U.S. management holding company of Bayer Schering Pharma AG, a pharmaceutical company. From 1997 to September 2007, Mr. Nicholson served as Schering Berlin Inc.’s Vice President of Corporate Development and Treasurer. From 2001 to September 2007, he concurrently served as President of Schering Berlin Insurance Co., and from February 2007 through September 2007, he also concurrently served as President of Bayer Pharma Chemicals and Schering Berlin Capital Corp. Mr. Nicholson holds a B.B.A. from the University of Toledo. Bharatt M. Chowrira, Ph.D., J.D. has served as our Senior Vice President and Chief Operating Officer since May 2008, as well as Chairman of Nektar Therapeutics India Pvt. Ltd. From January 2007 until May 2008, Dr. Chowrira, served as Executive Director, Licensing / External Research at Merck & Co., Inc., a global pharmaceutical company. From January 2005 through 2006, Dr. Chowrira served as Chief Patent Counsel and Vice President, Legal Affairs of Sirna Therapeutics, Inc., a clinical-stage biotechnology company pioneering RNAi-based therapies for serious diseases and conditions that was acquired by Merck & Co. in January 2007. In that position, Dr. Chowrira was responsible for all legal and business licensing activities and general corporate matters. From January 2002 until December 2004, Dr. Chowrira was Vice President of Legal Affairs, Licensing and Patent Counsel at Sirna Therapeutics. Dr. Chowrira joined Sirna Therapeutics (then operating as Ribozyme Pharmaceuticals Inc.) in 1993 as a scientist. Dr. Chowrira holds a J.D. from the College of Law at the University of Denver and a Ph.D. in Microbiology and Molecular Genetics from the University of Vermont. Dr. Chowrira is a member of the Colorado Bar Association, admitted to practice in California as a registered in-house counsel, and is a registered patent attorney before the U.S. Patent and Trademark Office. He is also a member of the American Intellectual Property Law Association, Licensing Executive Society and the Association of Corporate Counsel. Lorianne K. Masuoka, M.D. has served as our Senior Vice President and Chief Medical Officer since November 30, 2009, and prior to that served as our Vice President of Clinical Development from August 2008 to June 2009. From 2003 until August 2008, Dr. Masuoka served as Vice President of Clinical Development at privately held Five Prime Therapeutics, a clinical stage biotechnology company. From 2000 until 2003, she was Director of Oncology at Chiron Corporation, a multi-national biotechnology firm, acquired by Novartis International AG in April 2006. From 1994 until 2000, Dr. Masuoka held positions of increasing 24 responsibility in clinical research at Berlex Laboratories, Inc., the U.S. pharmaceutical subsidiary of the German pharmaceutical firm Schering AG. Dr. Masuoka received her B.S. and M.D. from the University of California, Davis, was an American Epilepsy Society Fellow at Yale School of Medicine and is board certified in Neurology. Stephen K. Doberstein, Ph.D. has served as our Senior Vice President and Chief Scientific Officer since January 2010. From October 2008 through December 2009, Mr. Doberstein served as Vice President, Research at Xoma (US) LLC, a publicly traded clinical stage biotechnology company. From July 2004 until August 2008, he served as Vice President, Research at privately held Five Prime Therapeutics, a clinical stage biotechnology company. From September 2001 until July 2004, Mr. Doberstein was Vice President, Research at privately held Xencor, Inc., a clinical stage biotechnology company. From 1997 to 2000, he held various pharmaceutical research positions at Exelixis, Inc., a publicly traded clinical stage biotechnology company. Prior to working at Exelixis, Mr. Doberstein was a Howard Hughes Postdoctoral Fellow and a Muscular Dystrophy Association Senior Postdoctoral Fellow at the University of California Berkeley. Mr. Doberstein received his Ph.D. Biochemistry, Cell and Molecular Biology from the Johns Hopkins University School of Medicine and received a B.S. in Chemical Engineering from the University of Delaware. Gil M. Labrucherie has served as our Senior Vice President, General Counsel and Secretary since April 2007, responsible for all aspects of our legal affairs. Mr. Labrucherie served as our Vice President, Corporate Legal from October 2005 through April 2007. From October 2000 to September 2005, Mr. Labrucherie was Vice President of Corporate Development at E2open. While at E2open, Mr. Labrucherie was responsible for global corporate alliances and merger and acquisition activity. Prior to E2open, he was the Senior Director of Corporate Development at AltaVista Company, an Internet search company, where he was responsible for strategic partnerships and mergers and acquisitions. Mr. Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati and Graham & James (DLA Piper Rudnick). Mr. Labrucherie received his J.D. from the Berkeley Law School and a B.A. from the University of California Davis. Jillian B. Thomsen has served as our Senior Vice President Finance and Chief Accounting Officer since February 2010. From March 2006 through March 2008, Ms. Thomsen served as our Vice President Finance and Corporate Controller and from April 2008 through January 2010 she served as our Vice President Finance and Chief Accounting Officer. Before joining Nektar, Ms. Thomsen was Vice President Finance and Deputy Corporate Controller of Calpine Corporation from September 2002 to February 2006. Ms. Thomsen is a certified public accountant and previously was a senior manager at Arthur Andersen LLP, where she worked from 1990 to 2002, and specialized in audits of multinational consumer products, life sciences, manufacturing and energy companies. Ms. Thomsen holds a Masters of Accountancy from the University of Denver and a B.A. in Business Economics from Colorado College. Item 1A. Risk Factors We are providing the following cautionary discussion of risk factors, uncertainties and possibly inaccurate assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the Exchange Act and Section 27A of the Securities Act. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Risks Related to Our Business Drug development is an inherently uncertain process and there is a high risk of failure at every stage of development and development failures can significantly harm our business. We have a number of proprietary product candidates and partnered product candidates in research and development ranging from the early discovery research phase through preclinical testing and clinical trials. Preclinical testing and clinical trials are long, expensive and a highly uncertain processes. It will take us, or our collaborative partners, several years to complete clinical trials. Drug development is an uncertain scientific and medical endeavor and failure can unexpectedly occur at any stage of clinical development even after early preclinical or mid-stage clinical results suggest that the drug candidate has potential as a new therapy that may benefit patients and health authority approval would be anticipated. Typically, there is a high rate of attrition for product candidates in preclinical and clinical trials due to scientific feasibility, safety, efficacy, changing standards of medical care and other variables. We or our partners have a number of important product candidates in mid- to late-stage development such as Bayer’s Amikacin Inhale, 25 Oral NKTR-118 (oral PEGylated naloxol) and NKTR-119 which we partnered with AstraZeneca, Affymax’s Hematide, and NKTR-102 (PEGylated irinotecan) in a number of oncology indications including breast, colorectal and ovarian cancers. We also have an ongoing Phase 1 clinical trial for NKTR-105 (PEGylated docetaxel) for patients with refractory solid tumors. Any one of these trials could fail at any time as clinical development of drug candidates presents numerous unpredictable risks and is very uncertain at all times prior to regulatory approval by one or more health authorities in major markets. Even with success in preclinical testing and clinical trials, the risk of clinical failure remains high prior to regulatory approval. A number of companies in the pharmaceutical and biotechnology industries have suffered significant unforeseen setbacks in later stage clinical trials (i.e., Phase 2 or Phase 3 trials) due to factors such as inconclusive efficacy results and adverse medical events, even after achieving positive results in earlier trials that were satisfactory both to them and to reviewing regulatory agencies. Although we announced positive Phase 2 clinical results for Oral NKTR-118 (oral PEGylated naloxol) in 2009, there are still substantial risks and uncertainties associated with the future outcome of a Phase 3 clinical trial and the regulatory review process even following the AstraZeneca transaction. While NKTR-102 (PEGylated irinotecan) continues in Phase 2 clinical development for multiple cancer indications, it is possible this product candidate could fail in one or all of the cancer indications in which it is currently being studied due to efficacy, safety or other commercial or regulatory factors. On January 12, 2010, we announced preliminary positive results from stage one of our Phase 2 trial for ovarian cancer patients. These results were based on preliminary data only and such results could change based on final data gathering and analysis review procedures. In addition, the preliminary results from stage 1 of the NKTR-102 clinical study for ovarian cancer is not necessarily indicative or predictive of the future results from stage 2 of this clinical study or the other cancer indication where we are studying NKTR-102. As a result, there remains a significant uncertainty as to the success or failure of NKTR-102 and whether this drug candidate will eventually receive regulatory approval or be a commercial success even if approved by one or more health authorities in any of the cancer indications for which it is being studied. The risk of failure is increased for our product candidates that are based on new technologies, such as the application of our advanced polymer conjugate technology to small molecules, including without limitation Oral NKTR-118, Oral NKTR-119, NKTR-102, NKTR-105 and other drug candidates currently in the discovery research or preclinical development phases. If our PEGylation and advanced polymer conjugate technologies fail to generate new drug candidates with positive clinical trial results and approved drugs, our business, results of operations, and financial condition would be materially harmed. If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer. We intend to continue to seek partnerships with pharmaceutical and biotechnology partners to fund a portion of our research and development expenses and develop and commercialize our product candidates, including NKTR-102. In September 2009, we entered into a license agreement with AstraZeneca for NKTR-118 and NKTR-119 which included an upfront payment of $125.0 million. The completion of the AstraZeneca transaction was critical to our financial results and financial condition for the year ended December 31, 2009. We intend to seek a collaboration partner for NKTR-102 prior to commencing any Phase 3 clinical trials for this drug candidate. Whether we ultimately enter into a collaboration agreement for NKTR-102 will depend on the partnership opportunities available to us. Our ability to successfully conclude a collaboration partnership for NKTR-102 on commercially favorable terms, or at all, will have a significant impact on our business and financial position in 2010. The timing of any future partnership, as well as the terms and conditions of the partnership, will affect our ability to benefit from the relationship. If we are unable to find suitable partners or to negotiate collaborative arrangements with favorable commercial terms with respect to our existing and future product candidates or the licensing of our technology, or if any arrangements we negotiate, or have negotiated, are terminated, our business, results of operations and financial condition could suffer. We may not be able to obtain intellectual property licenses related to the development of our technology on a commercially reasonable basis, if at all. Numerous pending and issued U.S. and foreign patent rights and other proprietary rights owned by third parties relate to pharmaceutical compositions, medical devices and equipment and methods for preparation, packaging and delivery of pharmaceutical compositions. We cannot predict with any certainty which, if any, patent references will be considered relevant to our or our collaborative partners’ technology by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. In certain cases, we have existing licenses or cross- licenses with third parties however the scope and adequacy of these licenses is very uncertain and can change substantially during long development and commercialization cycles for biotechnology and pharmaceutical products. There can be no assurance that we 26 can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternate technology. If we are required to enter into a license with a third party, our potential economic benefit for the products subject to the license will be diminished. The failure to obtain licenses on commercially reasonable terms, or at all, if needed, would have a material adverse effect on us. If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection. The patent positions of pharmaceutical, medical device and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues. We own approximately 100 U.S. and approximately 380 foreign patents and a number of pending patent applications that cover various aspects of our technologies. We have filed patent applications, and plan to file additional patent applications, covering various aspects of our PEGylation and advanced polymer conjugate technologies and our proprietary product candidates. There can be no assurance that patents that have issued will be valid and enforceable or that patents for which we apply will issue with broad coverage, if at all. The coverage claimed in a patent application can be significantly reduced before the patent is issued and, as a consequence, our patent applications may result in patents with narrow coverage. Since publication of discoveries in scientific or patent literature often lags behind the date of such discoveries, we cannot be certain that we were the first inventor of inventions covered by our patents or patent applications. As part of the patent application process, we may have to participate in interference proceedings declared by the U.S. Patent and Trademark Office, which could result in substantial cost to us, even if the eventual outcome is favorable. Further, an issued patent may undergo further proceedings to limit its scope so as not to provide meaningful protection and any claims that have issued, or that eventually issue, may be circumvented or otherwise invalidated. Any attempt to enforce our patents or patent application rights could be time consuming and costly. An adverse outcome could subject us to significant liabilities to third parties, require disputed rights to be licensed from or to third parties or require us to cease using the technology in dispute. Even if a patent is issued and enforceable, because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may expire early and provide only a short period of protection, if any, following commercialization of related products. There are many laws, regulations and judicial decisions that dictate and otherwise influence the manner in which patent applications are filed and prosecuted and in which patents are granted and enforced. Changes to these laws, regulations and judicial decisions are subject to influences outside of our control and may negatively affect our business, including our ability to obtain meaningful patent coverage or enforcement rights to any of our issued patents. New laws, regulations and judicial decisions may be retroactive in effect, potentially reducing or eliminating our ability to implement our patent-related strategies to these changes. Changes to laws, regulations and judicial decisions that affect our business are often difficult or impossible to foresee, which limits our ability to adequately adapt our patent strategies to these changes. The commercial potential of a drug candidate in development is difficult to predict and if the market size for a new drug is significantly smaller than we anticipated, it could significantly and negatively impact our revenue, results of operations and financial condition. It is very difficult to estimate the commercial potential of product candidates due to factors such as safety and efficacy compared to other available treatments, including potential generic drug alternatives with similar efficacy profiles, changing standards of care, third party payer reimbursement, patient and physician preferences, the availability of competitive alternatives that may emerge either during the long drug development process or after commercial introduction, and the availability of generic versions of our successful product candidates following approval by health authorities based on the expiration of regulatory exclusivity or our inability to prevent generic versions from coming to market in one or more geographies by the assertion of one or more patents covering such approved drug. If due to one or more of these risks the market potential for a product candidate is lower than we anticipated, it could significantly and negatively impact the commercial terms of any collaboration partnership potential for such product candidate or, if we have already entered into a collaboration for such drug candidate, the revenue potential from royalty and milestones could be significantly diminished and would negatively impact our revenue, results of operations and financial condition. Our revenue is exclusively derived from our collaboration agreements, which can result in significant fluctuation in our revenue from period to period, and our past revenue is therefore not necessarily indicative of our future revenue. Our revenue is derived from our collaboration agreements with partners, under which we may receive contract research payments, milestone payments based on clinical progress, regulatory progress or net sales achievements, royalties or manufacturing revenue. 27 Significant variations in the timing of receipt of cash payments and our recognition of revenue can result from the nature of significant milestone payments based on the execution of new collaboration agreements, the timing of clinical, regulatory or sales events which result in single milestone payments and the timing and success of the commercial launch of new drugs by our collaboration partners. The amount of our revenue derived from collaboration agreements in any given period will depend on a number of unpredictable factors, including our ability to find and maintain suitable collaboration partners, the timing of the negotiation and conclusion of collaboration agreements with such partners, whether and when we or our partner achieve clinical and sales milestones, whether the partnership is exclusive or whether we can seek other partners, the timing of regulatory approvals in one or more major markets and the market introduction of new drugs or generic versions of the approved drug, as well as other factors. If our partners, on which we depend to obtain regulatory approvals for and to commercialize our partnered products, are not successful, or if such collaborations fail, the development or commercialization of our partnered products may be delayed or unsuccessful. When we sign a collaborative development agreement or license agreement to develop a product candidate with a pharmaceutical or biotechnology company, the pharmaceutical or biotechnology company is generally expected to: (cid:129) (cid:129) design and conduct large scale clinical studies; prepare and file documents necessary to obtain government approvals to sell a given product candidate; and/or (cid:129) market and sell our products when and if they are approved. Our reliance on collaboration partners poses a number of risks to our business, including risks that: (cid:129) we may be unable to control whether, and the extent to which, our partners devote sufficient resources to the development programs or commercial marketing and sales efforts; (cid:129) (cid:129) (cid:129) (cid:129) (cid:129) (cid:129) disputes may arise in the future with respect to the ownership of rights to technology or intellectual property developed with partners; disagreements with partners could lead to delays in, or termination of, the research, development or commercialization of product candidates or to litigation or arbitration proceedings; contracts with our partners may fail to provide us with significant protection, or to be effectively enforced, in the event one of our partners fails to perform; partners have considerable discretion in electing whether to pursue the development of any additional product candidates and may pursue alternative technologies or products either on their own or in collaboration with our competitors; partners with marketing rights may choose to devote fewer resources to the marketing of our partnered products than they do to products of their own development or products in-licensed from other third parties; the timing and level of resources that our partners dedicate to the development program will affect the timing and amount of revenue we receive; (cid:129) we do not have the ability to unilaterally terminate agreements (or partner companies may have extension or renewal rights) that we believe are not on commercially reasonable terms or consistent with our current business strategy; (cid:129) (cid:129) partners may be unable to pay us as expected; and partners may terminate their agreements with us unilaterally for any or no reason, in some cases with the payment of a termination fee penalty and in other cases with no termination fee penalty. 28 Given these risks, the success of our current and future partnerships is highly unpredictable and can have substantial negative or positive impact on our business. We have entered into collaborations in the past that have been subsequently terminated, such as our collaboration with Pfizer for the development and commercialization of inhaled insulin that was terminated by Pfizer in November 2007. If other collaborations are suspended or terminated, our ability to commercialize certain other proposed product candidates could also be negatively impacted. If our collaborations fail, our product development or commercialization of product candidates could be delayed or cancelled, which would negatively impact our business, results of operations and financial condition. If we or our partners do not obtain regulatory approval for our product candidates on a timely basis, if at all, or if the terms of any approval impose significant restrictions or limitations on use, our business, results of operations and financial condition will be negatively affected. We or our partners may not obtain regulatory approval for product candidates on a timely basis, if at all, or the terms of any approval (which in some countries includes pricing approval) may impose significant restrictions or limitations on use. Product candidates must undergo rigorous animal and human testing and an extensive FDA mandated or equivalent foreign authorities’ review process for safety and efficacy. This process generally takes a number of years and requires the expenditure of substantial resources. The time required for completing testing and obtaining approvals is uncertain, and the FDA and other U.S. and foreign regulatory agencies have substantial discretion to terminate clinical trials, require additional clinical development or other testing at any phase of development, delay or withhold registration and marketing approval and mandate product withdrawals, including recalls. In addition, undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restricted label or the delay or denial of regulatory approval by regulatory authorities. Even if we or our partners receive regulatory approval of a product, the approval may limit the indicated uses for which the product may be marketed. Our partnered products that have obtained regulatory approval, and the manufacturing processes for these products, are subject to continued review and periodic inspections by the FDA and other regulatory authorities. Discovery from such review and inspection of previously unknown problems may result in restrictions on marketed products or on us, including withdrawal or recall of such products from the market, suspension of related manufacturing operations or a more restricted label. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition. We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition. We currently derive, and expect to derive in the foreseeable future, all of our revenue from collaboration agreements with biotechnology and pharmaceutical companies. These collaboration agreements contain complex commercial terms, including: (cid:129) (cid:129) (cid:129) (cid:129) (cid:129) (cid:129) clinical development and commercialization obligations that are based on certain commercial reasonableness performance standards that can often be difficult to enforce if disputes arise as to adequacy of performance; research and development performance and reimbursement obligations for our personnel and other resources allocated to partnered product development programs; clinical and commercial manufacturing agreements, some of which are priced on an actual cost basis for products supplied by us to our partners with complicated cost allocation formulas and methodologies; intellectual property ownership allocation between us and our partners for improvements and new inventions developed during the course of the partnership; royalties on end product sales based on a number of complex variables, including net sales calculations, geography, patent life, generic competitors, and other factors; and indemnity obligations for third-party intellectual property infringement, product liability and certain other claims. 29 On September 20, 2009, we entered into a worldwide exclusive license agreement with AstraZeneca for the further development and commercialization of NKTR-118 and NKTR-119. In addition, we have also entered into complex commercial agreements with Novartis in connection with the sale of certain assets related to our pulmonary business, associated technology and intellectual property to Novartis (Novartis Pulmonary Asset Sale), which was completed on December 31, 2008. Our agreements with AstraZeneca and Novartis contain complex representations and warranties, covenants and indemnification obligations that could result in substantial future liability and harm our financial condition if we breach any of our agreements with AstraZeneca or Novartis or any third party agreements impacted by this complex transaction. As part of the Pulmonary Asset Sale, we entered an exclusive license agreement with Novartis Pharma pursuant to which Novartis Pharma grants back to us an exclusive, irrevocable, perpetual, royalty-free and worldwide license under certain specific patent rights and other related intellectual property rights necessary for us to satisfy certain continuing contractual obligations to third parties, including in connection with development, manufacture, sale and commercialization activities related to our partnered program for BAY41-6551 with Bayer Healthcare LLC . We also entered into a service agreement pursuant to which we have subcontracted to Novartis certain services to be performed related to our partnered program for BAY41-6551 and a transition services agreement pursuant to which Novartis and we will provide each other with specified services for limited time periods following the closing of the Novartis Pulmonary Asset Sale to facilitate the transition of the acquired assets and business from us to Novartis. From time to time, we have informal dispute resolution discussions with third parties regarding the appropriate interpretation of the complex commercial terms contained in our agreements. One or more disputes may arise in the future regarding our collaboration agreements, transaction documents, or third party license agreements that may ultimately result in costly litigation and unfavorable interpretation of contract terms, which would have a material adverse impact on our business, results of operations or financial condition. If we or our partners are not able to manufacture drugs in quantities and at costs that are commercially feasible, our proprietary and partnered product candidates may experience clinical delays or constrained commercial supply which could significantly harm our business. If we are not able to scale-up manufacturing to meet the drug quantities required to support large clinical trials or commercial manufacturing in a timely manner or at a commercially reasonable cost, we risk delaying our clinical trials or those of our partners, may breach contractual obligations and incur associated damages and costs, and reduce or even eliminate associated revenues. In some cases, we may subcontract manufacturing or other services. For instance, we entered a service agreement with Novartis pursuant to which we subcontract to Novartis certain important services to be performed in relation to our partnered program for BAY41-6551 with Bayer Healthcare LLC. If our subcontractors do not dedicate adequate resources to our programs, we risk breach of our obligations to our partners. Building and validating large scale clinical or commercial-scale manufacturing facilities and processes, recruiting and training qualified personnel and obtaining necessary regulatory approvals is complex, expensive and time consuming. In the past we have encountered challenges in scaling up manufacturing to meet the requirements of large scale clinical trials without making modifications to the drug formulation, which may cause significant delays in clinical development. Further, our drug and device combination products, such as BAY41-6551 and the Cipro Inhale program, require significant device design, formulation development work and manufacturing scale-up activities. Further, we have experienced delays in starting the Phase 3 clinical development program for BAY41-6551 as we work to finalize the device design with a demonstrated capability to be manufactured at commercial scale. This work is ongoing. Drug/device combination products are particularly complex, expensive, time-consuming and uncertain due to the number of variables involved in the final product design, including ease of patient/doctor use, maintenance of clinical efficacy, reliability and cost of manufacturing, regulatory approval requirements and standards and other important factors. Failure to manufacture products in quantities or at costs that are commercially feasible could cause us not to meet our supply requirements, contractual obligations or other requirements for our proprietary product candidates and, as a result, would significantly harm our business, results of operations and financial condition. We purchase some of the starting material for drugs and drug candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause production delays, clinical trial delays, substantial loss of revenue and contract liability to third parties. We often face very limited supply of a critical raw material that can only be obtained from a single, or a limited number of, suppliers, which could cause production delays, clinical trial delays, substantial lost revenue opportunity or contract liability to third parties. For example, there are only a limited number of qualified suppliers, and in some cases single source suppliers, for the raw 30 materials included in our PEGylation and advanced polymer conjugate drug formulations, and any interruption in supply or failure to procure such raw materials on commercially feasible terms could harm our business by delaying our clinical trials, impeding commercialization of approved drugs or increasing operating loss to the extent we cannot pass on increased costs to a manufacturing customer. We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition. We rely on trade secret protection for our confidential and proprietary information. No assurance can be given that others will not independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our trade secrets. In addition, unpatented proprietary rights, including trade secrets and know-how, can be difficult to protect and may lose their value if they are independently developed by a third party or if their secrecy is lost. Any loss of trade secret protection or other unpatented proprietary rights could harm our business, results of operations and financial condition. We expect to continue to incur substantial losses and negative cash flow from operations and may not achieve or sustain profitability in the future. For the year ended December 31, 2009, we reported a net loss of $102.5 million. If and when we achieve profitability depends upon a number of factors, including the timing and recognition of milestone payments and royalties received, the timing of revenue under our collaboration agreements, the amount of investments we make in our proprietary product candidates and the regulatory approval and market success of our product candidates. We may not be able to achieve and sustain profitability. Other factors that will affect whether we achieve and sustain profitability include our ability, alone or together with our partners, to: (cid:129) (cid:129) develop products utilizing our technologies, either independently or in collaboration with other pharmaceutical or biotech companies; receive necessary regulatory and marketing approvals; (cid:129) maintain or expand manufacturing at necessary levels; (cid:129) (cid:129) achieve market acceptance of our partnered products; receive royalties on products that have been approved, marketed or submitted for marketing approval with regulatory authorities; and (cid:129) maintain sufficient funds to finance our activities. If we do not generate sufficient cash flow through increased revenue or raising additional capital, we may not be able to meet our substantial debt obligations. As of December 31, 2009, we had cash, cash equivalents, and short-term investments in marketable securities valued at approximately $396.2 million and approximately $240.7 million of indebtedness, including approximately $215.0 million in convertible subordinated notes due September 2012, $20.3 million in capital lease obligations, and $5.4 million of other long-term liabilities. Our substantial indebtedness has and will continue to impact us by: (cid:129) making it more difficult to obtain additional financing; (cid:129) constraining our ability to react quickly in an unfavorable economic climate; 31 (cid:129) (cid:129) constraining our stock price; and constraining our ability to invest in our proprietary product development programs. Currently, we are not generating positive cash flow. If we are unable to satisfy our debt service requirements, substantial liquidity problems could result. In relation to our convertible subordinated notes, since the market price of our common stock is significantly below the conversion price, the holders of our outstanding convertible subordinated notes are unlikely to convert the notes to common stock in accordance with the existing terms of the notes. If we do not generate sufficient cash from operations to repay principal or interest on our remaining convertible subordinated notes, or satisfy any of our other debt obligations, when due, we may have to raise additional funds from the issuance of equity or debt securities or otherwise restructure our obligations. Any such financing or restructuring may not be available to us on commercially acceptable terms, if at all. If we cannot raise additional capital, our financial condition will suffer. We have no material credit facility or other material committed sources of capital. To the extent operating and capital resources are insufficient to meet our future capital needs, we will have to raise additional funds from new collaboration partnerships or the capital markets to continue the marketing and development of our technologies and proprietary products. Such funds may not be available on favorable terms, if at all. We may be unable to obtain suitable new collaboration partners on attractive terms and our substantial indebtedness may limit our ability to obtain additional capital markets financing. If adequate funds are not available on reasonable terms, we may be required to curtail operations significantly or obtain funds by entering into financing, supply or collaboration agreements on unattractive terms. Our inability to raise capital could harm our business and our stock price. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of such securities would result in dilution to our stockholders. If government and private insurance programs do not provide reimbursement for our partnered products or proprietary products, those products will not be widely accepted, which would have a negative impact on our business, results of operations and financial condition. In both domestic and foreign markets, sales of our partnered and proprietary products that have received regulatory approval will depend in part on market acceptance among physicians and patients, pricing approvals by government authorities and the availability of reimbursement from third-party payers, such as government health administration authorities, managed care providers, private health insurers and other organizations. Such third-party payers are increasingly challenging the price and cost effectiveness of medical products and services. Therefore, significant uncertainty exists as to the pricing approvals for, and the reimbursement status of, newly approved healthcare products. Moreover, legislation and regulations affecting the pricing of pharmaceuticals may change before regulatory agencies approve our proposed products for marketing and could further limit pricing approvals for, and reimbursement of, our products from government authorities and third-party payers. A government or third-party payer decision not to approve pricing for, or provide adequate coverage and reimbursements of, our products would limit market acceptance of such products. We depend on third parties to conduct the clinical trials for our proprietary product candidates and any failure of those parties to fulfill their obligations could harm our development and commercialization plans. We depend on independent clinical investigators, contract research organizations and other third-party service providers to conduct clinical trials for our proprietary product candidates. Though we rely heavily on these parties for successful execution of our clinical trials and are ultimately responsible for the results of their activities, many aspects of their activities are beyond our control. For example, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial, but the independent clinical investigators may prioritize other projects over ours or communicate issues regarding our products to us in an untimely manner. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The early termination of any of our clinical trial arrangements, the failure of third parties to comply with the regulations and requirements governing clinical trials or our reliance on results of trials that we have not directly conducted or monitored could hinder or delay the development, approval and commercialization of our product candidates and would adversely affect our business, results of operations and financial condition. 32 Our manufacturing operations and those of our contract manufacturers are subject to governmental regulatory requirements, which, if not met, would have a material adverse effect on our business, results of operations and financial condition. We and our contract manufacturers are required in certain cases to maintain compliance with current good manufacturing practices (“cGMP”), including cGMP guidelines applicable to active pharmaceutical ingredients, and are subject to inspections by the FDA or comparable agencies in other jurisdictions to confirm such compliance. We anticipate periodic regulatory inspections of our drug manufacturing facilities and the manufacturing facilities of our contract manufacturers for compliance with applicable regulatory requirements. Any failure to follow and document our or our contract manufacturers’ adherence to such cGMP regulations or satisfy other manufacturing and product release regulatory requirements may disrupt our ability to meet our manufacturing obligations to our customers, lead to significant delays in the availability of products for commercial use or clinical study, result in the termination or hold on a clinical study or delay or prevent filing or approval of marketing applications for our products. Failure to comply with applicable regulations may also result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could harm our business. The results of these inspections could result in costly manufacturing changes or facility or capital equipment upgrades to satisfy the FDA that our manufacturing and quality control procedures are in substantial compliance with cGMP. Manufacturing delays, for us or our contract manufacturers, pending resolution of regulatory deficiencies or suspensions would have a material adverse effect on our business, results of operations and financial condition. Significant competition for our polymer conjugate chemistry technology platforms and our partnered and proprietary products and product candidates could make our technologies, products or product candidates obsolete or uncompetitive, which would negatively impact our business, results of operations and financial condition. Our PEGylation and advanced polymer conjugate chemistry platforms and our partnered and proprietary products and product candidates compete with various pharmaceutical and biotechnology companies. Competitors of our PEGylation and polymer conjugate chemistry technologies include The Dow Chemical Company, Enzon Pharmaceuticals, Inc., SunBio Corporation, Mountain View Pharmaceuticals, Inc., Novo Nordisk A/S (formerly assets held by Neose Technologies, Inc.), and NOF Corporation. Several other chemical, biotechnology and pharmaceutical companies may also be developing PEGylation technologies or technologies that have similar impact on target drug molecules. Some of these companies license or provide the technology to other companies, while others are developing the technology for internal use. Inc., Pfizer There are several competitors for our proprietary product candidates currently in development. For BAY41-6551 (Amikacin inhale), the current standard of care includes several approved intravenous antibiotics for the treatment of either hospital-acquired pneumonia or ventilator-associated pneumonia in patients on mechanical ventilators. For Oral NKTR-118 (PEGylated naloxol), there are currently several alternative therapies used to address opioid-induced constipation (OIC) and opioid-induced bowel dysfunction (OBD), including over-the-counter laxatives and stool softeners such as docusate sodium, senna and milk of magnesia. In addition, there are a number of companies developing potential products which are in various stages of clinical development and are being evaluated for the treatment of OIC and OBD in different patient populations, including Adolor Corporation, GlaxoSmithKline plc, Progenics Pharmaceuticals, (via Wyeth acquisition completed in 2009), Mundipharma Int. Limited, Sucampo Pharmaceuticals and Takeda Pharmaceutical Company Limited. For NKTR-102 (PEG-irinotecan), there are a number of approved therapies for the treatment of colorectal cancer, including Eloxatin, Camptosar, Avastin, Erbitux, Vectibux, Xeloda, Adrucil and Wellcovorin. In addition, there are a number of drugs in various stages of preclinical and clinical development from companies exploring cancer therapies or improved chemotherapeutic agents to potentially treat colorectal cancer, including, but not limited to, products in development from Bristol-Myers Squibb Company, Pfizer, Inc., GlaxoSmithKline plc, Antigenics, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Cell Therapeutics, Inc., Neopharm Inc., Meditech Research Ltd, Alchemia Limited, Enzon Pharmaceuticals, Inc. and others. There are also a number of chemotherapies and cancer therapies approved today and in various stages of clinical development for ovarian and breast cancers including but not limited to: Avastin® (bevacizumab), Camptosar® (irinotecan), Doxil® (doxorubicin HCl ), Ellence® (epirubicin), Gemzar® (gemcitabine), Herceptin® (trastuzumab), Hycamtin® (topotecan), Paraplatin® (carboplatin), and Taxol® (paclitaxel). These therapies are only partially effective in treating ovarian or breast cancers. Major pharmaceutical or biotechnology companies with approved drugs or drugs in development for these cancers include Bristol- Meyers Squibb, Genentech, Inc., GlaxoSmithKline plc, Johnson and Johnson, Pfizer, Inc., Eli Lilly & Co., and many others. There can be no assurance that we or our partners will successfully develop, obtain regulatory approvals and commercialize next- generation or new products that will successfully compete with those of our competitors. Many of our competitors have greater 33 financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies. As a result, our competitors may succeed in developing competing technologies, obtaining regulatory approval or gaining market acceptance for products before we do. These developments could make our products or technologies uncompetitive or obsolete. We could be involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business, results of operations and financial condition. From time to time, third parties have asserted, and may in the future assert, that we or our partners infringe their proprietary rights. The third party often bases its assertions on a claim that its patents cover our technology. Similar assertions of infringement could be based on future patents that may issue to third parties. In certain of our agreements with our partners, we are obligated to indemnify and hold harmless our partners from intellectual property infringement, product liability and certain other claims, which could cause us to incur substantial costs if we are called upon to defend ourselves and our partners against any claims. If a third party obtains injunctive or other equitable relief against us or our partners, they could effectively prevent us, or our partners, from developing or commercializing, or deriving revenue from, certain products or product candidates in the U.S. and abroad. For instance, F. Hoffmann-La Roche Ltd, to which we license our proprietary PEGylation reagent for use in the MIRCERA product, was a party to a significant patent infringement lawsuit brought by Amgen Inc. related to Roche’s proposed marketing and sale of MIRCERA to treat chemotherapy anemia in the U.S. In October 2008, a federal court ruled in favor of Amgen, issuing a permanent injunction preventing Roche from marketing or selling MIRCERA in the U.S. In December 2009, the U.S. District court for the District of Massachusetts entered a final judgment and permanent injunction, and Roche and Amgen entered into a settlement and limited license agreement which allows Roche to begin selling MIRCERA in the U.S. in July 2014. Third-party claims could also result in the award of substantial damages to be paid by us or a settlement resulting in significant payments to be made by us. For instance, a settlement might require us to enter a license agreement under which we pay substantial royalties to a third party, diminishing our future economic returns from the related product. In 2006, we entered into a litigation settlement related to an intellectual property dispute with the University of Alabama in Huntsville pursuant to which we paid $11.0 million and agreed to pay an additional $10.0 million in equal $1.0 million installments over ten years ending with the last payment due on July 1, 2016. We cannot predict with certainty the eventual outcome of any pending or future litigation. Costs associated with such litigation, substantial damage claims, indemnification claims or royalties paid for licenses from third parties could have a material adverse effect on our business, results of operations and financial condition. If product liability lawsuits are brought against us, we may incur substantial liabilities. The manufacture, clinical testing, marketing and sale of medical products involve inherent product liability risks. If product liability costs exceed our product liability insurance coverage, we may incur substantial liabilities that could have a severe negative impact on our financial position. Whether or not we are ultimately successful in any product liability litigation, such litigation would consume substantial amounts of our financial and managerial resources and might result in adverse publicity, all of which would impair our business. Additionally, we may not be able to maintain our clinical trial insurance or product liability insurance at an acceptable cost, if at all, and this insurance may not provide adequate coverage against potential claims or losses. Our future depends on the proper management of our current and future business operations and their associated expenses. Our business strategy requires us to manage our business to provide for the continued development and potential commercialization of our proprietary and partnered product candidates. Our strategy also calls for us to undertake increased research and development activities and to manage an increasing number of relationships with partners and other third parties, while simultaneously managing the expenses generated by these activities. If we are unable to manage effectively our current operations and any growth we may experience, our business, financial condition and results of operations may be adversely affected. If we are unable to effectively manage our expenses, we may find it necessary to reduce our personnel-related costs through further reductions in our workforce, which could harm our operations, employee morale and impair our ability to retain and recruit talent. Furthermore, if adequate funds are not available, we may be required to obtain funds through arrangements with partners or other sources that may require us to relinquish rights to certain of our technologies or products that we would not otherwise relinquish. 34 We are dependent on our management team and key technical personnel, and the loss of any key manager or employee may impair our ability to develop our products effectively and may harm our business, operating results and financial condition. Our success largely depends on the continued services of our executive officers and other key personnel. The loss of one or more members of our management team or other key employees could seriously harm our business, operating results and financial condition. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are also dependent on the continued services of our technical personnel because of the highly technical nature of our products and the regulatory approval process. Because our executive officers and key employees are not obligated to provide us with continued services, they could terminate their employment with us at any time without penalty. We do not have any post-employment noncompetition agreements with any of our employees and do not maintain key person life insurance policies on any of our executive officers or key employees. Because competition for highly qualified technical personnel is intense, we may not be able to attract and retain the personnel we need to support our operations and growth. We must attract and retain experts in the areas of clinical testing, manufacturing, regulatory, finance, marketing and distribution and develop additional expertise in our existing personnel. We face intense competition from other biopharmaceutical companies, research and academic institutions and other organizations for qualified personnel. Many of the organizations with which we compete for qualified personnel have greater resources than we have. Because competition for skilled personnel in our industry is intense, companies such as ours sometimes experience high attrition rates with regard to their skilled employees. Further, in making employment decisions, job candidates often consider the value of the stock options they are to receive in connection with their employment. Our equity incentive plan and employee benefit plans may not be effective in motivating or retaining our employees or attracting new employees, and significant volatility in the price of our stock may adversely affect our ability to attract or retain qualified personnel. If we fail to attract new personnel or to retain and motivate our current personnel, our business and future growth prospects could be severely harmed. If earthquakes and other catastrophic events strike, our business may be harmed. Our corporate headquarters, including a substantial portion of our research and development operations, are located in the San Francisco Bay Area, a region known for seismic activity and a potential terrorist target. In addition, we own facilities for the manufacture of products using our PEGylation and advanced polymer conjugate technologies in Huntsville, Alabama and lease offices in Hyderabad, India. There are no backup facilities for our manufacturing operations located in Huntsville, Alabama. In the event of an earthquake or other natural disaster or terrorist event in any of these locations, our ability to manufacture and supply materials for drug candidates in development and our ability to meet our manufacturing obligations to our customers would be significantly disrupted and our business, results of operations and financial condition would be harmed. Our collaborative partners may also be subject to catastrophic events, such as hurricanes and tornadoes, any of which could harm our business, results of operations and financial condition. We have not undertaken a systematic analysis of the potential consequences to our business, results of operations and financial condition from a major earthquake or other catastrophic event, such as a fire, sustained loss of power, terrorist activity or other disaster, and do not have a recovery plan for such disasters. In addition, our insurance coverage may not be sufficient to compensate us for actual losses from any interruption of our business that may occur. We have implemented certain anti-takeover measures, which make it more difficult to acquire us, even though such acquisitions may be beneficial to our stockholders. Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even though such acquisitions may be beneficial to our stockholders. These anti-takeover provisions include: (cid:129) (cid:129) (cid:129) establishment of a classified board of directors such that not all members of the board may be elected at one time; lack of a provision for cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates; the ability of our board to authorize the issuance of “blank check” preferred stock to increase the number of outstanding shares and thwart a takeover attempt; 35 (cid:129) (cid:129) (cid:129) prohibition on stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of stockholders; establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon by stockholders at stockholder meetings; and limitations on who may call a special meeting of stockholders. Further, we have in place a preferred share purchase rights plan, commonly known as a “poison pill.” The provisions described above, our “poison pill” and provisions of Delaware law relating to business combinations with interested stockholders may discourage, delay or prevent a third party from acquiring us. These provisions may also discourage, delay or prevent a third party from acquiring a large portion of our securities or initiating a tender offer or proxy contest, even if our stockholders might receive a premium for their shares in the acquisition over the then current market prices. We also have a change of control severance benefits plan which provides for certain cash severance, stock award acceleration and other benefits in the event our employees are terminated (or, in some cases, resign for specified reasons) following an acquisition. This severance plan could discourage a third party from acquiring us. Risks Related to Our Securities The price of our common stock and senior convertible debt are expected to remain volatile. Our stock price is volatile. During the year ended December 31, 2009, based on closing bid prices on the NASDAQ Global Select Market, our stock price ranged from $4.03 to $10.47 per share. We expect our stock price to remain volatile. In addition, as our convertible senior notes are convertible into shares of our common stock, volatility or depressed prices of our common stock could have a similar effect on the trading price of our notes. Also, interest rate fluctuations can affect the price of our convertible senior notes. A variety of factors may have a significant effect on the market price of our common stock or notes, including: (cid:129) (cid:129) (cid:129) (cid:129) (cid:129) (cid:129) (cid:129) (cid:129) (cid:129) (cid:129) (cid:129) announcements of data from, or material developments in, our clinical trials or those of our competitors, including delays in clinical development, approval or launch; announcements by collaboration partners as to their plans or expectations related to products using our technologies; announcements or terminations of collaboration agreements by us or our competitors; fluctuations in our results of operations; developments in patent or other proprietary rights, including intellectual property litigation or entering into intellectual property license agreements and the costs associated with those arrangements; announcements of technological innovations or new therapeutic products that may compete with our approved products or products under development; announcements of changes in governmental regulation affecting us or our competitors; hedging activities by purchasers of our convertible senior notes; litigation brought against us or third parties to whom we have indemnification obligations; public concern as to the safety of drug formulations developed by us or others; and general market conditions. 36 Our stockholders may be diluted, and the price of our common stock may decrease, as a result of the exercise of outstanding stock options and warrants or the future issuances of securities. We may issue additional common stock, preferred stock, restricted stock units or securities convertible into or exchangeable for our common stock. Furthermore, substantially all shares of common stock for which our outstanding stock options or warrants are exercisable are, once they have been purchased, eligible for immediate sale in the public market. The issuance of additional common stock, preferred stock, restricted stock units or securities convertible into or exchangeable for our common stock or the exercise of stock options or warrants would dilute existing investors and could adversely affect the price of our securities. Item 1B. Unresolved Staff Comments None. Item 2. Properties California We currently lease approximately 100,000 square feet of facilities in San Carlos, California under a capital lease which expires in 2016. The San Carlos facility is home to our administrative headquarters, as well as research and development for our PEGylation and advanced polymer conjugate technology operations. On September 30, 2009, we entered into a sublease with Pfizer Inc. for a 102,283 square foot facility located in the Mission Bay Area of San Francisco, California (the “Mission Bay Facility”). The Mission Bay Facility is currently under construction and is scheduled to be completed by the end of 2010. When construction is completed, we will relocate all of our functions currently located in San Carlos, California, including our corporate headquarters, to the Mission Bay Facility. We are currently seeking a sublease tenant for our San Carlos facility following our transition to the Mission Bay Facility. Until December 31, 2008, we leased approximately 230,000 additional square feet in San Carlos, which housed our pulmonary manufacturing facility, as well as research and development laboratories and administrative offices, under a lease which expired in 2012. This lease was assigned to Novartis Pharmaceuticals Corporation in connection with our sale to Novartis of certain of our pulmonary assets on December 31, 2008. Alabama We currently own two facilities consisting of 145,000 square feet in Huntsville, Alabama, which house laboratories as well as administrative, clinical and commercial manufacturing facilities for our PEGylation and advanced polymer conjugate technology operations. India We completed construction of a research and development facility, totaling approximately 88,000 square feet, near Hyderabad, India at the end of 2009. In addition, we lease approximately 19,000 square feet of facilities in Hyderabad, India under various operating leases, with expiration dates ranging from 2010 to 2012. Item 3. Legal Proceedings From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. We are not currently a party to or aware of any proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Item 4. Submission of Matters to a Vote of Security Holders No matters were submitted to a vote of our security holders in the three-month period ended December 31, 2009. 37 PART II Item 5. Market for Registrant’s Common Equity Related Stockholder Matters and Issuer Purchases of Equity Securities Our common stock trades on the NASDAQ Global Select Market under the symbol “NKTR.” The table below sets forth the high and low closing sales prices for our common stock as reported on the NASDAQ Global Select Market during the periods indicated. Year Ended December 31, 2008: 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter Year Ended December 31, 2009: 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter Holders of Record High Low $ $ 7.50 7.35 5.36 5.97 5.79 6.94 10.47 10.05 $ 6.12 3.35 3.10 2.83 $ 4.03 5.02 5.89 8.07 As of February 26, 2010, there were approximately 285 holders of record of our common stock. Dividend Policy We have never declared or paid any cash dividends on our common stock. We currently expect to retain any future earnings for use in the operation and expansion of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. There were no sales of unregistered securities and there were no common stock repurchases made during the year ended December 31, 2009. Securities Authorized for Issuance Under Equity Compensation Plans Information regarding our equity compensation plans as of December 31, 2009 is disclosed in Item 12 “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” of this Annual Report on Form 10-K and is incorporated herein by reference from our proxy statement for our 2010 annual meeting of stockholders to be filed with the SEC pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. Performance Measurement Comparison The material in this section is being furnished and shall not be deemed “filed” with the SEC for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall the material in this section be deemed to be incorporated by reference in any registration statement or other document filed with the SEC under the Securities Act or the Exchange Act, except as otherwise expressly stated in such filing. The following graph compares, for the five year period ended December 31, 2009, the cumulative total stockholder return (change in stock price plus reinvested dividends) of our common stock with (i) the NASDAQ Composite Index, (ii) the NASDAQ Pharmaceutical Index, (iii) the RGD SmallCap Pharmaceutical Index, (iv) the NASDAQ Biotechnology Index and (v) the RDG SmallCap Biotechnology Index. Measurement points are the last trading day of each of our fiscal years ended December 31, 2004, December 31, 2005, December 31, 2006, December 31, 2007, December 31, 2008 and December 31, 2009. The graph assumes that $100 was invested on December 31, 2004 in the common stock of the Company, the NASDAQ Composite Index, the Nasdaq 38 Pharmaceutical Index, the RGD SmallCap Pharmaceutical Index, the NASDAQ Biotechnology Index and the RDG SmallCap Biotechnology Index and assumes reinvestment of any dividends. The stock price performance in the graph is not intended to forecast or indicate future stock price performance. COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN* $140 $120 $100 $80 $60 $40 $20 $0 12/04 12/05 12/06 12/07 12/08 12/09 Nektar Therapeutics RDG SmallCap Pharmaceutical NASDAQ Composite NASDAQ Biotechnology NASDAQ Pharmaceutical RDG SmallCap Biotechnology *$100 invested on 12/31/04 in stock or index, including reinvestment of dividends. Fiscal year ending December 31. 39 Item 6. Selected Financial Data SELECTED CONSOLIDATED FINANCIAL INFORMATION (In thousands, except per share information) The selected consolidated financial data set forth below should be read together with the consolidated financial statements and related notes, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and the other information contained herein. Statements of Operations Data: Revenue: Product sales and royalties (1) License, collaboration and other revenue (2) Total revenue Total operating costs and expenses (3)(4) Loss from operations Gain (loss) on debt extinguishment Interest and other income (expense), net Provision (benefit) for income taxes Net loss Basic and diluted net loss per share (5) Shares used in computing basic and diluted net loss per share (5) Balance Sheet Data: Cash, cash equivalents and investments Working capital Total assets Deferred revenue Convertible subordinated notes Other long-term liabilities Accumulated deficit Total stockholders’ equity 2009 2008 2007 2006 2005 Years ended December 31, $ $ $ 35,288 $ 36,643 41,255 $ 48,930 180,755 $ 92,272 153,556 $ 64,162 71,931 167,063 (95,132) — (7,640) (253) 90,185 172,837 (82,652) 50,149 (2,639) (806) 273,027 309,175 (36,148) — 4,696 1,309 217, 718 376,948 (159,230) — 5,297 828 29,366 96,913 126,279 308,912 (182,633) (303) (2,312) (137) (102,519) $ (34,336) $ (32,761) $ (154,761) $ (185,111) (1.11) $ (0.37) $ (0.36) $ (1.72) $ (2.15) 92,772 92,407 91,876 89,789 85,915 2009 2008 2007 2006 2005 As of December 31, 396,211 $ 260,650 $ 575,518 $ 192,372 $ 214,955 $ 23,344 $ 466,977 $ $ 369,457 $ $ 768,177 $ $ 40,106 $ $ 417,653 $ $ $ 29,189 $ $ (1,226,609) $ (1,124,090) $ (1,089,754) $ (1,056,993) $ 227,060 $ $ 378,994 $ 337,846 $ 560,536 $ 65,577 $ 214,955 $ 25,585 $ 482,353 $ 425,191 $ 725,103 $ 80,969 $ 315,000 $ 27,543 $ 102,367 $ 214,439 $ 190,154 $ 566,423 450,248 858,554 23,861 417,653 27,598 (902,232) 326,811 (1) 2006 and 2007 product sales and royalties include commercial manufacturing revenue from Exubera bulk dry powder insulin and Exubera inhalers. (2) 2007, 2006, and 2005 collaboration and other revenue included Exubera commercialization readiness revenue. (3) We changed our method of accounting for stock based compensation on January 1, 2006 in connection with the adoption of SFAS No. 123R, Share-Based Payment. (4) Operating costs and expenses includes the Gain on sale of pulmonary assets of $69.6 million in 2008 and the Gain on termination of collaborative agreements, net of $79.2 million in 2007. (5) Basic and diluted net loss per share is based upon the weighted average number of common shares outstanding. 40 Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed here. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this section as well as factors described in “Part I, Item 1A—Risk Factors.” Overview Strategic Direction of Our Business We are a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize our PEGylation and advanced polymer conjugate technology platforms to improve the therapeutic benefits of drugs. Our proprietary product pipeline is comprised of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives and immunology. We create our innovative product candidates by using our proprietary chemistry platform to modify the chemical structure of drugs using unique polymer conjugates. Additionally, we may utilize established pharmacologic targets to engineer a new drug candidate relying on a combination of the known properties of these targets and the attributes of our customized polymer chemistry. Our drug candidates are designed to correct deficiencies in the pharmacokinetics, half-life, oral bioavailability, metabolism or distribution of drugs to improve their therapeutic efficacy. During 2009, we continued to make substantial investments to advance our pipeline of drug candidates from early stage discovery research through clinical development. On September 20, 2009, we entered into a License Agreement with AstraZeneca (the AstraZeneca License) for the worldwide development and commercialization of NKTR-118 and NKTR-119 (a co-formulated product candidate including a long-acting opioid and NKTR-118). We have several Phase 2 clinical trials for NKTR-102 (PEGylated irinotecan) directed at a number of different indications in the oncology therapeutic area that we were advancing during 2009 and we expect to continue in 2010. In January 2010, we announced preliminary results from stage one of the ongoing Phase 2 development program for NKTR-102 for platinum resistant ovarian cancer patients. In February 2009, we announced that we had dosed the first patient in a Phase 1 clinical trial for NKTR-105 (PEGylated docetaxel) for patients with refractory solid tumors and this clinical trial is currently ongoing. We also have other products in the early discovery research or preclinical development. Our focus on research and clinical development requires substantial investments that continue to increase as we advance each drug candidate through each phase of the development cycle. While we believe that our strategy has the potential to create significant value if one or more of our drug candidates demonstrates positive clinical results and/or receives regulatory approval in one or more major markets, drug development is an inherently uncertain process and there is a high risk of failure at every stage prior to approval and the timing and outcome of clinical trial results are very difficult to predict. Clinical development success and failures can have an unpredictable and disproportionate positive or negative impact on our scientific and medical prospects, financial prospects, financial condition, and market value. We decide on a program-by-program basis whether we wish to continue development into Phase 3 pivotal clinical trials and commercialize products on our own, or seek a partner, or pursue a combination of these approaches. Following completion of Phase 2 development, or earlier in the development cycle in certain circumstances, we will generally be seeking collaborations with one or more biotechnology or pharmaceutical companies to conduct Phase 3 clinical development, to be responsible for the regulatory approval process and, if such drug candidate is approved, to market and sell the drug in one or more global markets. To date, we have partnered our proprietary drug development programs prior to Phase 3 clinical development. For example, we intend to seek a collaboration partner for NKTR-102 prior to commencing any Phase 3 clinical trials for this drug candidate. Whether we ultimately enter into a collaboration agreement for NKTR-102 will depend on the partnership opportunities available to us. The financial terms of such future collaborations, if any, including, without limitation, upfront payments, development and sales milestone payments, and royalty rates, will be critical to the future prospects of our business and financial condition. There can be no assurance that any future collaborations will be available to us for NKTR-102 or other of our development programs, on favorable terms or at all. We also have a number of existing license and collaboration agreements with third parties who have licensed our proprietary technologies for drugs that have either received regulatory approval in one or more markets or drug candidates that are still in the clinical development stage. For example, the future clinical and commercial success of Bayer’s Amikacin Inhale (BAY41-6551 or NKTR-061), UCB’s CIMZIA™ , Roche’s MIRCERA and Affymax’s Hematide, among others, will together have a material impact 41 on our long-term financial results and financial condition, as will the success of Bayer’s Cipro Inhale program, in relation to which we have certain royalty rights. Because drug development and commercialization is subject to numerous risks and uncertainties, there is a risk that our future revenue from one or more of these agreements will be less than we anticipate. Historically, we entered into a number of license and supply contracts under which we manufactured and supplied proprietary PEGylation reagents on a cost-plus or fixed price basis. Our current strategy is to manufacture and supply PEGylation reagents to support our proprietary drug candidates or for third party collaborators where we have a strategic development and commercialization relationship. As a result, whenever possible, we are renegotiating or not seeking renewal of legacy manufacturing supply arrangements that do not include a strategic development or commercialization component. While this will result in some revenue loss in the short-term, product sales from these legacy agreements is generally low-margin. Our strategy allows us to focus our proprietary manufacturing expertise and capacity on drugs and drug candidates where we have significant future economic opportunity. Key Developments and Trends in Liquidity and Capital Resources At December 31, 2009, we had approximately $396.2 million in cash, cash equivalents, and short-term investments and $240.7 million in indebtedness. We may from time to time purchase or retire convertible subordinated notes through cash purchase or exchanges for our other securities in open market or privately negotiated transactions, depending on, among other factors, our levels of available cash and the price at which such convertible notes are available for purchase. For instance, in the fourth quarter of 2008, we repurchased approximately $100.0 million in par value of our 3.25% convertible subordinated notes for an aggregate purchase price of $47.8 million. We will evaluate similar future transactions, if any, in light of then-existing market conditions. These transactions, individually or in the aggregate, may be material to our business. In 2010, we plan to relocate all of our functions currently located in San Carlos, California, including our corporate headquarters, to the Mission Bay area of San Francisco, California, which we have subleased from Pfizer Inc. In connection with the move, we expect to spend approximately $25.0 million for tenant improvements to complete the Mission Bay Facility and office and laboratory equipment in 2010. We have financed our operations primarily through revenue from product sales and royalties, development and commercialization collaboration contracts and debt and equity financings. In October 2009, we received a payment of $125.0 million from AstraZeneca under the AstraZeneca License as an upfront payment for the worldwide rights to further develop and commercialize Oral NKTR-118 and NKTR-119. In December 2009, we also received a payment of $31.0 million from the exercise of a license option extension by one of our existing collaboration partners. Similar to 2009, the results of our collaboration partnering efforts will also have a material impact on our cash position at the end of 2010. To date we have incurred substantial debt as a result of our issuances of subordinated notes that are convertible into our common stock. Our substantial debt, the market price of our securities, and the general economic climate, among other factors, could have material consequences for our financial condition and could affect our sources of short-term and long-term funding. Our ability to meet our ongoing operating expenses and repay our outstanding indebtedness is dependent upon our and our partners’ ability to successfully complete clinical development of, obtain regulatory approvals for and successfully commercialize new drugs. Even if we or our partners are successful, we may require additional capital to continue to fund our operations and repay our debt obligations as they become due. There can be no assurance that additional funds, if and when required, will be available to us on favorable terms, if at all. Results of Operations Years Ended December 31, 2009, 2008, and 2007 Revenue (in thousands, except percentages) Years ended December 31, 2007 2008 2009 Increase/ (Decreas) 2009 vs. 2008 Increase/ (Decrease) 2008 vs. 2007 Percentage Increase/ (Decrease) 2009 vs. 2008 Percentage Increase/ (Decrease) 2008 vs. 2007 $ 35,288 $ 41,255 $ 180,755 $ (5,967) $ (139,500) (14)% Product sales and royalties License, collaboration and other 36,643 48,930 92,272 (12,287) (43,342) Total revenue $ 71,931 $ 90,185 $ 273,027 $(18,254) $ (182,842) 42 (77)% (47)% (67)% (25)% (20)% Total revenue decreased for the year ended December 31, 2009 compared to the year ended December 31, 2008 primarily as a result of the sale of certain of our pulmonary assets to Novartis completed on December 31, 2008 (Novartis Pulmonary Asset Sale) and lower product manufacturing volumes required by our collaboration partners. In connection with the Novartis Pulmonary Asset Sale, our collaboration agreement with Novartis for TIP was terminated and our collaboration agreement with Bayer Schering Pharma AG for Cipro Inhale was assigned to Novartis. For the year ended December 31, 2009, two of our partners, AstraZeneca AB and UCB Pharma, represented 35% and 17%, respectively, of our total revenue. For the year ended December 31, 2008, the decrease in total revenue from the year ended December 31, 2007 was primarily attributable to the termination of our collaboration agreements with Pfizer related to Exubera and NGI, which accounted for $182.4 million, or 67%, of our total revenue during the year ended December 31, 2007. We had no revenue from Pfizer related to Exubera or NGI for the year ended December 31, 2008 or 2009. Four of our customers, Bayer (including Bayer Healthcare LLC and Bayer Schering Pharma AG), UCB Pharma, Novartis, and Roche represented 24%, 16%, 15%, and 14%, respectively, of our total revenue during the year ended December 31, 2008. Product sales and royalties Product sales include cost-plus and fixed price manufacturing and supply agreements with our collaboration partners. We also receive royalty revenue from certain of our collaboration partners based on their net sales once their products are approved for commercial sale. Royalty revenues were $5.2 million, $3.5 million, and $3.7 million for the years ended December 31, 2009, 2008, and 2007, respectively. In 2010, we expect product sales and royalties to remain at approximately the same level as 2009. Lower product demand from our collaboration partners resulted in decreased product sales of approximately $7.7 million for the year ended December 31, 2009 compared to the year ended December 31, 2008. For the year ended December 31, 2009, an increase in royalties of approximately $1.7 million partially offset the decrease in product sales compared to the year ended December 31, 2008. For the year ended December 31, 2007, Exubera product sales to Pfizer accounted for $132.9 million of our total revenue. We had no revenue from Pfizer related to Exubera for the year ended December 31, 2008 or 2009. Non-Exubera product sales and royalties decreased by approximately $6.6 million, or 14%, for the year ended December 31, 2008, compared to the year ended December 31, 2007. The decrease in non-Exubera product sales and royalties is primarily attributable to the November 30, 2007 sale of Aerogen Ireland Ltd., one of our former subsidiaries that manufactured and supplied general purpose nebulizer devices, which accounted for $5.5 million in revenue for the year ended December 31, 2007. License, collaboration and other revenue License, collaboration and other revenue includes amortization of upfront payments and performance milestone payments received in connection with our license and collaboration agreements and reimbursed research and development expenses. The level of license, collaboration and other revenues depends in part upon the estimated amortization period of the upfront and milestone payments, the achievement of future milestones, the continuation of existing collaborations, the amount of reimbursed research and development work, and the signing of new collaborations. The decrease in License, collaboration and other revenue for the year ended December 31, 2009 compared to the year ended December 31, 2008 is primarily attributable to elimination of any revenue from Novartis related to TIP and from Bayer Schering Pharma AG for Cipro Inhale as a result of the Novartis Pulmonary Asset Sale. In addition, 2008 included revenue related to a new intellectual property license agreement we entered into with Roche and higher revenue from Bayer under our collaboration agreement for BAY41-6551. This decrease is partially off-set by $25.1 million in revenue recognized related to our agreement with AstraZeneca for NKTR-118 and NKTR-119. In 2009, we recognized $23.6 million of the $125.0 million upfront payment received form AstraZeneca and $1.5 million in reimbursement of technology transfer costs incurred by us. We expect to recognize the remainder of this upfront payment in 2010. We expect License, collaboration and other revenue to increase in 2010 due to the recognition of the remaining amount of the upfront payment we received from the AstraZeneca collaboration transaction. 43 For the year ended December 31, 2007, License, collaboration and other revenue from Pfizer related to Exubera and NGI accounted for $49.5 million of our License, collaboration and other revenue. We had no collaboration and other revenue from Pfizer related to Exubera or NGI for the year ended December 31, 2008 or the year ended December 31, 2009. The increase in non-Pfizer collaboration and other revenue of $6.1 million during the year ended December 31, 2008 compared to the year ended December 31, 2007 is primarily attributable to revenue received from an intellectual property license agreement with Roche that we entered into in 2008. For the year ended December 31, 2008, we have recognized increased License, collaboration and other revenue from Bayer (including Bayer Healthcare LLC and Bayer Schering Pharma AG) of $12.3 million under our collaboration agreements for BAY41- 6551 and Cipro Inhale. These increases are offset by decreased collaboration and other revenue of $3.3 million from Novartis Vaccines and Diagnostics, Inc. under our collaboration agreement for TIP and of $3.7 million from Solvay Pharmaceuticals, Inc. and Zelos Therapeutics Inc. following the termination of those collaboration agreements in 2008. The timing and future success of our drug development programs and those of our collaboration partners are subject to a number of risks and uncertainties. See “Part I, Item 1A—Risk Factors” for discussion of the risks associated with our partnered research and development programs. Revenue by geography Revenue by geographic area is based on locations of our partners. The following table sets forth revenue by geographic area (in thousands): United States European countries Total revenue Years ended December 31, 2007 2008 2009 $ 29,511 42,420 $ 30,800 59,385 $ 212,990 60,037 $ 71,931 $ 90,185 $ 273,027 The decrease in revenue attributable to the United States for the year ended December 31, 2008 compared to the year ended December 31, 2007 is primarily attributable to the termination of our Exubera collaboration with Pfizer in 2007. Cost of goods sold (in thousands, except percentages) Years ended December 31, 2007 2008 2009 Increase/ (Decrease) 2009 vs. 2008 Increase/ (Decrease) 2008 vs. 2007 Percentage Increase/ (Decrease) 2009 vs. 2008 Percentage Increase/ (Decrease) 2008 vs. 2007 $ 30,948 4,340 $ 28,216 13,039 $ 137,696 43,059 $ 2,732 (8,699) $ (109,480) (30,020) 10% (67)% (80)% (70)% 12% 32% 24% Cost of goods sold Product gross profit Product gross margin The decrease to product gross margin during the year ended December 31, 2009 compared to the year ended December 31, 2008 is primarily attributable to lower manufacturing volumes and a $2.1 million success fee that became due to one of our former consulting firms as the final payment due under the agreement in 2009. The decrease in cost of goods sold and product gross margin during the year ended December 31, 2008 compared to the year ended December 31, 2007 was primarily due to the termination of our Exubera collaboration agreement with Pfizer. During the year ended December 31, 2007, Exubera cost of goods sold was $103.6 million and Exubera gross margin was $29.3 million. The increase in product gross margin percentage resulted from the change in product mix with our product sales based on our proprietary PEGylation materials having a relatively higher gross margin than Exubera. Cost of goods sold during the year ended December 31, 2007 includes Exubera manufacturing costs through the November 9, 2007 termination of the Pfizer agreements. Costs related to our Exubera manufacturing operations after November 9, 2007 are included in other cost of revenue. 44 As a result of the fixed cost base associated with our manufacturing activities, we expect product gross margin to fluctuate in future periods depending on the level of manufacturing orders from our customers. Other cost of revenue (in thousands, except percentages) Other cost of revenue $ — $ 6,821 $ 9,821 $ (6,821) $ (3,000) Years ended December 31, 2008 2009 2007 Increase/ (Decrease) 2009 vs. 2008 Increase/ (Decrease) 2008 vs. 2007 Percentage Increase/ (Decrease) 2009 vs. 2008 n/a Percentage Increase/ (Decrease) 2008 vs. 2007 (31)% Other cost of revenue included the idle Exubera manufacturing capacity costs that were incurred by us prior to the termination of all of our inhaled insulin programs in April 2008 and Exubera commercialization readiness costs incurred in 2007. Idle Exubera manufacturing capacity costs includes the costs of maintaining our manufacturing operating capacity after the termination of the Pfizer agreements on November 9, 2007 through the termination of our inhaled insulin programs on April 9, 2008. Idle Exubera manufacturing capacity costs include amounts payable to Pfizer and Tech Group under interim manufacturing capacity maintenance agreements and an allocation of manufacturing costs shared between commercial operations and research and development, including employee compensation and benefits, rent, and utilities. Idle Exubera manufacturing costs were nil, $6.8 million, and $6.3 million for the year ended December 31, 2009, 2008, and 2007, respectively. Exubera commercialization readiness costs were start-up manufacturing costs we incurred in our Exubera inhalation bulk powder manufacturing facility and our Exubera inhaler device third party contract manufacturing locations in preparation for commercial scale manufacturing beginning in early 2006. Exubera commercialization readiness costs were nil, nil, and $3.5 million for the years ended December 31, 2009, 2008, and 2007, respectively. We do not expect to incur any additional idle Exubera manufacturing capacity or Exubera commercialization readiness costs. Research and development expense (in thousands, except percentages) Years ended December 31, 2007 2008 2009 Increase/ (Decrease) 2009 vs. 2008 Increase/ (Decrease) 2008 vs. 2007 Percentage Increase/ (Decrease) 2009 vs. 2008 Percentage Increase/ (Decrease) 2008 vs. 2007 Research & development expense $ 95,109 $ 154,417 $ 153,575 $ (59,308) $ 842 (38)% 1% Research and development expense consists primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations (CROs), materials and supplies, licenses and fees and overhead allocations consisting of various support and facilities related costs. The costs incurred in connection with our research and development programs, including an allocation of shared resources and overhead costs to programs, are as follows (in thousands): NKTR-102 (PEGylated irinotecan) NKTR-118 (oral PEGylated naloxol) (2) BAY41-6551 (NKTR-061, Amikacin Inhale) (3) NKTR-105 (PEGylated docetaxel) Other PEGylation product candidates Tobramycin inhalation powder (TIP) (4) Cipro Inhale (5) Inhaled Insulin (6) Other pulmonary product candidates (7) Other Research and development expense Clinical Study Status(1) Phase 2 Phase 2 Phase 2 Phase 1 Various n/a n/a n/a Various Years ended December 31, 2007 2008 2009 $ 31,500 20,276 13,621 4,986 24,460 — — — 166 100 $ 95,109 $ 24,205 24,579 17,676 8,384 21,030 19,674 11,447 3,511 17,990 5,921 $ 154,417 $ 12,741 12,852 15,196 400 16,165 16,255 8,321 37,647 28,107 5,891 $ 153,575 45 (1) Clinical Study Status definitions are provided in the chart found in Part I, Item 1. Business. (2) Partnered with AstraZeneca AB on September 20, 2009. (3) Partnered with Bayer Healthcare LLC in August 2007. As part of the Novartis Pulmonary Asset Sale, we retained an exclusive license to this technology for the development and commercialization of this product which was originally developed by Nektar. (4) The collaboration agreement with Novartis was terminated on December 31, 2008 in connection with the Novartis Pulmonary Asset Sale. (5) The collaboration agreement with Bayer Schering Pharma AG was assigned to Novartis on December 31, 2008 in connection with the Novartis Pulmonary Asset Sale. (6) Partnership for the collaboration and development of Exubera inhalation powder and the next generation inhaled insulin with Pfizer was terminated on November 9, 2007. We terminated all of our inhaled insulin programs in April 2008. (7) Certain proprietary pulmonary intellectual property was transferred to Novartis as part of the Novartis Pulmonary Asset Sale. In connection with the Novartis Pulmonary Asset Sale, we transferred approximately 140 of our personnel dedicated to our pulmonary operations and our San Carlos research and manufacturing facility to Novartis. In addition, we ceased research activities on the TIP research and development program, the Cipro Inhale program and certain other proprietary pulmonary development programs. During 2009, we had several Phase 2 clinical trials ongoing for NKTR-102 with treatment sites around the world for ovarian, breast, and colorectal cancers; we completed our Phase 2 clinical trial for NKTR-118 in March 2009 and performed development activities to prepare for a Phase 3 clinical trial; we continued to develop the nebulizer device for BAY41-6551 in preparation for the Phase 3 clinical trial that we are targeting to start in 2010; and we continued to enroll patients in our Phase 1 clinical trial for NKTR-105. The decrease in research and development expense for the year ended December 31, 2009 compared to the year ended December 31, 2008 is primarily attributable to the divestiture of certain pulmonary research and development programs as part of the Novartis Pulmonary Asset Sale. Research and development expense related to terminated pulmonary programs totaled $52.6 million for the year ended December 31, 2008 which was comprised of facility, employee related and other costs. Additionally, in 2008 we recorded approximately $5.9 million in other expenses related to the workforce reduction executed in February 2008 and additional severance costs related to the Novartis Pulmonary Asset Sale. We expect research and development expense will increase in 2010 as compared to 2009, as we complete or continue the Phase 2 clinical trials for NKTR-102 and the Phase 1 clinical trial for NKTR-105 and advance various product candidates through the research and pre-clinical phase. Research and development expense remained at a consistent level in 2008 as compared to 2007 despite a significant increase in our investment in clinical development of our proprietary drug candidates in 2008. This was a result of the continued transition of our business to focus on our internal proprietary drug candidates in 2008 and a decrease in other research and development activities. Salaries, benefits, and stock-based compensation expense decreased by approximately $14.0 million for the year ended December 31, 2008 compared to the year ended December 31, 2007, as we continued to realize the benefits of our workforce reduction plans implemented in May 2007 and February 2008. Facilities and equipment expense decreased by approximately $8.0 million primarily as a result of lower depreciation due to the write-off of the Pfizer-related equipment in 2007 and certain pulmonary property and equipment classified as held for sale at September 30, 2008. These decreases were offset by increased costs related to our ongoing clinical trials for our proprietary drug candidates, comprised increased outside services of $13.4 million, including costs to CROs, and increased materials and supplies expense of $8.2 million. During the year ended December 31, 2008, research and development expense included approximately $2.7 million in additional costs related to the Novartis Pulmonary Asset Sale, including one-time termination benefits and other costs. During the year ended December 31, 2008, our research and development spending in our partnered drug development programs decreased compared to the year ended December 31, 2007 after the termination of our Pfizer agreements for inhaled insulin in November 2007. Spending related to our proprietary drug development programs increased as we continued to advance clinical development for NKTR-102, NKTR-118, and NKTR-105. 46 The estimated completion dates for our programs are not reasonably certain. See Item 1a. Risk Factors for discussion of the risks associated with drug candidates in development and the risks and uncertainties associated with clinical development at any stage. General and administrative expense (in thousands, except percentages) Years ended December 31, 2007 2008 2008 Increase/ (Decrease) 2009 vs. 2008 Increase/ (Decrease) 2008 vs. 2007 Percentage Increase/ (Decrease) 2009 vs. 2008 Percentage Increase/ (Decrease) 2008 vs. 2007 General & administrative expense $ 41,006 $ 51,497 $ 58,865 $ (10,491) $ (7,368) (20)% (13)% General and administrative expenses are associated with administrative staffing, business development, finance, marketing, and legal. The decrease in general and administrative expenses for the year ended December 31, 2009 compared to the year ended December 31, 2008, is primarily attributable to decreased employee compensation costs of $4.1 million, decreased professional fees of $4.3 million, and decreased marketing costs of $1.7 million due to our election to terminate our co-promotion rights and obligations under the collaboration agreement with Bayer for BAY41-6551. In 2010, we expect general and administrative expenses to remain at a level consistent with 2009. The decrease in general and administrative expenses for the year ended December 31, 2008 compared to the year ended December 31, 2007 is primarily attributable to decreased professional fees of $5.1 million and decreased salaries and benefits of $8.8 million, partially offset by increased marketing costs of $1.7 million related to our co-promotion obligations with Bayer Healthcare LLC for BAY41-6551 and decreased corporate overhead costs allocated out of general and administrative departments to manufacturing and research and development of $4.0 million. Impairment of long lived assets (in thousands except percentages) Years ended December 31, 2008 2009 2007 Increase/ (Decrease) 2009 vs. 2008 Increase/ (Decrease) 2008 vs. 2007 Percentage Increase/ (Decrease) 2009 vs. 2008 Percentage Increase/ (Decrease) 2008 vs. 2007 Impairment of long-lived assets $ — $ 1,458 $ 28,396 $ (1,458) $ (26,938) n/a (95)% During the year ended December 31, 2008, impairment of long lived assets included an impairment charge of $1.5 million related to a specialized dryer designed for our PEGylation manufacturing facility. The dryer was not functioning properly and was not being used in operations. We determined the carrying value of the manufacturing equipment exceeded the fair value based on a discounted cash flow model. During the year ended December 31, 2007, impairment of long lived assets includes an impairment charge of $28.4 million for Exubera-related assets following the termination of our collaborative agreements with Pfizer. Gain on sale of pulmonary assets (in thousands except percentages) Years ended December 31, 2007 2008 2009 Increase/ (Decrease) 2009 vs. 2008 Increase/ (Decrease) 2008 vs. 2007 Percentage Increase/ (Decrease) 2009 vs. 2008 Percentage Increase/ (Decrease) 2008 vs. 2007 Gain on sale of pulmonary assets $ — $ (69,572) $ — $ (69,572) $ 69,572 n/a n/a On December 31, 2008, we sold certain of our pulmonary assets to Novartis for $115.0 million. The gain on sale of pulmonary assets includes the purchase price received from Novartis less the net book value of property and equipment of $37.3 million, an equity investment in Pearl Therapeutics, Inc. of $2.7 million, transaction costs of $4.6 million, and other costs of $0.9 million. 47 Gain on termination of collaborative agreements, net (in thousands except percentages) Years ended December 31, 2009 2008 2007 Increase/ (Decrease) 2009 vs. 2008 Increase/ (Decrease) 2008 vs. 2007 Percentage Increase/ (Decrease) 2009 vs. 2008 Percentage Increase/ (Decrease) 2008 vs. 2007 Gain on termination of collaborative agreements, net $ — $ — $ (79,178) $ — $ (79,178) n/a n/a On November 9, 2007, we terminated our collaborative development and license agreement with Pfizer and all other agreements between us and Pfizer related to Exubera and NGI. Pursuant to the termination agreement, we received a one-time payment of $135.0 million from Pfizer in full satisfaction and release of all contract obligations. The gain on termination of collaborative agreements, net, includes the Pfizer termination payment received of $135.0 million less our contractual aggregate liability to certain subcontractors, Bespak and Tech Group, of $32.4 million and less settlement of outstanding receivables and payables with Pfizer of $23.5 million. Interest income (in thousands except percentages) Years ended December 31, 2007 2008 2009 Increase/ (Decrease) 2009 vs. 2008 Increase/ (Decrease) 2008 vs. 2007 Percentage Increase/ (Decrease) 2009 vs. 2008 Percentage Increase/ (Decrease) 2008 vs. 2007 Interest income $ 3,688 $ 12,495 $ 22,201 $ (8,807) $ (9,706) (70)% (44)% The decreases in interest income for the years ended December 31, 2009 and 2008 compared to the previous years, was primarily attributable to lower interest rates on our cash, cash equivalents, and available-for-sale investments. Interest expense (in thousands except percentages) Years ended December 31, 2007 2008 2009 Increase/ (Decrease) 2009 vs. 2008 Increase/ (Decrease) 2008 vs. 2007 Percentage Increase/ (Decrease) 2009 vs. 2008 Percentage Increase/ (Decrease) 2008 vs. 2007 Interest expense $ 12,176 $ 15,192 $ 18,638 $ (3,016) $ (3,446) (20)% (18)% We repurchased $100.0 million par value of our 3.25% convertible subordinated notes (Notes) in the fourth quarter of 2008. This resulted in a lower average balance of Notes outstanding and a corresponding decrease in interest expense in 2009 compared to 2008 and in 2008 compared to 2007. The Notes are due in September 2012. We expect 2010 interest expense to remain at a level consistent with 2009. Gain on debt extinguishment (in thousands except percentages) Years ended December 31, 2007 2008 2009 Increase/ (Decrease) 2009 vs. 2008 Increase/ (Decrease) 2008 vs. 2007 Percentage Increase/ (Decrease) 2008 vs. 2007 Percentage Increase/ (Decrease) 2008 vs. 2007 Gain on debt extinguishment $ — $ 50,149 $ — $ (50,149) $ 50,149 n/a n/a During the three months ended December 31, 2008, we repurchased approximately $100.0 million in par value of our 3.25% convertible subordinated notes for an aggregate purchase price of $47.8 million. The recognized gain on debt extinguishment is net of transaction costs of $1.0 million and accelerated amortization of our deferred financing costs of $1.1 million. 48 Liquidity and Capital Resources We have financed our operations primarily through revenue from product sales, royalties and research and development contracts, as well as public and private placements of debt and equity. As of December 31, 2009, we had cash, cash equivalents and investments in marketable securities of $396.2 million and indebtedness of $240.7 million, including $215.0 million of convertible subordinated notes, $20.3 million in capital lease obligations and $5.4 million in other liabilities. Additionally at December 31, 2009, we had letter of credit arrangements with certain financial institutions and vendors, including our landlord, totaling $2.9 million. These letters of credit expire during 2010 and are secured by investments of similar amounts. Due to the continuing difficult environment in the credit markets, we may experience reduced liquidity with respect to some of our short-term investments. These investments are generally held to maturity, which is less than one year. However, if the need arose to liquidate such securities before maturity, we may experience losses on liquidation. As of December 31, 2009, we held $363.1 million of available-for-sale investments, excluding money market funds, with an average time to maturity of 153 days. Based on our available cash and our expected operating cash requirements, we do not intend to sell these securities and it is more likely than not that we will not be required to sell these securities before we recover the amortized cost basis. To date we have not experienced any liquidity issues with respect to these securities, but should such issues arise, we may be required to hold some, or all, of these securities until maturity. We believe that, even allowing for potential liquidity issues with respect to these securities, our remaining cash and cash equivalents and short-term investments will be sufficient to meet our anticipated cash needs for at least the next twelve months. On September 30, 2009, we entered into a sublease with Pfizer Inc. for a 102,283 square foot facility located in the Mission Bay Area of San Francisco, California (Mission Bay Facility). The Mission Bay Facility is currently under construction and is scheduled to be completed by the end of 2010. We anticipate that our capital requirements for 2010 related to the Mission Bay Facility will total approximately $25.0 million for tenant improvements and office and laboratory equipment. When construction is completed, we will relocate all of our functions currently located in San Carlos, California, including our corporate headquarters, to the Mission Bay Facility. We are currently seeking a sublease tenant for our San Carlos facility following our transition to the Mission Bay Facility. Cash flows from operating activities During the year ended December 31, 2009, net cash provided by operating activities totaled $39.7 million, which included the $125.0 million upfront payment received from AstraZeneca under the license agreement we entered into for NKTR-118 and NKTR-119 and $31.0 million license extension payment received from Roche in December 2009. In 2010, we expect that 2010 cash flows from operating activities, excluding upfront payments received, if any, will increase in 2009 as a result of increased spending on our proprietary research and development programs. During the year ended December 31, 2008, net cash used for our operating activities was $145.8 million. The decrease in net cash provided by our operating activities for the year ended December 31, 2008 as compared to the year ended December 31, 2007, resulted from the $135.0 million cash payment received from Pfizer in 2007 under the Exubera termination agreement and upfront payments of $50.0 million and $24.6 million received in 2007 from Bayer Healthcare LLC and Pfizer, respectively. In addition, the net cash used for our operating activities for the year ended December 31, 2008 included a number of significant items including a $10.0 million clinical development milestone received from Bayer Healthcare LLC under our collaboration agreement for BAY41- 6551, payments by us to Bespak Europe Ltd. and Tech Group North America, Inc. of $39.9 million for amounts due under termination agreements with these Exubera inhaler device contract manufacturers, all of which was recorded as an expense in 2007, $6.8 million paid to maintain Exubera manufacturing capacity through April 2008, and $5.4 million for severance, employee benefits, and outplacement services in connection with our workforce reduction plans. Cash flows from investing activities We purchased $16.4 million, $18.9 million, and $32.8 million of property and equipment in the years ended December 31, 2009, 2008, and 2007, respectively. Additionally, we made advanced payments on property and equipment purchases of $4.3 million in the year ended December 31, 2009. We expect our capital expenditures to increase in 2010, as we construct the leasehold improvements for the Mission Bay sublease and complete our research and development facility in Hyderabad, India. 49 On December 31, 2008, we completed the sale of certain pulmonary assets to Novartis for a purchase price of $115.0 million. We paid $0.2 million in transaction costs related to the sale during the year ended December 31, 2008 and $4.4 million in transaction costs during the year ended December 31, 2009. In July 2008, we invested $4.2 million in Pearl Therapeutics Inc. (Pearl). In 2007, we granted Pearl a limited field intellectual property license to certain of our proprietary pulmonary delivery technology. In connection with the Novartis Pulmonary Asset Sale, we transferred our ownership interest in Pearl to Novartis and assigned the intellectual property license we had in place with Pearl to Novartis. Cash flows used in financing activities During the year ended December 31, 2008, we repurchased approximately $100.0 million in par value of our 3.25% convertible subordinated notes for an aggregate purchase price of $47.8 million. The $215.0 million of 3.25% convertible subordinated notes outstanding at December 31, 2008, are due in September 2012. We repaid $102.7 million of convertible subordinated notes during the year ended December 31, 2007. Contractual Obligations Payments due by period 2-3 yrs 2011-2012 <=1 yr 2010 4-5 yrs 2013-2014 Total Obligations (1) Convertible subordinated notes, including interest Capital leases, including interest Operating leases (2) Purchase commitments (3) Litigation settlement, including interest $ 234,167 34,107 21,320 11,141 7,000 $ 6,986 4,752 — 11,141 1,000 $ 227,181 9,810 — — 2,000 $ — $ 10,231 1,509 — 2,000 2015+ — 9,314 19,811 — 2,000 $ 307,735 $ 23,879 $ 238,991 $ 13,740 $ 31,125 (1) The above table does not include certain commitments and contingencies which are discussed in Note 7 of Item 8. Financial Statements and Supplementary Data. (2) On September 30, 2009, we entered into an operating sublease for a new facility which will include our corporate headquarters and an R&D center at 455 Mission Bay Blvd in San Francisco, California. The lease is discussed in Note 6 of Item 8. Financial Statements and Supplementary Data. (3) Substantially all of this amount was subject to open purchase orders as of December 31, 2009 that were issued under existing contracts. This amount does not represent minimum contract termination liability for our existing contracts. Given our current cash requirements, we forecast that we will have sufficient cash to meet our net operating expense requirements and contractual obligations at least through December 31, 2011. We plan to continue to invest in our growth and our future cash requirements will depend upon the timing and results of these investments. Our capital needs will depend on many factors, including continued progress in our research and development programs, progress with preclinical and clinical trials of our proprietary and partnered drug candidates, our ability to successfully enter into additional collaboration agreements for one or more of our proprietary drug candidates or intellectual property that we control, the time and costs involved in obtaining regulatory approvals, the costs of developing and scaling our clinical and commercial manufacturing operations, the costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims, the need to acquire licenses to new technologies and the status of competitive products. To date we have incurred substantial debt as a result of our issuances of subordinated notes that are convertible into our common stock. Our substantial debt, the market price of our securities, and the general economic climate, among other factors, could have material consequences for our financial condition and could affect our sources of short-term and long-term funding. Our ability to meet our ongoing operating expenses and repay our outstanding indebtedness is dependent upon our and our partners’ ability to 50 successfully complete clinical development of, obtain regulatory approvals for and successfully commercialize new drugs. Even if we or our partners are successful, we may require additional capital to continue to fund our operations and repay our debt obligations as they become due. There can be no assurance that additional funds, if and when required, will be available to us on favorable terms, if at all. Off Balance Sheet Arrangements We do not utilize off-balance sheet financing arrangements as a source of liquidity or financing. Critical Accounting Policies The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources, and evaluate our estimates on an ongoing basis. Actual results may differ from those estimates under different assumptions or conditions. We have determined that for the periods reported in this report, the following accounting policies and estimates are critical in understanding our financial condition and results of our operations. Revenue Recognition License, collaboration and other research revenue includes amortization of upfront fees. Upfront fees are recognized ratably over the expected performance period under the arrangement. Management makes its best estimate of the period over which we expect to fulfill our performance obligations, which may include technology transfer assistance, clinical development activities, or manufacturing activities through the commercial life of the product. Given the complexities and uncertainties of research and development collaborations, significant judgment is required to determine the duration of the performance period. As of December 31, 2009, we have $51.8 million of deferred upfront fees related to five research and collaboration agreements that are being amortized over 6 to 24 years, or an average of 12 years. For our research and collaboration agreements, our performance obligations may span the life of the agreement. For these, the shortest reasonable period is the end of the development period (estimated to be 4 to 6 years) and the longest period is the contractual life of the agreement, which is generally 10-12 years from the first commercial sale. Given the statistical probability of drug development success in the bio-pharmaceutical industry, drug development programs have only a 5% to 10% probability of reaching commercial success. If we had determined a longer or shorter amortization period was appropriate, our annual upfront fee amortization could be as low as $4.0 million or as high as $17.0 million. As of December 31, 2009, we also have $136.2 million of deferred upfront fees related to three license agreements that are being amortized over 1.2, 2, and 6 years, respectively. Our performance obligations for these agreements may include technology transfer assistance and/or back-up manufacturing and supply services for a specified period of time; therefore, the time estimated to complete the performance obligations related to licenses is much shorter than research and collaboration agreements. We may experience delays in the execution of the technology transfer plans, which would result in a longer amortization period. Our original estimates are periodically evaluated to determine if circumstances have caused the estimates to change and if so, amortization of revenue is adjusted prospectively. Stock-Based Compensation We use the Black-Scholes option valuation model adjusted for the estimated historical forfeiture rate for the respective grant to determine the estimated fair value of our stock-based compensation arrangements on the date of grant (grant date fair value) and expense this value ratably over the service period of the option or performance period of the Restricted Stock Unit award (RSU). The Black-Scholes option pricing model requires the input of highly subjective assumptions. Because our employee stock options have 51 characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect fair value estimates, in management’s opinion, the existing models may not provide a reliable single measure of the fair value of our employee stock options or common stock purchased under our employee stock purchase plan. In addition, management continually assesses the assumptions and methodologies used to calculate the estimated fair value of stock-based compensation. Circumstances may change and additional data may become available over time, which could result in changes to the assumptions and methodologies, and which could materially impact our fair value determination, as well as our stock-based compensation expense. Clinical Trial Accruals We record accruals for the estimated costs of our clinical trials. Most of our clinical trials are performed by third-party CROs, which are a significant component of our Research and development expense. We accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. If the actual timing of these phases varies from the estimate, we will adjust the accrual prospectively. We accrue costs associated with treatment phase of clinical trials based on the total estimated cost of the clinical trials and are expensed ratably based on patient enrollment in the trials. Recent Accounting Pronouncements FASB Accounting Standards Update 2009-13, Revenue Recognition (Topic 605) – Multiple-Deliverable Revenue Arrangements In October 2009, the FASB published FASB Accounting Standards Update (ASU) 2009-13, which amends the criteria to identify separate units of accounting within Subtopic 605-25, Revenue Recognition-Multiple-Element Arrangements. The revised guidance also expands the disclosure required for multiple-element revenue arrangements. FASB ASU No. 2009-13 is effective for fiscal years beginning on or after June 15, 2010, and may be applied retrospectively for all periods presented or prospectively to arrangements entered into or materially modified after the adoption date. Early adoption is permitted provided that the revised guidance is retroactively applied to the beginning of the year of adoption. We are currently evaluating the impact of adoption on our financial position and our results of operations. FASB ASU No. 2010-6, Improving Disclosures About Fair Value Measurements In January 2010, the FASB issued ASU No. 2010-6, Improving Disclosures About Fair Value Measurements, that adds required disclosures about items transferring into and out of Levels 1 and 2 in the fair value hierarchy; adding separate disclosures about purchase, sales, issuances, and settlements relative to Level 3 measurements; and clarifying, among other things, the existing fair value disclosures about the level of disaggregation. FASB ASU No. 2010-6 is effective for interim and annual reporting periods beginning after December 15, 2009, except for the requirement to provide level 3 purchases, sales, issuances, and settlements on a gross basis, which is effective for fiscal years beginning after December 15, 2010. Since this standard impacts disclosure requirements only, we do not expect its adoption will have a material impact on our financial statements. Item 7A. Quantitative and Qualitative Disclosures About Market Risk Interest Rate and Market Risk The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in short-term securities and maintain a weighted average maturity of one year or less. A hypothetical 50 basis point increase in interest rates would result in an approximate $0.8 million decrease, less than 1%, in the fair value of our available-for-sale securities at December 31, 2009. This potential change is based on sensitivity analyses performed on our investment securities at December 31, 2009. Actual results may differ materially. The same hypothetical 50 basis point increase in interest rates would have resulted in an approximate $0.4 million decrease, less than 1%, in the fair value of our available-for-sale securities at December 31, 2008. 52 Due to the adverse developments in the credit markets in 2009, we may experience reduced liquidity with respect to some of our short-term investments. These investments are generally held to maturity, which is less than one year. However, if the need arose to liquidate such securities before maturity, we may experience losses on liquidation. As of December 31, 2009, we held $363.1 million of available-for-sale investments, excluding money market funds, with an average time to maturity of 153 days. To date we have not experienced any liquidity issues with respect to these securities, but should such issues arise, we may be required to hold some, or all, of these securities until maturity. We believe that, even allowing for potential liquidity issues with respect to these securities, our remaining cash and cash equivalents and short-term investments will be sufficient to meet our anticipated cash needs for at least the next twelve months. We have the ability and intent to hold our debt securities to maturity when they will be redeemed at full par value. Accordingly, we consider unrealized losses to be temporary and have not recorded a provision for impairment. Foreign Currency Risk The majority of our revenue, expense, and capital purchasing activities are transacted in U.S. dollars. However, since a portion of our operations consists of research and development activities outside the United States, we have entered into transactions in other currencies, primarily the Indian Rupee, and we therefore are subject to foreign exchange risk. Our international operations are subject to risks typical of international operations, including, but not limited to, differing economic conditions, changes in political climate, differing tax structures, other regulations and restrictions, and foreign exchange rate volatility. We do not utilize derivative financial instruments to manage our exchange rate risks. 53 Item 8. Financial Statements and Supplementary Data NEKTAR THERAPEUTICS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Reports of Independent Registered Public Accounting Firm Consolidated Balance Sheets at December 31, 2009 and 2008 Consolidated Statements of Operations for each of the three years in the period ended December 31, 2009 Consolidated Statements of Stockholders’ Equity for each of the three years in the period ended December 31, 2009 Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2009 Notes to Consolidated Financial Statements Page 55 57 58 59 60 61 54 The Board of Directors and Stockholders of Nektar Therapeutics Report of Independent Registered Public Accounting Firm We have audited the accompanying consolidated balance sheets of Nektar Therapeutics as of December 31, 2009 and 2008, and the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2009. Our audits also included the financial statement schedule listed in the Index at Item 15(a)(2). These financial statements and schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Nektar Therapeutics at December 31, 2009 and 2008, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2009, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Nektar Therapeutics’ internal control over financial reporting as of December 31, 2009, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 2, 2010, expressed an unqualified opinion thereon. /s/ Ernst & Young LLP Palo Alto, CA March 2, 2010 55 The Board of Directors and Stockholders of Nektar Therapeutics Report of Independent Registered Public Accounting Firm We have audited Nektar Therapeutics’ internal control over financial reporting as of December 31, 2009, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). Nektar Therapeutics’ management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the company’s internal control over financial reporting based on our audit. We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. In our opinion, Nektar Therapeutics maintained, in all material respects, effective internal control over financial reporting as of December 31, 2009, based on the COSO criteria. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Nektar Therapeutics as of December 31, 2009 and 2008, and the related consolidated statements of operations, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2009 of Nektar Therapeutics and our report dated March 2, 2010 expressed an unqualified opinion thereon. /s/ Ernst & Young LLP Palo Alto, CA March 2, 2010 56 NEKTAR THERAPEUTICS CONSOLIDATED BALANCE SHEETS (In thousands, except per share information) Current assets: ASSETS Cash and cash equivalents Short-term investments Accounts receivable, net of allowance of nil and $92 at December 31, 2009 and 2008, respectively Inventory Other current assets Total current assets Property and equipment, net Goodwill Other assets Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable Accrued compensation Accrued clinical trial expenses Accrued expenses Deferred revenue, current portion Other current liabilities Total current liabilities Convertible subordinated notes Capital lease obligations, less current portion Deferred revenue, less current portion Deferred gain Other long-term liabilities Total liabilities Commitments and contingencies Stockholders’ equity: Preferred stock, 10,000 shares authorized Series A, $0.0001 par value; 3,100 shares designated; no shares issued or outstanding at either December 31, 2009 or 2008 Common stock, $0.0001 par value; 300,000 authorized; 93,281 shares and 92,503 shares issued and outstanding at December 31, 2009 and 2008, respectively Capital in excess of par value Accumulated other comprehensive income Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity December 31, 2009 2008 $ $ $ $ 49,597 346,614 4,801 6,471 6,183 413,666 78,263 76,501 7,088 155,584 223,410 11,161 9,319 6,746 406,220 73,578 76,501 4,237 $ 575,518 $ 560,536 $ $ $ $ 3,066 10,052 14,167 4,354 115,563 5,814 153,016 214,955 18,800 76,809 5,027 4,544 13,832 11,570 17,622 9,923 10,010 5,417 68,374 214,955 20,347 55,567 5,901 5,238 $ 473,151 $ 370,382 — — 9 1,327,942 1,025 (1,226,609) 9 1,312,796 1,439 (1,124,090) 102,367 190,154 $ 575,518 $ 560,536 The accompanying notes are an integral part of these consolidated financial statements. 57 NEKTAR THERAPEUTICS CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share information) Revenue: Product sales and royalties License, collaboration and other revenue Total revenue Operating costs and expenses: Cost of goods sold Other cost of revenue Research and development General and administrative Impairment of long-lived assets Gain on sale of pulmonary assets Gain on termination of collaborative agreements, net Total operating costs and expenses Loss from operations Non-operating income (expense): Interest income Interest expense Other income (expense), net Gain on extinguishment of debt Total non-operating income (expense), net Loss before (benefit) provision for income taxes (Benefit) provision for income taxes Net loss Basic and diluted net loss per share Years ended December 31, 2009 2008 2007 $ $ 35,288 36,643 71,931 $ $ 41,255 48,930 90,185 $ $ 180,755 92,272 273,027 30,948 — 95,109 41,006 — — — 28,216 6,821 154,417 51,497 1,458 (69,572) — 137,696 9,821 153,575 58,865 28,396 — (79,178) $ 167,063 $ 172,837 $ 309,175 (95,132) (82,652) (36,148) 3,688 (12,176) 848 — (7,640) 12,495 (15,192) 58 50,149 47,510 22,201 (18,638) 1,133 — 4,696 $ (102,772) $ (253) (35,142) $ (806) (31,452) 1,309 $ (102,519) $ (34,336) $ (32,761) $ (1.11) $ (0.37) $ (0.36) Shares used in computing basic and diluted net loss per share 92,772 92,407 91,876 The accompanying notes are an integral part of these consolidated financial statements. 58 NEKTAR THERAPEUTICS CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (in thousands) Common Shares Par Value Capital In Excess of Par Value Accumulated Other Comprehensive Income/(Loss) Accumulated Deficit Total Stockholders’ Equity Balance at December 31, 2006 Stock option exercises and RSU release Stock-based compensation Shares issued for employee plans (1) Other comprehensive income Net loss Comprehensive loss Balance at December 31, 2007 Stock option exercises and RSU release Stock-based compensation Shares issued for Employee Stock Purchase Plan Other comprehensive loss Net loss Comprehensive loss Balance at December 31, 2008 Stock option exercises and RSU release Stock-based compensation Shares issued for Employee Stock Purchase Plan Other comprehensive loss Net loss Comprehensive loss 91,280 761 — 260 — — 92,301 146 — 56 — — 92,503 742 — 36 — — $ $ $ 9 — — — — — 9 — — — — — 9 — — — — — $ 1,283,982 2,915 13,193 2,451 — — $ 1,302,541 122 9,871 262 — — $ 1,312,796 4,696 10,326 124 — — $ 62 — — — 1,581 — $ 1,643 — — — (204) — $ 1,439 — — — (414) — $ (1,056,993) $ — — — — (32,761) $ (1,089,754) $ — — — — (34,336) $ (1,124,090) $ — — — — (102,519) 227,060 2,915 13,193 2,451 1,581 (32,761) (31,180) 214,439 122 9,871 262 (204) (34,336) (34,540) 190,154 4,696 10,326 124 (414) (102,519) (102,933) Balance at December 31, 2009 93,281 $ 9 $ 1,327,942 $ 1,025 $ (1,226,609) $ 102,367 (1) Employee plans include our Employee Stock Purchase and 401K Plans The accompanying notes are an integral part of these consolidated financial statements. 59 NEKTAR THERAPEUTICS CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation and amortization Stock-based compensation Other non-cash transactions Gain on sale of pulmonary assets Gain on extinguishment of debt Impairment of long-lived assets Changes in assets and liabilities: Decrease (increase) in trade accounts receivable Decrease (increase) in inventory Decrease (increase) in other assets Increase (decrease) in accounts payable Increase (decrease) in accrued compensation Increase (decrease) in accrued clinical trial expenses Increase (decrease) in accrued expenses to contract manufacturers Increase (decrease) in accrued expenses Increase (decrease) in deferred revenue Increase (decrease) in other liabilities Net cash provided by (used in) operating activities Cash flows from investing activities: Purchases of property and equipment Advance payments for property and equipment Maturities of investments Sales of investments Purchases of investments Proceeds from sale of pulmonary assets Investment in Pearl Therapeutics Net cash provided by (used in) investing activities Cash flows from financing activities: Issuance of common stock, net of issuance costs Payments of loan and capital lease obligations Repayments of convertible subordinated notes Net cash provided by (used in) financing activities Effect of exchange rates on cash and cash equivalents Net (decrease) increase in cash and cash equivalents Cash and cash equivalents at beginning of year Cash and cash equivalents at end of year Supplemental disclosure of cash flows information: Cash paid for interest Cash paid for income taxes Supplemental schedule of non-cash investing and financing activities: Property acquired through capital leases Years ended December 31, 2009 2008 2007 $ (102,519) $ (34,336) $ (32,761) 14,881 10,326 (657) — — — 6,034 2,848 (200) (8,046) (1,518) (3,455) — (4,191) 126,795 (559) 22,489 9,871 1,251 (69,572) (50,149) 1,458 10,476 2,868 1,166 6,181 (3,382) 14,727 (40,444) (1,332) (15,392) (1,662) 29,028 14,779 109 — — 28,396 24,318 1,503 7,443 (3,147 ) 986 907 40,444 (5,200 ) 40,863 (1,366 ) $ 39,739 $ (145,782) $ 146,302 (16,390) (4,312) 310,707 17,318 (451,918) (4,440) — (18,855) — 588,168 70,060 (475,316) 114,831 (4,236) (32,796) — 591,202 2,057 (593,118) — — $ (149,035) $ 274,652 $ (32,655) 4,820 (1,285) — 384 (2,368) (47,757) 3,780 (2,895) (102,653) $ 3,535 $ (49,741) $ (101,768) (226) $ (105,987) $ 155,584 162 79,291 76,293 49,597 $ 155,584 11,225 743 $ $ 14,702 812 654 12,533 63,760 76,293 17,389 801 $ $ $ $ — $ — $ 4,445 $ $ $ $ The accompanying notes are an integral part of these consolidated financial statements. 60 NEKTAR THERAPEUTICS NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2009 Note 1—Organization and Summary of Significant Accounting Policies Organization We are a clinical-stage biopharmaceutical company headquartered in San Carlos, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our PEGylation and advanced polymer conjugate technology platforms designed to improve the therapeutic benefits of drugs. Basis of Presentation, Principles of Consolidation and Use of Estimates Our consolidated financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Nektar Therapeutics AL, Corporation (Nektar AL), Nektar Therapeutics (India) Private Limited, Nektar Therapeutics UK, Ltd. (Nektar UK) and Aerogen, Inc. All intercompany accounts and transactions have been eliminated in consolidation. The merger of Nektar AL, an Alabama corporation, with and into its parent corporation, Nektar Therapeutics, was made effective July 31, 2009. As of the effective date, the separate existence of the Alabama corporation ceased, and all rights, privileges, powers and franchises of the Alabama corporation are vested in Nektar Therapeutics, the surviving corporation. Our consolidated financial statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary’s financial results into U.S. dollars for purposes of reporting our consolidated financial results. Translation gains and losses are included in accumulated other comprehensive loss in the stockholders’ equity section of the balance sheet. To date, such cumulative translation adjustments have not been material to our consolidated financial position. Aggregate gross foreign currency transaction gains (losses) recorded in operations for the years ended December 31, 2009, 2008, and 2007 were not material. The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, we evaluate our estimates, including those related to deferred revenue amortization periods, inventories and related impairment of investments and long-lived assets, restructuring and contingencies, stock-based compensation, and litigation, amongst others. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications have not impacted previously reported revenues, operating loss or net loss. Cash, Cash Equivalents, and Investments and Fair Value of Financial Instruments We consider all investments in marketable securities with an original maturity of three months or less to be cash equivalents. Investments are designated as available-for-sale and are carried at fair value, with unrealized gains and losses reported in stockholders’ equity as accumulated other comprehensive income (loss). The disclosed fair value related to our investments is based primarily on the reported fair values in our period-end brokerage statements. We independently validate these fair values using available market quotes and other information. Investments with maturities greater than one year from the balance sheet date, if any, are classified as long-term. Interest and dividends on securities classified as available-for-sale, as well as amortization of premiums and accretion of discounts to maturity, are included in interest income. Realized gains and losses and declines in value of available-for-sale securities judged to be other-than-temporary, if any, are included in other income (expense). The cost of securities sold is based on the specific identification method. 61 The carrying value of cash, cash equivalents, and investments approximates fair value and is based on quoted market prices. Accounts Receivable and Significant Customer Concentrations Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S. and Europe. Our accounts receivable balance contains billed and unbilled trade receivables from product sales and royalties and collaborative research agreements. We provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We generally do not require collateral from our customers. We perform a regular review of our customers’ payment histories and associated credit risk. We have not experienced significant credit losses from our accounts receivable. At December 31, 2009, four different customers represented 30%, 29%, 13%, and 13%, respectively, of our accounts receivable. At December 31, 2008, three different customers represented 29%, 19%, and 15%, respectively, of our accounts receivable. Inventories and Significant Supplier Concentrations Inventories are computed on a first-in, first-out basis and stated net of reserves at the lower of cost or market. Inventory costs include direct materials, direct labor, and manufacturing overhead. Supplies inventory related to research and development activities are expensed when purchased. We are dependent on our partners and vendors to provide raw materials, drugs and devices of appropriate quality and reliability and to meet applicable regulatory requirements. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our products could be impaired, which could have a material adverse effect on our business, financial condition and results of operation. Property and Equipment Property and equipment are stated at cost. Major improvements are capitalized, while maintenance and repairs are expensed when incurred. Manufacturing, laboratory and other equipment are depreciated using the straight-line method generally over estimated useful lives of three to seven years. Leasehold improvements and buildings are depreciated using the straight-line method over the shorter of the estimated useful life or the remaining term of the lease. We periodically review our property and equipment for recoverability whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Generally, an impairment loss would be recognized if the carrying amount of an asset exceeds the sum of the discounted cash flows expected to result from the use and eventual disposal of the asset (See Note 12). Goodwill Goodwill represents the excess of the price paid for another entity over the fair value of the assets acquired and liabilities assumed in a business combination. We test for impairment in the fourth quarter of each year using an October 1 measurement date, as well as at other times when impairment indicators exist or when events occur or circumstances change that would indicate the carrying amount may not be fully recoverable. We are organized in one reporting unit and have evaluated the goodwill for the Company as a whole. Goodwill is tested for impairment using a two-step approach. The first step is to compare the fair value of our net assets, including assigned goodwill, to the book value of our net assets, including assigned goodwill. If the fair value is greater than our net book value, the assigned goodwill is not considered impaired. If the fair value is less than our net book value, we perform a second step to measure the amount of the impairment, if any. The second step would be to compare the book value of our assigned goodwill to the implied fair value of our goodwill. As of December 31, 2009 and 2008, the carrying value of our goodwill was $76.5 million. We did not recognize any goodwill-related impairment charges during 2009, 2008 or 2007. Revenue Recognition Product sales and royalties Product sales are primarily derived from cost-plus manufacturing and supply agreements with our collaboration partners and revenue is recognized in accordance with the terms of the related agreement. We have not experienced any significant returns from our customers. 62 Generally, we are entitled to royalties from our partners based on their net sales once their products are approved for commercial sale. We recognize royalty revenue when the cash is received or when the royalty amount to be received is estimable and collection is reasonably assured. License, collaboration and other We enter into technology license agreements and collaborative research and development arrangements with pharmaceutical and biotechnology partners that may involve multiple deliverables. Our arrangements may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees. Each deliverable in the arrangement is evaluated to determine whether it meets the criteria to be accounted for as a separate unit of accounting or whether it should be combined with other deliverables. Revenue is recognized for each element when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured. Upfront fees received for license and collaborative agreements are recognized ratably over our expected performance period under the arrangement. Management makes its best estimate of the period over which we expect to fulfill our performance obligations, which may include technology transfer assistance, clinical development activities, and manufacturing activities from development through the commercialization of the product. Given the uncertainties of research and development collaborations, significant judgment is required to determine the duration of the performance period. Performance milestones payments received are deferred and recorded as revenue ratably over the period of time from the achievement of the milestone and our estimated date on which the next milestone will be achieved. Management makes its best estimate of the period of time until the next milestone is reached. Final milestone payments are recorded and recognized upon achieving the respective milestone, provided that collection is reasonably assured. The original estimated amortization periods for upfront fees and milestone payments are periodically evaluated to determine if circumstances have caused the estimate to change and if so, amortization of revenue is adjusted prospectively. Shipping and Handling Costs We record costs related to shipping and handling of product to customers in cost of goods sold. Stock-Based Compensation Stock-based compensation arrangements include stock option grants and restricted stock unit (RSU) awards under our equity incentive plans and our Employee Stock Purchase Plan (ESPP), in which employees may purchase our common stock at a discount to the market price. We use the Black-Scholes option valuation model, adjusted for the estimated historical forfeiture rate, for the respective grant to determine the estimated fair value of the option or RSU award on the date of grant (grant date fair value) and the estimated fair value of common stock purchased under the ESPP. The Black-Scholes option pricing model requires the input of highly subjective assumptions. Because our employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models may not provide a reliable single measure of the fair value of our employee stock options or common stock purchased under the ESPP. Management will continue to assess the assumptions and methodologies used to calculate estimated fair value of stock-based compensation. Circumstances may change and additional data may become available over time, which could result in changes to these assumptions and methodologies, and which could materially impact our fair value determination. We expense the value of the portion of the option or award that is ultimately expected to vest on a straight line basis over the requisite service periods in our Consolidated Statements of Operations. Stock-based compensation expense for purchases under the ESPP are recognized based on the estimated fair value of the common stock during each offering period and the percentage of the purchase discount. Expense amounts are allocated among inventory, cost of goods sold, research and development expenses, and general and administrative expenses based on the function of the applicable employee. 63 Research and Development Expense Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Costs associated with treatment phase of clinical trials are accrued based on the total estimated cost of the clinical trials and are expensed ratably based on patient enrollment in the trials. Costs associated with the start-up and reporting phases of the clinical trials are expensed ratably over the duration of the reporting and start-up phases. Net Loss Per Share Basic net loss per share is calculated based on the weighted-average number of common shares outstanding during the periods presented. For all periods presented in the Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. Basic and diluted net loss per share are the same due to our historical net losses and the requirement to exclude potentially dilutive securities which would have an anti-dilutive effect on net loss per share. The weighted average of these potentially dilutive securities has been excluded from the diluted net loss per share calculation and is as follows (in thousands): Convertible subordinated notes Stock options Total Income Taxes Years ended December 31, 2009 2008 2007 9,989 10,653 13,804 14,147 15,781 11,108 20,642 27,951 26,889 We account for income taxes under the liability method; under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax reporting bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We utilize a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. We have incurred net operating losses since inception and we do not have any significant unrecognized tax benefits. Our policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for taxes in the consolidated statements of operations. If we are eventually able to recognize our uncertain positions, our effective tax rate may be reduced. We currently have a full valuation allowance against our net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future. Any adjustments to our uncertain tax positions would result in an adjustment of our net operating loss or tax credit carry forwards rather than resulting in a cash outlay. We file income tax returns in the U.S., California, Alabama, India and the U.K. We are currently not the subject of any income tax examinations. In general, the earliest open year subject to examination is 2006 for U.S. and Alabama and 2005 for California, although depending upon the jurisdiction tax years may remain open, subject to certain limitations. Recent Accounting Pronouncements FASB Accounting Standards Update 2009-13, Revenue Recognition (Topic 605) – Multiple-Deliverable Revenue Arrangements In October 2009, the FASB published FASB Accounting Standards Update (ASU) 2009-13, which amends the criteria to identify separate units of accounting within Subtopic 605-25, Revenue Recognition-Multiple-Element Arrangements. The revised guidance 64 also expands the disclosure required for multiple-element revenue arrangements. FASB ASU No. 2009-13 is effective for fiscal years beginning on or after June 15, 2010, and may be applied retrospectively for all periods presented or prospectively to arrangements entered into or materially modified after the adoption date. Early adoption is permitted provided that the revised guidance is retroactively applied to the beginning of the year of adoption. We are currently evaluating the impact of adoption on our financial position and results of operations. FASB ASU No. 2010-6, Improving Disclosures About Fair Value Measurements In January 2010, the FASB issued ASU No. 2010-6, Improving Disclosures About Fair Value Measurements, that adds required disclosures about items transferring into and out of Levels 1 and 2 in the fair value hierarchy; adding separate disclosures about purchase, sales, issuances, and settlements relative to Level 3 measurements; and clarifying, among other things, the existing fair value disclosures about the level of disaggregation. FASB ASU No. 2010-6 is effective for interim and annual reporting periods beginning after December 15, 2009, except for the requirement to provide level 3 purchases, sales, issuances, and settlements on a gross basis, which is effective for fiscal years beginning after December 15, 2010. Since this standard impacts disclosure requirements only, we do not expect its adoption will have a material impact on our financial statements. Note 2—Cash, Cash Equivalents, and Available-For-Sale Investments Cash, cash equivalents, and available-for-sale investments are as follows (in thousands): Cash and cash equivalents Short-term investments (less than one year to maturity) Total cash, cash equivalents, and available-for-sale investments Estimated Fair Value at December 31, 2009 December 31, 2008 $ 49,597 346,614 $ 396,211 $ 155,584 223,410 $ 378,994 Our portfolio of cash, cash equivalents, and available-for-sale investments includes (in thousands): Obligations of U.S. corporations Obligations of U.S. government agencies U.S. corporate commercial paper Obligations of U.S. states and municipalities Cash and money market funds Total cash, cash equivalents, and available-for-sale investments Estimated Fair Value at December 31, 2009 December 31, 2008 $ 160,458 125,731 71,923 4,995 33,104 $ 396,211 $ 26,275 91,667 115,658 — 145,394 $ 378,994 The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in short-term securities and maintain a weighted average maturity of one year or less. At December 31, 2009, the average portfolio duration was approximately five months and the contractual maturity of any single investment did not exceed twelve months. At December 31, 2008, the average portfolio duration was approximately two months and the contractual maturity of any single investment did not exceed twelve months. Gross unrealized gains and losses were insignificant at December 31, 2009 and at December 31, 2008. The gross unrealized losses were primarily due to changes in interest rates on fixed income securities. Based on our available cash and our expected operating cash requirements we do not intend to sell these securities and it is more likely than not that we will not be required to sell these securities before we recover the amortized cost basis. Accordingly, we believe there are no other-than-temporary impairments on these securities and have not recorded a provision for impairment. 65 During the years ended December 31, 2009 and 2008, we sold available-for-sale securities totaling $17.3 million and $70.1 million, respectively. We realized gains in the income statement of $0.1 million and $0.1 million in 2009 and 2008, respectively. In 2009, we sold securities in response to a tender offer from a bond issuer and we sold securities which no longer met the minimum credit rating required by our investment policy. During 2008 we sold securities to fund our convertible subordinated note repurchase. At December 31, 2009 and 2008, we had letter of credit arrangements with certain financial institutions and vendors, including our landlord, totaling $2.9 million. These letters of credit are secured by investments of similar amounts. The following table represents the fair value hierarchy for our financial assets measured at fair value on a recurring basis as of December 31, 2009 (in thousands): Money market funds U.S. corporate commercial paper Obligations of U.S. corporations Obligations of U.S. government agencies Obligations of U.S. states and municipalities Cash equivalents and available-for-sale investments Cash Cash, cash equivalents, and available-for-sale investments Level 1—Quoted prices in active markets for identical assets or liabilities. Level 1 Level 2 Level 3 Total $ 24,585 — — — — $ — $ — $ 71,923 160,458 125,731 4,995 — — — — 24,585 71,923 160,458 125,731 4,995 $ 24,585 $ 363,107 $ — $ 387,692 8,519 $ 396,211 Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Note 3—Inventory Inventory consists of the following (in thousands): Raw materials Work-in-process Finished goods Inventory December 31, 2009 2008 $ 5,937 — 534 $ 6,964 1,743 612 $ 6,471 $ 9,319 Inventory is manufactured upon receipt of firm purchase orders from our licensing partners. Inventory includes direct materials, direct labor, and manufacturing overhead and is computed on a first-in, first-out basis. Inventory is stated at the lower of cost or market and is net of reserves of $3.3 million and $5.0 million as of December 31, 2009 and December 31, 2008, respectively. Reserves are determined using specific identification plus an estimated reserve for potential defective or excess inventory based on historical experience or projected usage. 66 Note 4—Property and Equipment Property and equipment consist of the following (in thousands): Building and leasehold improvements Laboratory equipment Manufacturing equipment Furniture, fixtures and other equipment Depreciable Property and equipment at cost Less: accumulated depreciation Depreciable Property and equipment, net Construction-in-progress Property and equipment, net December 31, 2009 2008 $ $ 62,973 27,195 10,982 16,876 62,260 24,549 8,682 14,717 $ 118,026 (54,400) $ 110,208 (43,505) 63,626 14,637 66,703 6,875 $ 78,263 $ 73,578 Building and leasehold improvements include our commercial manufacturing, clinical manufacturing, research and development and administrative facilities and the related improvements to these facilities. Laboratory and manufacturing equipment includes assets that support both our manufacturing and research and development efforts. Construction-in-progress includes assets being built to enhance our manufacturing and research and development programs. Property and equipment includes assets acquired through capital leases (See Note 6). During 2009, we made advanced payments of $4.3 million for equipment that had not been received by December 31, 2009; these advances were classified as Other Assets on our Consolidated Balance Sheets. Depreciation expense, including depreciation of assets acquired through capital leases, for the years ended December 31, 2009, 2008, and 2007 was $12.7 million, $19.8 million, and $25.9 million, respectively. On December 31, 2008, we sold certain assets and obligations related to our pulmonary technology, development and manufacturing operations to Novartis Pharmaceuticals Corporation and Novartis Pharma AG (together referred to as Novartis), including property and equipment with a gross book value of $108.0 million, accumulated depreciation of $70.7 million, and a net book value of $37.3 million (See Note 10). Note 5—Convertible Subordinated Notes The outstanding balance of our convertible subordinated notes is as follows (in thousands): 3.25% Notes due September 2012 Semi-Annual Interest Payment Dates December 31, 2009 2008 March 28, September 28 $ 214,955 $ 214,955 Our convertible subordinated 3.25% notes due September 2012 (Notes) are unsecured and subordinated in right of payment to any future senior debt. Costs related to the issuance of these Notes are recorded in other assets in our Consolidated Balance Sheets and are generally amortized to interest expense on a straight-line basis over the contractual life of the Notes. The unamortized deferred financing costs were $1.0 million and $2.2 million as of December 31, 2009 and 2008, respectively. Gain on Extinguishment of Debt During the fourth quarter of 2008, we repurchased $100.0 million par value of the Notes for $47.8 million. The recognized gain on debt extinguishment of $50.1 million is net of transaction costs of $1.0 million and accelerated amortization of deferred financing costs of $1.1 million. 67 Conversion and Redemption The Notes are convertible at the option of the holder at any time on or prior to maturity into shares of our common stock. The Notes have a conversion rate of 46.4727 shares per $1,000 principal amount, which is equal to a conversion price of approximately $21.52 per share. Additionally, at any time prior to maturity, if a fundamental change as defined in the Note agreement occurs, we may be required to pay a make-whole premium on notes converted in connection therewith by increasing the applicable conversion rate. We may redeem the Notes in whole or in part for cash at a redemption price equal to 100% of the principal amount of the Notes plus any accrued but unpaid interest if the closing price of the common stock has exceeded 150% of the conversion price for at least 20 days in any consecutive 30 day trading period. Note 6—Leases Capital Leases We lease office space and office equipment under capital lease arrangements. The gross carrying value by major asset class and accumulated depreciation as of December 31, 2009 and 2008 are as follows (in thousands): Building and leasehold improvements Furniture, fixtures and other equipment Total assets recorded under capital leases Less: accumulated depreciation Net assets recorded under capital leases December 31, 2009 2008 $ $ $ 23,960 — $ 23,962 261 23,960 (10,072) $ 24,223 (8,050) 13,888 $ 16,173 We lease office space at 201 Industrial Road in San Carlos, California under capital lease arrangements. Under the terms of the lease, the rent will increase up to 3% annually. The lease termination date is October 5, 2016. Future minimum payments for our capital leases at December 31, 2009 are as follows (in thousands): Years ending December 31, 2010 2011 2012 2013 2014 2015 and thereafter Total minimum payments required Less: amount representing interest Present value of future payments Less: current portion Non-current portion Operating Leases $ $ $ $ 4,752 4,854 4,956 5,062 5,169 9,314 34,107 (13,760) 20,347 (1,547) 18,800 During 2008 and 2007, we were party to an operating lease for our San Carlos manufacturing facility through 2012. On December 31, 2008, this operating lease was assigned to Novartis Pharmaceuticals Inc as part of the pulmonary asset sale. See Note 10. We have no further liabilities related to this lease. 68 On September 30, 2009, we entered into an operating sublease (Sublease) with Pfizer, Inc. for a 102,283 square foot facility located at 455 Mission Bay Boulevard, San Francisco, California (Mission Bay Facility). The Mission Bay Facility is currently under construction and is scheduled to be completed by the end of 2010. We are responsible for all tenant improvement costs which we currently estimate to be approximately $20 million. When completed, the Mission Bay Facility will include an R&D center with biology, chemistry, pharmacology, and clinical development capabilities, as well as all of our functions currently located in San Carlos, California, including our corporate headquarters. Under the terms of the Sublease, we will begin making non-cancelable lease payments in 2014, after a four year free rent period currently estimated to end on August 1, 2014. The Sublease term commences in March 2010 and is 114 months, currently estimated to end on January 30, 2020. Monthly base rent will start at $2.95 per square foot and will escalate over the term of the sublease at various intervals to $3.42 per square foot in the final period of the Sublease term. Rent expense will be recognized ratably beginning March 2010, the inception of our tenant improvement construction period, though the end of the Sublease term. In addition, throughout the term of the Sublease, we are responsible for paying certain costs and expenses specified in the sublease, including insurance costs and a pro rata share of operating expenses and applicable taxes for the Mission Bay Facility. Our future minimum lease payments under the Mission Bay sublease are as follows (in thousands): Years ending December 31, 2010 2011 2012 2013 2014 2015 and thereafter Total future minimum lease payments $ — — — — 1,509 19,811 $ 21,320 We recognize rent expense on a straight-line basis over the lease period. For the years ended December 31, 2009, 2008, and 2007, rent expense for operating leases was approximately $0.7 million, $3.5 million, and $4.3 million. Note 7—Commitments and Contingencies Royalty Expense We have certain royalty commitments associated with the shipment and licensing of certain products. Royalty expense, which is reflected in cost of goods sold in our Consolidated Statements of Operations, was approximately $3.9 million, $4.8 million, and $3.9 million for the years ended December 31, 2009, 2008, and 2007, respectively. The overall maximum amount of the obligations is based upon sales of the applicable product and cannot be reasonably estimated. Legal Matters From time to time, we may be involved in lawsuits, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, ruling, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of operations of that period or on our cash flows and liquidity. Indemnifications in Connection with Commercial Agreements As part of our collaboration agreement with our partners related to the license, development, manufacture and supply of drugs based on our proprietary technologies, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual 69 property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual any time after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations. As part of our pulmonary asset sale to Novartis that closed on December 31, 2008, we and Novartis made representations and warranties and entered into certain covenants and ancillary agreements which are supported by an indemnity obligation. In the event it were determined that we breached any of the representations and warranties or covenants and agreements made by us in the transaction documents, we could incur an indemnification liability depending on the timing, nature, and amount of any such claims. To date we have not incurred costs to defend lawsuits or settle claims related to these indemnification obligations. If any of our indemnification obligations is triggered, we may incur substantial liabilities. Because the obligated amount under these agreements is not explicitly stated, the overall maximum amount of the obligations cannot be reasonably estimated. No liabilities have been recorded for these obligations on our Consolidated Balance Sheets as of December 31, 2009 or 2008. Indemnification of Underwriters and Initial Purchasers of our Securities In connection with our sale of equity and convertible debt securities, we have agreed to defend, indemnify and hold harmless our underwriters or initial purchasers, as applicable, as well as certain related parties from and against certain liabilities, including liabilities under the Securities Act of 1933, as amended. The term of these indemnification obligations is generally perpetual. There is no limitation on the potential amount of future payments we could be required to make under these indemnification obligations. We have never incurred costs to defend lawsuits or settle claims related to these indemnification obligations. If any of our indemnification obligations are triggered, however, we may incur substantial liabilities. Because the obligated amount of this agreement is not explicitly stated, the overall maximum amount of the obligations cannot be reasonably estimated. Historically, we have not been obligated to make significant payments for these obligations, and no liabilities have been recorded for these obligations in our Consolidated Balance Sheets as of December 31, 2009 or 2008. Director and Officer Indemnifications As permitted under Delaware law, and as set forth in our Certificate of Incorporation and our Bylaws, we indemnify our directors, executive officers, other officers, employees, and other agents for certain events or occurrences that arose while in such capacity. The maximum potential amount of future payments we could be required to make under this indemnification is unlimited; however, we have insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe any obligations under this indemnification are not material, other than an initial $500,000 per incident for securities related claims and $250,000 per incident for non-securities related claims retention deductible per our insurance policy. However, no assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations. Because the obligated amount of this agreement is not explicitly stated, the overall maximum amount of the obligations cannot be reasonably estimated. Historically, we have not been obligated to make significant payments for these obligations, and no liabilities have been recorded for these obligations in our Consolidated Balance Sheets as of December 31, 2009 or 2008. Note 8—Stockholders’ Equity Preferred Stock We have authorized 10,000,000 shares of Preferred Stock, each share having a par value of $0.0001. Of these shares, 3,100,000 shares are designated Series A Junior Participating Preferred Stock (Series A Preferred Stock). The remaining shares are undesignated. We have no preferred shares issued and outstanding as of December 31, 2009 or 2008. Series A Preferred Stock On June 1, 2001, the Board of Directors approved the adoption of a Share Purchase Rights Plan. Terms of the Rights Plan provide for a dividend distribution of one preferred share purchase right for each outstanding share of our Common Stock. The Rights have 70 certain anti-takeover effects and will cause substantial dilution to a person or group that attempts to acquire us on terms not approved by our Board of Directors. The dividend distribution was payable on June 22, 2001, to the stockholders of record on that date. Each Right entitles the registered holder to purchase from us one one-hundredth of a share of Series A Preferred Stock at a price of $225.00 per one one-hundredth of a share of Series A Preferred Stock, subject to adjustment. Each one one-hundredth of a share of Series A Preferred Stock has designations and powers, preferences and rights, and the qualifications, limitations and restrictions which make its value approximately equal to the value of one share of common stock. The Rights are not exercisable until the Distribution Date (as defined in the Certificate of Designation for the Series A Preferred Stock). The Rights will expire on June 1, 2011, unless the Rights are earlier redeemed or exchanged by us. Each share of Series A Preferred Stock will be entitled to a minimum preferential quarterly dividend payment of $1.00, or if greater than $1.00, will be entitled to an aggregate dividend of 100 times the dividend declared per share of Common Stock. In the event of liquidation, the holders of the Series A Preferred Stock would be entitled to $100 per share or, if greater than $100, an aggregate payment equal to 100 times the payment made per share of Common Stock. Each share of Series A Preferred Stock will have 100 votes, voting together with the Common Stock. Finally, in the event of any merger, consolidation or other transaction in which our Common Stock is exchanged, each share of Series A Preferred Stock will be entitled to receive 100 times the amount of consideration received per share of Common Stock. The Series A Preferred Stock would rank junior to any other future series of preferred stock. Until a Right is exercised, the holder thereof, as such, will have no rights as a stockholder, including, without limitation, the right to vote or to receive dividends. Reserved Shares At December 31, 2009, we have reserved shares of common stock for issuance as follows (in thousands): Convertible subordinated notes Stock option plans 401(k) retirement plans Total Stock Option Plans As of December 31, 2009 9,989 28,265 220 38,476 The following table summarizes information with respect to shares of our common stock that may be issued under our existing equity compensation plans as of December 31, 2009 (share number in thousands): Plan Category Equity compensation plans approved by security holders (2) Equity compensation plans not approved by security holders Total Number of securities to be issued upon exercise of outstanding options (a) (1) Weighted-average exercise price of outstanding options (b) Number of securities remaining available for issuance under equity compensation plans (excluding securities reflected in column(a)) (c) 8,726 5,513 14,239 $ 9.61 $ 9.17 $ 9.42 10,967 3,029 13,996 (1) Does not include options 31,738 shares we assumed in connection with the acquisition of Shearwater Corporation (with a weighted-average exercise price of $0.03 per share). (2) Includes shares of common stock available for future issuance under our ESPP as of December 31, 2009. 2008 Equity Incentive Plan Our 2008 Equity Incentive Plan (2008 Plan) was adopted by the Board of Directors on March 20, 2008 and was approved by our stockholders on June 6, 2008. The purpose of the 2008 Equity Incentive Plan is to attract and retain qualified personnel, to provide 71 additional incentives to our employees, officers, consultants and employee directors and to promote the success of our business. Pursuant to the 2008 Plan, we may grant or issue incentive stock options to employees and officers and non-qualified stock options, rights to acquire restricted stock, restricted stock units, and stock bonuses to consultants, employees, officers and non-employee directors. The maximum number of shares of our common stock that may be issued or transferred pursuant to awards under the 2008 Plan is 9,000,000 shares. Shares issued in respect of any stock bonus or restricted stock award granted under the 2008 Plan will be counted against the plan’s share limit as 1.5 shares for every one share actually issued in connection with the award. The 2008 Plan will terminate on March 20, 2018, unless earlier terminated by the Board of Directors. The maximum term of a stock option under the 2008 Equity Incentive Plan is eight years, but if the optionee at the time of grant has voting power of more than 10% of our outstanding capital stock, the maximum term of an incentive stock option is five years. The exercise price of stock options granted under the 2008 Plan must be at least equal to 100% (or 110% with respect to holders of more than 10% of the voting power of our outstanding capital stock) of the fair market value of the stock subject to the option as determined by the closing price of our common stock on the Nasdaq Global Market on the date of grant. To the extent that shares are delivered pursuant to the exercise of a stock option, the number of underlying shares as to which the exercise related shall be counted against the applicable share limits of the 2008 Plan, as opposed to only counting the shares actually issued. Shares that are subject to or underlie awards which expire or for any reason are cancelled or terminated, are forfeited, fail to vest or for any other reason are not paid or delivered under the 2008 Plan will again be available for subsequent awards under the 2008 Plan. 2000 Equity Incentive Plan On April 19, 2000 the Board of Directors adopted our 2000 Equity Incentive Plan (2000 Plan) by amending and restating our 1994 Equity Incentive Plan. On February 9, 2010, the 2000 Plan was terminated. As a result, no new options may be granted, but existing options granted remain outstanding. The purpose of the 2000 Equity Incentive Plan was to attract and retain qualified personnel, to provide additional incentives to our employees, officers, consultants and employee directors and to promote the success of our business. Pursuant to the 2000 Plan, we granted or issued incentive stock options to employees and officers and non-qualified stock options, rights to acquire restricted stock, restricted stock units, and stock bonuses to consultants, employees, officers and non-employee directors. The maximum term of a stock option under the 2000 Plan is eight years, but if the optionee at the time of grant has voting power of more than 10% of our outstanding capital stock, the maximum term of an incentive stock option is five years. The exercise price of incentive stock options granted under the 2000 Equity Incentive Plan must be at least equal to 100% (or 110% with respect to holders of more than 10% of the voting power of our outstanding capital stock) of the fair market value of the stock subject to the option as determined by the closing price of our common stock on the Nasdaq Global Market on the date of grant. 2000 Non-Officer Equity Incentive Plan Our 1998 Non-Officer Equity Incentive Plan was adopted by the Board of Directors on August 18, 1998, and was amended and restated in its entirety and renamed the 2000 Non-officer Equity Incentive Plan on June 6, 2000 (2000 Non-Officer Plan). The purpose of the 2000 Non-Officer Plan is to attract and retain qualified personnel, to provide additional incentives to employees and consultants and to promote the success of our business. Pursuant to the 2000 Non-Officer Plan, we may grant or issue non-qualified stock options, rights to acquire restricted stock and stock bonuses to employees and consultants who are neither Officers nor Directors of Nektar. The maximum term of a stock option under the 2000 Non-Officer Plan is eight years. The exercise price of stock options granted under the 2000 Non-Officer Plan are determined by the Board of Directors by reference to closing price of our common stock on the Nasdaq Global Market. Non-Employee Directors’ Stock Option Plan On February 10, 1994, our Board of Directors adopted the Non-Employee Directors’ Stock Option Plan under which options to purchase up to 400,000 shares of our Common Stock at the then fair market value may be granted to our non-employee directors. There are no remaining options available for grant under this plan as of December 31, 2009. 72 Restricted Stock Units During the years ended December 31, 2009, 2008 and 2007, we issued RSU awards to certain officers, non-employees, directors, employees and consultants. RSU awards are similar to restricted stock in that they are issued for no consideration; however, the holder generally is not entitled to the underlying shares of common stock until the RSU award vests. Also, because the RSU awards are issued for $0.01 per share, the grant-date fair value of the award is equal to the intrinsic value of our common stock on the date of grant. The RSU awards were issued under both the 2000 Plan and the 2000 Non-Officer Plan and are settled by delivery of shares of our common stock on or shortly after the date the awards vest. Beginning with shares granted in the year ended December 31, 2005, each RSU award depletes the pool of options available for grant under our equity incentive plans by a ratio of 1:1.5. Employee Stock Purchase Plan In February 1994, our Board of Directors adopted the ESPP, pursuant to section 423(b) of the Internal Revenue Code of 1986. Under the ESPP, 800,000 shares of common stock have been authorized for issuance. The terms of the ESPP provide eligible employees with the opportunity to acquire an ownership interest in Nektar through participation in a program of periodic payroll deductions for the purchase of our common stock. Employees may elect to enroll or re-enroll in the plan on a semi-annual basis. Stock is purchased at 85% of the lower of the closing price on the first day of the enrollment period or the last day of the enrollment period. 401(k) Retirement Plan We sponsor a 401(k) retirement plan whereby eligible employees may elect to contribute up to the lesser of 60% of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. The 401(k) plan permits us to make matching contributions on behalf of all participants, up to a maximum of $3,000 per participant. For the years ended December 31, 2009 and 2008, we recognized $0.8 million and $1.1 million, respectively, of compensation expense in connection with our 401(k) retirement plan. For the year ended December 31, 2007, we issued approximately 161,000 shares of common stock valued at $1.6 million in connection with our 401(k) retirement plan. Change in Control Severance Plan On December 6, 2006, the Board of Directors approved a Change of Control Severance Benefit Plan (CIC Plan) and on February 14, 2007 and October 21, 2008, the Board of Directors amended and restated the CIC Plan. The CIC Plan is designed to make certain benefits available to eligible employees of the Company in the event of a change of control of the Company and, following such change of control, an employee’s employment with the Company or a successor company is terminated in certain specified circumstances. We adopted the CIC Plan to support the continuity of the business in the context of a change of control transaction. The CIC Plan was not adopted in contemplation of any specific change of control transaction. A brief description of the material terms and conditions of the CIC Plan is provided below. Under the CIC Plan, in the event of a change of control of the Company and a subsequent termination of employment initiated by the Company or a successor company other than for Cause or initiated by the employee for a Good Reason Resignation (as hereinafter defined) in each case within twelve months following a change of control transaction, (i) the Chief Executive Officer would be entitled to receive cash severance pay equal to 24 months base salary plus annual target incentive pay, the extension of employee benefits over this severance period and the full acceleration of unvested outstanding equity awards, and (ii) the Senior Vice Presidents and Vice Presidents (including Principal Fellows) would each be entitled to receive cash severance pay equal to twelve months base salary plus annual target incentive pay, the extension of employee benefits over this severance period and the full acceleration of unvested outstanding equity awards. In the event of a change of control of the Company and a subsequent termination of employment initiated by the Company or a successor company other than for cause within twelve months following a change of control transaction, all other employees would each be entitled to receive cash severance pay equal to 6 months base salary plus annual target incentive pay, the extension of employee benefits over this severance period and the full acceleration of each such employee’s unvested outstanding equity awards. On December 6, 2006, the Board of Directors approved an amendment to all outstanding stock awards held by non-employee directors to provide for full acceleration of vesting in the event of a change of control transaction. 73 Note 9 —License and Collaboration Agreements We have entered into various license agreements and collaborative research and development agreements with pharmaceutical and biotechnology companies. Under these arrangements, we are entitled to receive license fees, upfront payments, milestone payments when and if certain development or regulatory milestones are achieved, and/or reimbursement for research and development activities. All of our research and development agreements are generally cancelable by our partners without significant financial penalty to the partner. Our costs of performing these services are included in Research and development expense. In accordance with these agreements, we recorded License, collaboration and other revenue as follows (in thousands): Partner Agreement NKTR-118 and NKTR-119 BAY41-6651 (NKTR-061, Amikacin Inhale) Pegasys Tobramycin inhalation powder (TIP) Cipro Inhale (CIP) Exubera® inhalation powder and Next-generation inhaled insulin (NGI) AstraZeneca AB Bayer Healthcare LLC F. Hoffmann La-Roche Novartis Vaccines and Diagnostics, Inc. Bayer Schering Pharma AG Pfizer Inc. Other License, collaboration and other revenue AstraZeneca AB NKTR-118 and NKTR-119 Years ended December 31, 2009 2008 2007 $ 25,073 4,928 214 564 — — 5,864 $ — $ 10,054 1,000 13,723 11,653 — 12,500 — 1,306 — 17,036 8,116 49,490 16,324 $ 36,643 $ 48,930 $ 92,272 On September 20, 2009, we entered into a License Agreement with AstraZeneca AB, a Swedish corporation (AstraZeneca), under which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing, and sublicensable license under our patents and other intellectual property to develop, sell and otherwise commercially exploit Oral NKTR-118 and NKTR-119. AstraZeneca will bear all costs associated with research, development and commercialization and will control product development and commercialization decisions for Oral NKTR-118 and NKTR-119. Under the terms of the agreement, AstraZeneca paid us an upfront payment of $125.0 million, which we received in the fourth quarter of 2009, of which we recognized $23.6 million as License, collaboration and other revenue in 2009. As of December 31, 2009, we have deferred revenue of approximately $101.4 million, which we expect to amortize over the technology transfer period, which is expected to be the end of 2010. We are also entitled to development milestones and sales milestones upon achievement of certain annual sales targets and royalties based on annual worldwide net sales of Oral NKTR-118 and NKTR-119 products. We recognized $1.5 million in reimbursement for technology transfer services related to this agreement during the year ended December 31, 2009. F. Hoffmann La-Roche Ltd and Hoffmann-LaRoche Inc. PEGASYS In February 1997, we entered into a license, manufacturing and supply agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche), under which we granted Roche a worldwide, exclusive license to use certain PEGylation materials in the manufacture of PEGASYS. As a result of Roche exercising a license extension option in December 2009, beginning in 2010 Roche has the right to manufacture all of its requirements for our proprietary PEGylation materials for PEGASYS and we would perform additional manufacturing, if any, only on an as requested basis. In connection with Roche’s exercise of the license option extension in December 2009, we received a payment of $31.0 million of which we have recognized $0.2 million during the year ended December 31, 2009. As of December 31, 2009, we have deferred revenue of approximately $30.8 million, which we expect to amortize over the period through which we are required to provide back-up manufacturing and supply services on an as-requested basis. 74 Bayer Healthcare LLC BAY41-6651 (NKTR-061, Amikacin Inhale) On August 1, 2007, we entered into a co-development, license and co-promotion agreement with Bayer Healthcare LLC to develop a specially-formulated inhaled Amikacin (BAY41-6651). We are responsible for any future development of the nebulizer device included in the Amikacin product through the completion of Phase 3 clinical trial, scale-up for commercialization, and commercial manufacturing and supply. Bayer Healthcare LLC is responsible for most future clinical development and commercialization costs, all activities to support worldwide regulatory filings, approvals and related activities, further development of BAY41-6651 and final product packaging. We received an upfront payment of $40.0 million in 2007 and performance milestone payments of $20.0 million, of which we have recognized $5.0 million, $10.1 million, and $1.3 million during the years ended December 31, 2009, 2008, and 2007, respectively. As of December 31, 2009, we have deferred revenue of approximately $33.8 million, which we expect to amortize through July 2021, the estimated end of the life of the agreement. We are entitled to development milestones and sales milestones upon achievement of certain development milestones and annual sales targets and royalties based on annual worldwide net sales of BAY 41-6651. Novartis Tobramycin inhalation powder (TIP) We were party to a collaborative research, development and commercialization agreement with Novartis Vaccines and Diagnostics, Inc. related to the development of Tobramycin inhalation powder (TIP) for the treatment of lung infections caused by the bacterium Pseudomonas aeruginosa in cystic fibrosis patients. Our collaborative research, development and commercialization agreement with Novartis Vaccines and Diagnostics, Inc. for related to TIP was terminated on December 31, 2008. As part of the termination, we relinquished our rights to future research and development funding and milestone payments, as well as to any future royalty payments or manufacturing revenue. Prior to the termination, we were reimbursed for the cost of work performed on a revenue per annual full-time equivalent (FTE) basis, plus out of pocket third party costs. Revenue recognized approximated the cost associated with these services and was $0.6 million, $14.3 million, and $17.0 million during the years ended December 31, 2009, 2008, and 2007, respectively. Bayer Schering Pharma AG Cipro Inhale We were party to a collaborative research, development and commercialization agreement with Bayer Schering Pharma AG related to the development of an inhaled powder formulation of Cipro Inhale for the treatment of chronic lung infections caused by Pseudomonas aeruginosa in cystic fibrosis patients. As of December 31, 2008, we assigned the collaborative research, development and commercialization agreement to Novartis Pharma AG through which we maintain the right to receive potential royalties in the future based on net product sales if Cipro Inhale receives regulatory approval and is successfully commercialized (See Note 10). Prior to the termination, we were reimbursed for the cost of work performed on a revenue per annual FTE basis and out of pocket third party costs, as well as milestone and upfront fees. Revenue recognized approximated the cost associated with these services and totaled nil, $10.3 million, and $7.7 million during the years ended December 31, 2009, 2008, and 2007, respectively. Pfizer Inc. Exubera® inhalation powder and Next-generation inhaled insulin (NGI) We were a party to collaboration agreements with Pfizer related to the development of Exubera and the next-generation inhaled insulin that terminated on November 9, 2007 (See Note 11). Under the terms of the collaboration agreements, we received contract research and development revenue as well as milestone and upfront fees related to the Exubera bulk powder insulin manufacturing, Exubera inhaler device manufacturing through our contract manufacturers, and development related to NGI. We were reimbursed for the cost of work performed on a revenue per annual FTE basis, plus out of pocket third party costs. Revenue recognized approximates the cost associated with these services and was nil, nil, and $18.5 million during the years ended December 31, 2009, 2008, and 2007, respectively. 75 Note 10—Novartis Pulmonary Asset Sale On December 31, 2008, we completed the sale of certain assets related to our pulmonary business, associated technology and intellectual property to Novartis Pharma AG and Novartis Pharmaceuticals Corporation (together referred to as Novartis) for a purchase price of $115.0 million in cash (the Novartis Pulmonary Asset Sale). Pursuant to the asset purchase agreement entered between Novartis and us, we transferred to Novartis certain assets and obligations related to our pulmonary technology, development and manufacturing operations including: (cid:129) dry powder and liquid pulmonary technology platform including but not limited to our pulmonary inhalation devices, formulation technology, manufacturing technology and related intellectual property; (cid:129) manufacturing and associated development services payments for the Cipro Inhale program; (cid:129) manufacturing and royalty rights to the TIP program; (cid:129) (cid:129) (cid:129) capital equipment, information systems and facility lease obligations for our pulmonary development and manufacturing facility in San Carlos, California; certain other interests that we had in two private companies, Pearl Therapeutics, Inc. and Stamford Devices Limited; and approximately 140 of our personnel primarily dedicated to our pulmonary technology, development programs, and manufacturing operations, whom Novartis hired immediately following the closing of the transaction. We have retained all of our rights to BAY41-6651 partnered with Bayer Healthcare LLC, certain royalty rights on commercial sales of Cipro Inhale by Bayer Schering Pharma AG, all rights to the development program for NKTR-063 and certain intellectual property rights specific to inhaled insulin. We also entered into a service agreement pursuant to which we have subcontracted to Novartis certain services to be performed related to BAY41-6551 and a transition services agreement in which Novartis and we will provide each other with specified services for limited time periods following the closing of the Novartis Pulmonary Asset Sale to facilitate the transition of the acquired assets and business from us to Novartis. Gain on sale of pulmonary assets On December 31, 2008, we recognized a Gain on sale of pulmonary assets for certain assets sold to Novartis, which is comprised of the following (in thousands): Proceeds from sale of certain pulmonary assets Transaction costs (1) Net book value of property and equipment sold Equity investment in Pearl Therapeutics, net Goodwill related to pulmonary assets sold Other, net Gain on sale of pulmonary assets Year ended December 31, 2008 $ 115,000 (4,609) (37,291) (2,658) (1,930) 1,060 $ 69,572 (1) Transaction costs of $4.4 million related to the Novartis Pulmonary Asset Sale were paid in 2009. Additional Costs In addition to the transaction costs recorded as part of the gain, we recognized approximately $0.1 million and $2.7 million of additional costs in connection with the Novartis Pulmonary Asset Sale for the years ended December 31, 2009 and 2008, respectively, of one-time employee termination and other costs that were recorded in Research and development expense in our Consolidated Statement of Operations. All costs incurred have been paid as of December 31, 2009. We expect to incur approximately $1.0 million as a result of the Novartis Pulmonary Asset Sale when we relocate our IT server room in 2010. 76 Note 11—Termination of Pfizer Agreements and Inhaled Insulin Program On November 9, 2007, we entered into a termination agreement and mutual release of our collaborative development and license agreement with Pfizer and all other related agreements (Pfizer agreements). Under the termination agreement, we received a one-time payment of $135.0 million in November 2007 from Pfizer in satisfaction of all outstanding contractual obligation under our existing agreements related to Exubera and NGI. Contractual obligations included billed and unbilled product sales and contract research revenue through November 9, 2007, outstanding accounts receivable and unrecovered capital costs as of November 9, 2007, and contract termination costs. February 12, 2008, we entered into a Termination and 2008 Continuation Agreement (TCA) with Tech Group pursuant to which the manufacturing and supply agreement for the Exubera inhaler device (Exubera Inhaler MSA) was terminated in its entirety and we agreed to pay Tech Group $13.8 million in termination costs and $4.8 million in satisfaction of outstanding accounts payable. As part of the TCA, we agreed to compensate Tech Group to retain a limited number of core Exubera inhaler manufacturing personnel and its dedicated Exubera inhaler manufacturing facility for a limited period in 2008. We also entered into a letter agreement with Pfizer to retain a limited number of Exubera manufacturing personnel at Pfizer’s Terre Haute, Indiana, manufacturing facility during March and April 2008. On February 14, 2008, we entered into a Termination and Mutual Release Agreement with Bespak pursuant to which the Exubera Inhaler MSA was terminated in its entirety and we agreed to pay Bespak £11.0 million, or approximately $21.6 million, including $3.0 million in satisfaction of outstanding accounts payable and $18.6 million in termination costs and expenses that were due and payable under the termination provisions of the Exubera Inhaler MSA, which included reimbursement of inventory, inventory purchase commitments, unamortized depreciation on property and equipment, severance costs and operating lease commitments. On April 9, 2008, we announced that we had ceased all negotiations with potential partners for Exubera and NGI as a result of new data analysis from ongoing clinical trials conducted by Pfizer which indicated an increase in the number of new cases of lung cancer in Exubera patients who were former smokers as compared to patients in the control group who were former smokers. Following the termination of our inhaled insulin programs on April 9, 2008, we terminated our continuation agreements with Tech Group and Pfizer. Gain on Termination of Collaborative Agreements, Net During the year ended December 31, 2007, we recognized a Gain on termination of collaborative agreements, net which is comprised of the following (in thousands): Pfizer termination settlement payment received Exubera Inhaler Manufacturing and Supply Agreement Termination Tech Group Bespak Settlement of assets and liabilities related to Pfizer Gain on termination of collaborative agreements, net Idle Exubera Manufacturing Capacity Costs Year ended December 31, 2007 $ 135,000 (13,765) (18,598) 102,637 (23,459) $ 79,178 Idle Exubera manufacturing capacity costs, which is disclosed as a component of Other cost of revenue, include costs payable to Pfizer and Tech Group under our continuation agreements and internal salaries, benefits and stock-based compensation related to Exubera commercial manufacturing employees, overhead at our San Carlos manufacturing facility, including rent, utilities and maintenance and depreciation of property and equipment. We incurred these costs from the termination of the Pfizer Agreements on November 9, 2007 through the termination of our inhaled insulin programs in April 2008. For the years ended December 31, 2009, 2008 and 2007, we recognized idle Exubera manufacturing capacity costs of nil, $6.8 million, and $6.3 million, respectively. 77 Accrued Expenses to Contract Manufacturer As of December 31, 2007, we recorded $40.4 million of accrued expenses to Bespak and Tech Group for outstanding accounts payable and termination costs and expenses that were due and payable under the termination provisions of the Exubera Inhaler MSA. This liability was repaid in its entirety in 2008. As of December 31, 2008, we had no further liabilities related to the Pfizer Agreements. Note 12—Impairment of Long Lived Assets During the years ended December 31, 2009, 2008, and 2007, we recorded charges for the Impairment of long-lived assets of nil, $1.5 million, and $28.4 million, respectively. During 2008, we determined that a specialized dryer used in our PEGylation manufacturing facility was not functioning properly and was not being used in operations currently. We performed an impairment analysis and determined the carrying value of the dryer exceeded its fair value based on a discounted cash flow model. As a result, we recorded an impairment loss for the related net book value of $1.5 million. On November 9, 2007, we entered into a termination agreement and mutual release with Pfizer related to Exubera and NGI. As a result, we performed an impairment analysis of the property and equipment that supported Exubera commercial operations and NGI (Exubera-related assets), including machinery and equipment at our contract manufacturer locations and machinery, equipment, and leasehold improvements in San Carlos, and determined the fair value of such assets based on a discounted cash flow model. As of December 31, 2007, we concluded the carrying value of the Exubera-related assets exceeded the estimated future cash flows and recorded an impairment charge of $28.4 million (See Note 11). Note 13—Workforce Reduction Plans In an effort to reduce ongoing operating costs and improve our organizational structure, efficiency and productivity, we executed workforce reduction plans in May 2007 (2007 Plan) and February 2008 (2008 Plan) designed to streamline the Company, consolidate corporate functions, and strengthen decision-making and execution within our business units. The 2007 Plan and 2008 Plan reduced our workforce by approximately 290 full-time employees; both plans were substantially complete at December 31, 2008. For the years ended December 31, 2009, 2008, and 2007 workforce reduction charges, comprised of severance, medical insurance, and outplacement services, were as follows (in thousands): Cost of goods sold, net of inventory change Other cost of revenue Research and development expense General and administrative expense Total workforce reduction charges Note 14—Stock-Based Compensation Years ended December 31, 2009 2008 2007 $ — $ — — — 148 1,221 3,087 517 $ 974 — 5,791 1,617 $ — $ 4,973 $ 8,382 We issued stock-based awards from our equity incentive plans, which are more fully described in Note 8. Stock-based compensation cost was recorded as follows (in thousands): Cost of goods sold, net of change in inventory Research and development General and administrative Total compensation cost for share-based arrangements 78 Years ended December 31, 2009 2008 2007 $ 295 3,377 6,654 $ 269 4,642 4,960 $ 1,003 6,275 5,915 $ 10,326 $ 9,871 $ 13,193 For the years ended December 31, 2009, 2008, and 2007, we recorded approximately $0.8 million, $2.2 million, and $0.5 million, respectively, of stock-based compensation expense related to modifications of certain stock grants in connection with employment separation agreements. Generally, the modifications extended the option holder’s exercise period beyond the 90 day period after termination and accelerated a portion of the option holder’s unvested grants. Stock-based compensation charges are non-cash charges and as such have no impact on our reported cash flows. For the year ended December 31, 2009, the annual forfeiture rate for options issued to directors and employees was estimated to be 15% and 11%, respectively. For the year ended December 31, 2008, the annual forfeiture rate for options issued to directors and employees was estimated to 0% and 11%, respectively, and the annual forfeiture rate for employee RSU awards was estimated to be 25%. For the year ended December 31, 2007, the annual forfeiture rate for options issued to both directors and to employees was estimated to be 4.7%. All forfeiture rates are based on our qualitative and quantitative analysis of our historical forfeitures. Aggregate Unrecognized Stock-based Compensation Expense As of December 31, 2009, total unrecognized compensation expense related to unvested stock-based compensation arrangements is expected to be recognized over a weighted-average period of 1.88 years as follows (in thousands): Fiscal Year 2010 2011 2012 2013 and thereafter Black-Scholes Assumptions As of December 31, 2009 $ 10,056 8,311 3,787 1,640 $ 23,794 The following tables list the Black-Scholes assumptions used to calculate the fair value of employee stock options and ESPP purchases. Average risk-free interest rate Dividend yield Volatility factor Weighted average expected life Year ended December 31, 2009 Year ended December 31, 2008 Year ended December 31, 2007 Employee Stock Options 1.6% 0.0% 61.0% ESPP 0.3% 0.0% 82.4% Employee Stock Options 2.5% 0.0% 51.6% ESPP 2.0% 0.0% 72.3% Employee Stock Options 4.2% 0.0% 53.3% ESPP 4.8% 0.0% 38.4% 4.9 years 0.5 years 5.0 years 0.5 years 5.1 years 0.5 years Expected volatility is based on historical volatility of our common stock. As permitted by the Securities and Exchange Commission (SEC) Staff Accounting Bulletin Topic 14.D.2, we estimated the expected life of stock options using the “simplified” method during the years ended December 31, 2009, 2008, and 2007. Under this method, the expected life was equal to the arithmetic average of the vesting term and the original contractual term of the option. We are using this method because we believe that applying historical data for options and awards is not a true reflection of future exercise patterns and timelines. Generally our stock-based grants have expected terms ranging from 51 months to 61 months. 79 Summary of Stock Option Activity The table below presents a summary of stock option activity under our equity incentive plans (in thousands, except for price per share and contractual life information): Balance at December 31, 2006 Options granted Options exercised Options forfeited & canceled Balance at December 31, 2007 Options granted Options exercised Options forfeited & canceled Balance at December 31, 2008 Options granted Options exercised Options forfeited & canceled Balance at December 31, 2009 Exercisable at December 31, 2009 Exercisable at December 31, 2008 Exercisable at December 31, 2007 Options Outstanding Number of Shares Exercise Price Per Share 10,707 5,257 (429) (3,323) 12,212 6,180 (39) (4,802) 13,551 4,608 (714) (3,437) $ 0.01–61.63 5.98–15.24 0.01–14.25 4.50–55.19 $ 0.01–61.63 2.83–7.13 0.03–7.33 0.01–61.63 $ 0.01–60.88 4.20–9.61 0.01–9.49 3.35–60.88 Weighted- Average Exercise Price Per Share $ 18.97 9.87 6.80 18.47 $ 15.62 6.02 5.72 12.93 $ 12.13 5.53 6.58 15.53 14,008 $ 0.03–54.75 $ 9.41 6,904 7,144 7,023 $ 12.47 $ 16.57 $ 19.15 Weighted- Average Remaining Contractual Life (in years) Aggregate Intrinsic Value (1) 4.78 $ 15,348 $ $ $ $ $ 1,770 643 42 2,032 1,379 $ 34,151 $ 11,358 276 $ 584 $ 5.20 4.84 5.40 3.96 2.89 3.64 (1) Aggregate Intrinsic Value represents the difference between the exercise price of the option and the closing market price of our common stock on the exercise date or December 31, as applicable. The weighted-average grant-date fair value of options granted during the years ended December 31, 2009, 2008, and 2007 was $2.86, $2.79, and $5.11, respectively. The estimated fair value of options that vested during the years ended December 31, 2009, 2008, and 2007 was $9.0 million, $9.8 million, and $8.7 million, respectively. The following table provides information regarding our outstanding stock options as of December 31, 2009 (in thousands except for price per share and contractual life information): Range of Exercise Prices $0.03 – $4.37 $4.44 – $4.65 $4.67 – $6.34 $6.36 – $6.46 $6.50 – $6.65 $6.67 – $7.78 $7.84 – $11.38 $11.41 – $16.85 $17.01 – $27.69 $27.88 – $54.75 Options Outstanding Options Exercisable Number of Shares Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life (in years) Number of Shares Weighted-Average Exercise Price Per Share 6.28 7.10 6.44 5.90 5.72 5.75 5.89 4.02 1.68 0.83 5.40 315 482 532 310 909 707 741 1,066 1,368 474 6,904 $ $ $ $ $ $ $ $ $ $ $ 3.77 4.64 5.25 6.46 6.65 7.05 9.55 13.95 21.65 32.23 12.47 799 2,927 1,455 659 1,930 1,410 1,540 1,405 1,409 474 14,008 $ $ $ $ $ $ $ $ $ $ $ 4.00 4.65 5.62 6.46 6.65 7.01 9.37 14.06 21.57 32.23 9.41 80 RSU Awards We issued RSU awards to certain officers and employees; the RSU awards granted in 2006 vest upon achievement of pre-determined performance milestones, while the RSU awards granted in 2007 and 2008 have a time-based vesting schedule. We expense the grant date fair value of the RSU awards ratably over the expected service or performance period. The weighted average life of the 2009, 2008, and 2007 RSU awards is estimated to be 1.0 years, 0.8 years, and 1.2 years, respectively. We granted 1,088,300 performance-based RSU awards in 2006, which included three pre-determined milestones. The first performance milestone was achieved and the RSU awards were vested and released in 2007. In 2007, we determined the second performance milestone would not be achieved and we reversed previously recorded compensation expense of $2.8 million. We currently expect the third milestone will be achieved in 2012. If our actual experience in future periods differs from these current estimates, we may change our estimate of the period in which the milestone will be achieved and prospectively adjust the amortization period of the stock based compensation expense associated with these awards. A summary of RSU award activity is as follows (in thousands except for contractual life and per share amounts): Balance at December 31, 2006 Granted Released Forfeited & canceled Balance at December 31, 2007 Granted Released Forfeited & canceled Balance at December 31, 2008 Granted Released Forfeited & canceled Balance at December 31, 2009 Weighted-Average Remaining Contractual Life (in years) Weighted-Average Grant-Date Fair value Aggregate Intrinsic Value (1) Units Issued 1,084 345 (334) (360) 735 48 (107) (411) 265 35 (28) (37) 235 1.52 2.03 2.48 1.99 $ 11.01 $ 5.26 $ 8.37 $ 16,479 $ $ $ $ $ $ 3,808 4,925 487 1,472 142 2,188 (1) Aggregate Intrinsic Value represents the difference between the exercise price of the award and the closing market price of our common stock on the exercise date or December 31, as applicable. Note 15—Income Taxes For financial reporting purposes, “Loss before provision for income taxes,” includes the following components (in thousands): Years ended December 31, 2009 2008 2007 Domestic Foreign Total $ (103,295) $ (69,350) $ (30,143) (1,309 ) 34,208 523 $ (102,772) $ (35,142) $ (31,452) 81 (Benefit) Provision for Income Taxes The (benefit) provision for income taxes consists of the following (in thousands): Current: Federal State Foreign Total Current Deferred: Federal State Foreign Total Deferred (Benefit) Provision for income taxes Years ended December 31, 2009 2008 2007 $ (522) $ (970) $ (28) 352 (69) 519 194 782 333 (198) (520) 1,309 — — (55) (55) — — (286) (286) — — — — $ (253) $ (806) $ 1,309 In 2009, we received a federal tax refund of $0.9 million as a result of the Housing and Economic Recovery Act of 2008, which allowed us to utilize previously recorded deferred tax assets. Income tax (benefit) provision related to continuing operations differs from the amounts computed by applying the statutory income tax rate of 35% to pretax loss as follows (in thousands): Years ended December 31, 2009 2008 2007 U.S. federal provision (benefit) At statutory rate State taxes Change in valuation allowance Foreign tax differential Unrecognized tax credits Expiring tax attributes Capital lease true-up Foreign subsidiary investment Sale of Irish subsidiary Other Total $ (35,970) $ (12,300) $ (10,998) 782 27,829 — (13,109) — — — (3,604) 409 (69) 29,768 (11,754) (2,366) 1,508 (1,431) (4,777) — 615 (28) 34,327 114 (882) 1,569 — — — 617 $ (253) $ (806) $ 1,309 82 Deferred Tax Assets and Liabilities Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands): Deferred tax assets: Net operating loss carryforwards Research and other credits Capitalized research expenses Deferred revenue Reserve and accruals Stock based compensation Other Deferred tax assets before valuation allowance Valuation allowance for deferred tax assets Total deferred tax assets Deferred tax liabilities: Depreciation Acquisition related intangibles Other Total deferred tax liabilities Net deferred tax assets December 31, 2009 2008 $ $ 321,874 48,186 6,905 34,226 5,184 22,303 4,812 289,631 50,350 4,563 28,659 9,629 20,315 5,163 443,490 (442,473) 408,310 (402,907) $ 1,017 $ 5,403 (678) — — (1,479) (3,352) (286) $ $ (678) $ (5,117) 339 $ 286 Realization of our deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Because of our lack of U.S. earnings history, the net U.S. deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $39.9 million and $27.6 million during the years ended December 31, 2009 and 2008, respectively. The valuation allowance includes approximately $35.6 million of benefit at both December 31, 2009 and December 31, 2008 related to stock based compensation and exercises, prior to the implementation of SFAS No. 123R, that will be credited to additional paid in capital when realized. Undistributed earnings of our foreign subsidiary in India are considered to be permanently reinvested and accordingly, no deferred U.S. income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, we would be subject to U.S. income tax. Net Operating Loss and Tax Credit Carryforwards As of December 31, 2009, we had a net operating loss carryforward for federal income tax purposes of approximately $795.9 million, portions of which will begin to expire in 2010. We had a total state net operating loss carryforward of approximately $496.6 million, which will begin to expire in 2010. Utilization of the federal and state net operating loss and credit carryforwards may be subject to a substantial annual limitation due to the “change in ownership” provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization. We have federal research credits of approximately $21.3 million, which will begin to expire in 2010 and state research credits of approximately $14.2 million which have no expiration date. We have federal orphan drug credits of $12.8 million which will begin to expire in 2024. 83 Unrecognized tax benefits We have the following activity relating to unrecognized tax benefits (in thousands): Beginning balance Tax positions related to current year Additions: Federal State Reductions Tax positions related to prior year Additions: Federal State Reductions Settlements Lapses in statute of limitations Ending balance December 31, 2009 2008 2007 $ 11,660 $ 9,222 $ 7,176 415 318 — — — 691 — — — 1,274 1,164 — 1,497 548 — — — — — — — — — — — — — $ 13,084 $ 11,660 $ 9,222 It is reasonably possible that certain unrecognized tax benefits may increase or decrease within the next twelve months due to tax examination changes, settlement activities, expirations of statute of limitations, or the impact on recognition and measurement considerations related to the results of published tax cases or other similar activities. We do not anticipate any significant changes to unrecognized tax benefits over the next 12 months. During the years ended December 31, 2009 and 2008, no interest or penalties were required to be recognized relating to unrecognized tax benefits. Note 16—Segment Reporting We operate in one business segment which focuses on applying our technology platforms to improve the performance of established and novel medicines. We operate in one segment because our business offerings have similar economics and other characteristics, including the nature of products and production processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer and his management team. Within our one business segment we have two components, PEGylation technology and pulmonary technology. Our revenue is derived primarily from clients in the pharmaceutical and biotechnology industries. Two of our partners, AstraZeneca AB and UCB Pharma, represented 35% and 17%, respectively, of our total revenue during the year ended December 31, 2009. Four of our partners, Bayer (including Bayer Healthcare LLC and Bayer Schering Pharma AG), UCB Pharma, Novartis, and Roche represented 24%, 16%, 15%, and 14%, respectively, of our total revenue during the year ended December 31, 2008. Due to the termination of our collaborative agreements with Pfizer, Inc., we did not receive any revenue from Pfizer, Inc. in 2008 or 2009 related to Exubera or NGI. Revenue from Pfizer, Inc. represented 69% of our revenue for the year ended December 31, 2007. Revenue by geographic area is based on the locations of our partners. The following table sets forth revenue by geographic area (in thousands): United States European countries Total revenue Years ended December 31, 2009 2008 2007 $ 29,511 42,420 $ 30,800 59,385 $ 212,990 60,037 $ 71,931 $ 90,185 $ 273,027 84 At December 31, 2009, approximately $64.5 million, or approximately 82%, of the net book value of our property and equipment of $78.3 million was located in the United States and $13.8 million, or approximately 18%, was located in India. At December 31, 2008, $69.2 million, or approximately 94%, of the net book value of our property and equipment was located in the United States and $4.4 million, or approximately 6%, was located in India. Note 17—Selected Quarterly Financial Data (Unaudited) The following table sets forth certain unaudited quarterly financial data. In our opinion, the unaudited information set forth below has been prepared on the same basis as the audited information and includes all adjustments necessary to present fairly the information set forth herein. We have experienced fluctuations in our quarterly results. We expect these fluctuations to continue in the future. Due to these and other factors, we believe that quarter-to-quarter comparisons of our operating results will not be meaningful, and you should not rely on our results for any one quarter as an indication of our future performance. Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications have not impacted previously reported revenues, operating loss or net loss. All data is in thousands except per share information. Product sales and royalty revenue License, collaboration and other revenue Gross margin on product sales Research and development expenses General and administrative expenses Impairment of long lived assets Gain on sale of pulmonary assets Operating (loss) income Interest expense Gain on extinguishment of debt Net (loss) income Basic and diluted net income (loss) per share (1)(2) Fiscal Year 2009 Q1 Q2 Q3 Q4 Q1 Fiscal Year 2008 Q2 Q3 Q4 $ $ $ 6,470 $ 10,525 3,241 844 $ $ 2,463 146 $ $ $ 7,461 $ 10,832 $ 10,371 $ 9,010 $ 9,474 $ 12,400 2,762 1,327 $ 28,177 2,023 $ $ $ 9,621 3,144 $ 11,392 3,566 $ $ 11,965 4,125 $ $ 15,952 2,204 $ $ 23,363 $ 24,002 $ 23,031 $ 24,713 $ 37,373 $ 33,500 $ 38,265 $ 45,279 9,087 9,917 $ 10,982 $ 11,947 $ — $ — $ $ — $ — $ $ 13,835 $ 11,020 1,458 — $ — $ $ $ — $ (69,572) — $ $ (30,298) $ (30,480) $ (28,859) $ (5,495) $ (41,889) $ (33,358) $ (34,561) $ 27,156 $ $ 3,357 $ — $ 50,149 — $ $ (31,807) $ (32,069) $ (30,967) $ (7,676) $ (40,705) $ (33,375) $ (37,038) $ 76,782 — $ — $ — $ — $ — $ — $ $ — $ $ — $ $ — $ $ — $ $ — $ $ 13,329 $ 12,386 3,918 3,988 2,963 2,928 3,929 3,337 2,948 $ $ (0.34 ) $ (0.35 ) $ (0.33 ) $ (0.08 ) $ (0.44 ) $ (0.36 ) $ (0.40 ) $ 0.83 (1) Quarterly loss per share amounts may not total to the year-to-date loss per share due to rounding. (2) During the fourth quarter of 2008, there were approximately 81 dilutive shares outstanding. 85 NEKTAR THERAPEUTICS VALUATION AND QUALIFYING ACCOUNTS AND RESERVES YEARS ENDED DECEMBER 31, 2009, 2008, and 2007 SCHEDULE II Description 2009: Allowance for doubtful accounts Allowance for inventory reserves 2008: Allowance for doubtful accounts Allowance for inventory reserves 2007: Allowance for doubtful accounts Allowance for inventory reserves Balance at Beginning of Year $ 92 $ 4,989 $ 33 $ 5,772 $ 357 $ 4,160 Charged to Costs and Expenses, Net of Reversals Utilizations (In thousands) Balance At End of Year $ — $ 2,109 $ 61 $ 2,668 $ (92) $ (3,762) $ — $ 3,336 $ (2 ) $ (3,451) $ 92 $ 4,989 $ (16) $ 4,670 $ (308) $ (3,058) $ 33 $ 5,772 86 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure Not applicable. Item 9A. Controls and Procedures Disclosure Controls and Procedures We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial disclosure. As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon, and as of the date of, this evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures were effective. Accordingly, management believes that the financial statements included in this report fairly present in all material respects our financial condition, results of operations and cashflows for the periods presented. Management’s Annual Report on Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Our management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2009. In making its assessment of internal control over financial reporting, management used the criteria described in Internal Control— Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework described in Internal Control—Integrated Framework, our management concluded that our internal control over financial reporting was effective as of December 31, 2009. The effectiveness of our internal control over financial reporting as of December 31, 2009 has been audited by an independent registered public accounting firm, as stated in their report, which is included herein. Changes in Internal Control Over Financial Reporting We continuously seek to improve the efficiency and effectiveness of our internal controls. This results in refinements to processes throughout the Company. There was no change in our internal control over financial reporting during the quarter ended December 31, 2009, which was identified in connection with our management’s evaluation required by Exchange Act Rules 13a-15(f) and 15d-15(f) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Inherent Limitations on the Effectiveness of Controls Our management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls 87 can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Item 9B. Other Information None. 88 Item 10. Directors, Executive Officers and Corporate Governance PART III Information relating to our executive officers required by this item is set forth in Part I—Item 1 of this report under the caption “Executive Officers of the Registrant” and is incorporated herein by reference. The other information required by this Item is incorporated by reference from the definitive proxy statement for our 2010 Annual Meeting of Stockholders to be filed with the SEC pursuant to Regulation 14A (Proxy Statement) not later than 120 days after the end of the fiscal year covered by this Form 10-K under the captions “Corporate Governance and Board of Directors,” “Proposal 1—Election of Directors” and “Section 16(a) Beneficial Ownership Reporting Compliance.” Information regarding our audit committee financial expert will be set forth in the Proxy Statement under the caption “Audit Committee,” which information is incorporated herein by reference. In December 2003, we adopted a Code of Business Conduct and Ethics applicable to all employees, including the principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The Code of Business Conduct and Ethics is posted on our website at www.nektar.com. Amendments to, and waivers from, the Code of Business Conduct and Ethics that apply to any of these officers, or persons performing similar functions, and that relate to any element of the code of ethics definition enumerated in Item 406(b) of Regulation S-K will be disclosed at the website address provided above and, to the extent required by applicable regulations, on a current report on Form 8-K. As permitted by SEC Rule 10b5-1, certain of our executive officers, directors and other employees have set up a predefined, structured stock trading program with their broker to sell our stock. The stock trading program allows a broker acting on behalf of the executive officer, director or other employee to trade our stock during blackout periods or while such executive officer, director or other employee may be aware of material, nonpublic information, if the trade is performed according to a pre-existing contract, instruction or plan that was established with the broker during a non-blackout period and when such executive officer, director or employee was not aware of any material, nonpublic information. Our executive officers, directors and other employees may also trade our stock outside of the stock trading programs set up under Rule 10b5-1 subject to our blackout periods and insider trading rules. Item 11. Executive Compensation The information required by this Item is included in the Proxy Statement and incorporated herein by reference. Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters The information required by this Item is included in the Proxy Statement and incorporated herein by reference. Item 13. Certain Relationships and Related Transactions and Director Independence The information required by this Item is included in the Proxy Statement and incorporated herein by reference. Item 14. Principal Accountant Fees and Services The information required by this Item is included in the Proxy Statement and incorporated herein by reference. 89 PART IV Item 15. Exhibits, Financial Statement Schedules (a) The following documents are filed as part of this report: (1) Consolidated Financial Statements: The following financial statements are filed as part of this Annual Report on Form 10-K under Item 8 “Financial Statements and Supplementary Data.” Reports of Independent Registered Public Accounting Firm Consolidated Balance Sheets at December 31, 2009 and 2008 Consolidated Statements of Operations for each of the three years in the period ended December 31, 2009 Consolidated Statements of Stockholders’ Equity for each of the three years in the period ended December 31, 2009 Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2009 Notes to Consolidated Financial Statements (2) Financial Statement Schedules: Page 55 57 58 59 60 61 Schedule II, Valuation and Qualifying Accounts and Reserves, is filed as part of this Annual Report on Form 10-K under Item 8 “Financial Statements and Supplementary Data”. All other financial statement schedules have been omitted because they are not applicable, or the information required is presented in our consolidated financial statements and notes thereto under Item 8 of this Annual Report on Form 10-K. (3) Exhibits. Except as so indicated in Exhibit 32.1, the following exhibits are filed as part of, or incorporated by reference into, this Annual Report on Form 10-K. Exhibit Number 2.1 (1) Description of Documents Asset Purchase Agreement, dated October 20, 2008, by and between Nektar Therapeutics, a Delaware corporation, Inc., a Delaware corporation and wholly-owned subsidiary of Nektar Therapeutics, Novartis AeroGen, Pharmaceuticals Corporation, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation+ 3.1 3.2 3.3 3.4 3.5 3.6 3.7 4.1 4.2 4.3 (2) (3) (4) (5) (6) Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc. Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc. Certificate of Designation of Series A Junior Participating Preferred Stock of Nektar Therapeutics Certificate of Designation of Series B Convertible Preferred Stock of Nektar Therapeutics Certificate of Ownership and Merger of Nektar Therapeutics (26) Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics (7) Amended and Restated Bylaws of Nektar Therapeutics Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4, 3.5, 3.6 and 3.7. (6) (4) Specimen Common Stock certificate Rights Agreement, dated as of June 1, 2001, by and between Nektar Therapeutics and Mellon Investor Services LLC, as Rights Agent 90 4.4 4.5 4.6 10.1 10.2 10.3 10.4 10.5 (4) (8) (8) Form of Right Certificate Indenture, dated September 28, 2005, by and between Nektar Therapeutics, as Issuer, and J.P. Morgan Trust Company, National Association, as Trustee Registration Right Agreement, dated as of September 28, 2005, among Nektar Therapeutics and entities named therein (9) 1994 Non-Employee Directors’ Stock Option Plan, as amended++ (10) 1994 Employee Stock Purchase Plan, as amended and restated++ (11) 2000 Non-Officer Equity Incentive Plan, as amended and restated++ (12) Form of 2000 Non-Officer Equity Incentive Plan Stock Option Agreement (Nonstatutory Stock Option)++ (12) Form of 2000 Non-Officer Equity Incentive Plan Stock Option Agreement (Nonstatutory (Unapproved) Stock Option)++ 10.6 (13) Forms of 2000 Non-Officer Equity Incentive Plan Restricted Stock Unit Grant Notice and Restricted Stock Unit 10.7 10.8 10.9 10.10 10.11 10.12 Agreement++ (14) 2000 Equity Incentive Plan, as amended and restated++ (15) Form of Stock Option Agreement under the 2000 Equity Incentive Plan++ (13) Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the 2000 Equity Incentive Plan++ (16) Form of Non-Employee Director Stock Option Agreement under the 2000 Equity Incentive Plan++ (16) Form of Non-Employee Director Restricted Stock Unit Agreement under the 2000 Equity Incentive Plan++ (16) Employment Transition and Separation Release Agreement, executed effective on September 4, 2007, with Louis Drapeau++ 10.13 (16) Employment Transition and Separation Release Agreement, executed effective on October 5, 2007, with David Johnston++ 10.14 10.15 10.16 10.17 10.18 10.19 10.20 10.21 10.22 10.23 10.24 10.25 10.26 (17) Amended and Restated Compensation Plan for Non-Employee Directors++ (11) 401(k) Retirement Plan++ (26) 2010 Discretionary Performance-Based Incentive Compensation Policy++ (1) Amended and Restated Change of Control Severance Benefit Plan++ (19) Transition and Retirement Agreement, dated March 13, 2006, with Ajit S. Gill++ (20) Letter Amendment, dated October 5, 2006, with Ajit S. Gill, amending that certain Transition and Retirement (1) (1) (1) Agreement, dated March 13, 2006, with Mr. Gill++ 2008 Equity Incentive Plan++ Forms of Stock Option Grant Notice and of Stock Option Agreement under the 2008 Equity Incentive Plan++ Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the 2008 Equity Incentive Plan++ (21) Separation and General Release Agreement, dated November 17, 2008, with John S. Patton++ (22) Bonus and General Release Agreement, dated December 27, 2008, with Nevan C. Elam++ (16) Form of Severance Letter for executive officers of the company++ (1) Amended and Restated Letter Agreement, executed effective on December 1, 2008, with Howard W. Robin++ 91 10.27 10.28 (1) (1) Amended and Restated Letter Agreement, executed effective on December 1, 2008, with John Nicholson++ Amended and Restated Letter Agreement, executed effective on December 1, 2008, with Bharatt M. Chowrira, Ph.D., J.D.++ 10.29 (23) Separation and General Release Agreement between Nektar Therapeutics and Randall W. Moreadith, M.D., Ph.D., dated November 23, 2009.++ 10.30 (16) Amended and Restated Built-to-Suite Lease between Nektar Therapeutics and BMR-201 Industrial Road LLC, dated August 17, 2004, as amended on January 11, 2005 and July 19, 2007 10.31 10.32 (25) Sublease, dated as of September 30, 2009, by and between Pfizer Inc. and Nektar Therapeutics.+ (24) Settlement Agreement and General Release, dated June 30, 2006, by and between The Board of Trustees of the University of Alabama, The University of Alabama in Huntsville, Nektar Therapeutics AL Corporation (a wholly- owned subsidiary of Nektar Therapeutics), Nektar Therapeutics and J. Milton Harris 10.33 (16) Co-Development, License and Co-Promotion Agreement, dated August 1, 2007, between Nektar Therapeutics (and its subsidiaries) and Bayer Healthcare LLC+ 10.34 (18) Termination Agreement and Mutual Release, dated November 9, 2007, between Nektar Therapeutics and Pfizer Inc.+ 10.35 (1) Exclusive Research, Development, License and Manufacturing and Supply Agreement, by and among Nektar AL Corporation, Baxter Healthcare SA, and Baxter Healthcare Corporation, dated September 26, 2005, as amended+ 10.36 (1) Exclusive License Agreement, dated December 31, 2008, between Nektar Therapeutics, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation+ 10.37 (25) License Agreement by and between AstraZeneca AB and Nektar Therapeutics, dated September 20, 2009.+ 21.1 23.1 24 31.1 31.2 (26) Subsidiaries of Nektar Therapeutics (26) Consent of Independent Registered Public Accounting Firm Power of Attorney (reference is made to the signature page) (26) Certification of Nektar Therapeutics’ principal executive officer required by Rule 13a-14(a) or Rule 15d-14(a) (26) Certification of Nektar Therapeutics’ principal financial officer required by Rule 13a-14(a) or Rule 15d-14(a) 32.1* (26) Section 1350 Certifications + Confidential treatment with respect to specific portions of this Exhibit has been requested, and such portions are omitted and have been filed separately with the SEC. ++ Management contract or compensatory plan or arrangement. * (1) (2) (3) Exhibit 32.1 is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise stated in such filing. Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2008. Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 1998. Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2000. 92 (4) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on June 4, 2001. (5) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on January 8, 2002. (6) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on January 23, 2003. (7) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on December 12, 2007. (8) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on September 28, 2005. (9) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 1996. (10) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Registration Statement on Form S-8 (No. 333-98321), filed on August 19, 2002. (11) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2004. (12) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Registration Statement on Form S-8 (No. 333-71936), filed on October 19, 2001, as amended. (13) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Annual Report on Form 10-K, as amended, for the year ended December 31, 2005. (14) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on June 7, 2006. (15) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2000. (16) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. (17) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on December 14, 2009. (18) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2007. (19) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K/A, filed on March 16, 2006. (20) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2006. (21) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on November 21, 2008. 93 (22) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on January 2, 2009. (23) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on November 30, 2009. (24) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2006. (25) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2009. (26) Filed herewith. 94 Pursuant to the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Carlos, County of San Mateo, State of California on March 2, 2010. SIGNATURES By: /S/ JOHN NICHOLSON John Nicholson Senior Vice President and Chief Financial Officer By: /S/ JILLIAN B. THOMSEN Jillian B. Thomsen Senior Vice President and Chief Accounting Officer 95 POWER OF ATTORNEY KNOW ALL PERSON BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John Nicholson and Jillian B. Thomsen and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratify and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons in the capacities and on the dates indicated: SIGNATURE TITLE /S/ HOWARD W. ROBIN Howard W. Robin Chief Executive Officer, President and Director (Principal Executive Officer) /S/ JOHN NICHOLSON John Nicholson Senior Vice President and Chief Financial Officer (Principal Financial Officer) DATE March 2, 2010 March 2, 2010 /S/ JILLIAN B. THOMSEN Jillian B. Thomsen Senior Vice President Finance and Chief Accounting Officer (Principal Accounting Officer) March 2, 2010 /S/ ROBERT B. CHESS Robert B. Chess /S/ R. SCOTT GREER R. Scott Greer /S/ JOSEPH J. KRIVULKA Joseph J. Krivulka /S/ CHRISTOPHER A. KUEBLER Christopher A. Kuebler /S/ LUTZ LINGNAU Lutz Lingnau /S/ SUSAN WANG Susan Wang /S/ ROY A. WHITFIELD Roy A. Whitfield /S/ DENNIS L. WINGER Dennis L. Winger Director, Chairman of the Board of Directors March 2, 2010 Director Director Director Director Director Director Director 96 March 2, 2010 March 2, 2010 March 2, 2010 March 2, 2010 March 2, 2010 March 2, 2010 March 2, 2010 Except as so indicated in Exhibit 32.1, the following exhibits are filed as part of, or incorporated by reference into, this Annual Report on Form 10-K. Exhibit Number 2.1 (1) Description of Documents Asset Purchase Agreement, dated October 20, 2008, by and between Nektar Therapeutics, a Delaware corporation, AeroGen, Inc., a Delaware corporation and wholly-owned subsidiary of Nektar Therapeutics, Novartis Pharmaceuticals Corporation, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation+ 3.1 3.2 3.3 3.4 3.5 3.6 3.7 4.1 4.2 4.3 4.4 4.5 4.6 10.1 10.2 10.3 10.4 10.5 (2) (3) (4) (5) (6) Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc. Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc. Certificate of Designation of Series A Junior Participating Preferred Stock of Nektar Therapeutics Certificate of Designation of Series B Convertible Preferred Stock of Nektar Therapeutics Certificate of Ownership and Merger of Nektar Therapeutics (26) Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics (7) Amended and Restated Bylaws of Nektar Therapeutics Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4, 3.5, 3.6 and 3.7 (6) (4) (4) (8) (8) Specimen Common Stock certificate Rights Agreement, dated as of June 1, 2001, by and between Nektar Therapeutics and Mellon Investor Services LLC, as Rights Agent Form of Right Certificate Indenture, dated September 28, 2005, by and between Nektar Therapeutics, as Issuer, and J.P. Morgan Trust Company, National Association, as Trustee Registration Right Agreement, dated as of September 28, 2005, among Nektar Therapeutics and entities named therein (9) 1994 Non-Employee Directors’ Stock Option Plan, as amended++ (10) 1994 Employee Stock Purchase Plan, as amended and restated++ (11) 2000 Non-Officer Equity Incentive Plan, as amended and restated++ (12) Form of 2000 Non-Officer Equity Incentive Plan Stock Option Agreement (Nonstatutory Stock Option)++ (12) Form of 2000 Non-Officer Equity Incentive Plan Stock Option Agreement (Nonstatutory (Unapproved) Stock Option)++ 10.6 (13) Forms of 2000 Non-Officer Equity Incentive Plan Restricted Stock Unit Grant Notice and Restricted Stock Unit 10.7 10.8 10.9 10.10 10.11 10.12 Agreement++ (14) 2000 Equity Incentive Plan, as amended and restated++ (15) Form of Stock Option Agreement under the 2000 Equity Incentive Plan++ (13) Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the 2000 Equity Incentive Plan++ (16) Form of Non-Employee Director Stock Option Agreement under the 2000 Equity Incentive Plan++ (16) Form of Non-Employee Director Restricted Stock Unit Agreement under the 2000 Equity Incentive Plan++ (16) Employment Transition and Separation Release Agreement, executed effective on September 4, 2007, with Louis Drapeau++ 97 10.13 (16) Employment Transition and Separation Release Agreement, executed effective on October 5, 2007, with David Johnston++ 10.14 10.15 10.16 10.17 10.18 10.19 10.20 10.21 10.22 10.23 10.24 10.25 10.26 10.27 10.28 (17) Amended and Restated Compensation Plan for Non-Employee Directors++ (11) 401(k) Retirement Plan++ (26) 2010 Discretionary Performance-Based Incentive Compensation Policy++ (1) Amended and Restated Change of Control Severance Benefit Plan++ (19) Transition and Retirement Agreement, dated March 13, 2006, with Ajit S. Gill++ (20) Letter Amendment, dated October 5, 2006, with Ajit S. Gill, amending that certain Transition and Retirement (1) (1) (1) Agreement, dated March 13, 2006, with Mr. Gill++ 2008 Equity Incentive Plan++ Forms of Stock Option Grant Notice and of Stock Option Agreement under the 2008 Equity Incentive Plan++ Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the 2008 Equity Incentive Plan++ (21) Separation and General Release Agreement, dated November 17, 2008, with John S. Patton++ (22) Bonus and General Release Agreement, dated December 27, 2008, with Nevan C. Elam++ (16) Form of Severance Letter for executive officers of the company++ (1) (1) (1) Amended and Restated Letter Agreement, executed effective on December 1, 2008, with Howard W. Robin++ Amended and Restated Letter Agreement, executed effective on December 1, 2008, with John Nicholson++ Amended and Restated Letter Agreement, executed effective on December 1, 2008, with Bharatt M. Chowrira, Ph.D., J.D.++ 10.29 (23) Separation and General Release Agreement between Nektar Therapeutics and Randall W. Moreadith, M.D., Ph.D., dated November 23, 2009.++ 10.30 (16) Amended and Restated Built-to-Suite Lease between Nektar Therapeutics and BMR-201 Industrial Road LLC, dated August 17, 2004, as amended on January 11, 2005 and July 19, 2007 10.31 10.32 (25) Sublease, dated as of September 30, 2009, by and between Pfizer Inc. and Nektar Therapeutics.+ (24) Settlement Agreement and General Release, dated June 30, 2006, by and between The Board of Trustees of the University of Alabama, The University of Alabama in Huntsville, Nektar Therapeutics AL Corporation (a wholly- owned subsidiary of Nektar Therapeutics), Nektar Therapeutics and J. Milton Harris 10.33 (16) Co-Development, License and Co-Promotion Agreement, dated August 1, 2007, between Nektar Therapeutics (and its subsidiaries) and Bayer Healthcare LLC+ 10.34 (18) Termination Agreement and Mutual Release, dated November 9, 2007, between Nektar Therapeutics and Pfizer Inc.+ 10.35 (1) Exclusive Research, Development, License and Manufacturing and Supply Agreement, by and among Nektar AL Corporation, Baxter Healthcare SA, and Baxter Healthcare Corporation, dated September 26, 2005, as amended+ 10.36 (1) Exclusive License Agreement, dated December 31, 2008, between Nektar Therapeutics, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation+ 10.37 (25) License Agreement by and between AstraZeneca AB and Nektar Therapeutics, dated September 20, 2009.+ 21.1 23.1 (26) Subsidiaries of Nektar Therapeutics (26) Consent of Independent Registered Public Accounting Firm 98 24 31.1 31.2 Power of Attorney (reference is made to the signature page) (26) Certification of Nektar Therapeutics’ principal executive officer required by Rule 13a-14(a) or Rule 15d-14(a) (26) Certification of Nektar Therapeutics’ principal financial officer required by Rule 13a-14(a) or Rule 15d-14(a) 32.1* (26) Section 1350 Certifications + Confidential treatment with respect to specific portions of this Exhibit has been requested, and such portions are omitted and have been filed separately with the SEC. ++ Management contract or compensatory plan or arrangement. * (1) (2) (3) Exhibit 32.1 is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise stated in such filing. Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2008. Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 1998. Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2000. (4) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on June 4, 2001. (5) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on January 8, 2002. (6) (7) (8) (9) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on January 23, 2003. Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on December 12, 2007. Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on September 28, 2005. Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 1996. (10) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Registration Statement on Form S-8 (No. 333-98321), filed on August 19, 2002. (11) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2004. (12) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Registration Statement on Form S-8 (No. 333-71936), filed on October 19, 2001, as amended. (13) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Annual Report on Form 10-K, as amended, for the year ended December 31, 2005. 99 (14) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on June 7, 2006. (15) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2000. (16) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. (17) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on December 14, 2009. (18) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2007. (19) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K/A, filed on March 16, 2006. (20) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2006. (21) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on November 21, 2008. (22) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on January 2, 2009. (23) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Current Report on Form 8-K, filed on November 30, 2009. (24) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2006. (25) Incorporated by reference to the indicated exhibit in Nektar Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2009. (26) Filed herewith. 100 Subsidiaries of Nektar Therapeutics* Name Nektar Therapeutics UK, Ltd. Inhale Therapeutic Systems Deutschland GmbH Nektar Therapeutics (India) Pvt. Ltd Aerogen, Inc. Exhibit 21.1 Jurisdiction of Incorporation or Organization United Kingdom Germany India Delaware * Includes subsidiaries that do not fall under the definition of “Significant Subsidiary” as defined under Rule 1-02(w) of Regulation S-X. Exhibit 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-07969, 333-59735, 333-65919, 333-74669, 333-32788, 333-54078, 333-55032, 333-67342, 333-71936, 333-76638, 333-98321, 333-103040, 333-117975, 333- 136498, 333-145259 and 333-153106) pertaining to the amended and restated 1994 Equity Incentive Plan, the 1998 Non-Officer Equity Incentive Plan, the 2000 Non-Officer Equity Incentive Plan, the 401(k) Retirement Plan, the Employee Stock Purchase Plan, the 2000 Equity Incentive Plan, the 2008 Equity Incentive Plan, the Bradford Particle Design plc Share Option Schemes, the Shearwater Corporation 1996 Nonqualified Stock Option Plan, and in the Registration Statements (Form S-3 Nos. 333-54080, 333- 108859, 333-120009, 333-67340, 333-130591) of Nektar Therapeutics and in the related Prospectuses of our reports dated March 2, 2010, with respect to the consolidated financial statements and schedule of Nektar Therapeutics, and the effectiveness of internal control over financial reporting of Nektar Therapeutics, included in this Annual Report (Form 10-K) for the year ended December 31, 2009. /s/ Ernst & Young LLP Palo Alto, California March 2, 2010 Exhibit 31.1 I, Howard W. Robin, certify that: CERTIFICATIONS 1. I have reviewed this Annual Report on Form 10-K of Nektar Therapeutics for the year ended December 31, 2009; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be to provide reasonable assurance regarding the reliability of financial reporting and the designed under my supervision, preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting. 5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Date: March 2, 2010 /S/ HOWARD W. ROBIN Howard W. Robin Chief Executive Officer, President and Director Exhibit 31.2 I, John Nicholson, certify that: CERTIFICATIONS 1. I have reviewed this Annual Report on Form 10-K of Nektar Therapeutics for the year ended December 31, 2009; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be to provide reasonable assurance regarding the reliability of financial reporting and the designed under my supervision, preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting. 5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Date: March 2, 2010 /S/ JOHN NICHOLSON John Nicholson Senior Vice President and Chief Financial Officer SECTION 1350 CERTIFICATIONS* Exhibit 32.1 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), Howard W. Robin, Chief Executive Officer, President and Director of Nektar Therapeutics (the “Company”), and John Nicholson, Senior Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge: 1. The Company’s Annual Report on Form 10-K, for the year ended December 31, 2009, to which this Certification is attached as Exhibit 32.1 (the “Annual Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and 2. The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by the Annual Report. Dated: March 2, 2010 /S/ HOWARD W. ROBIN Howard W. Robin Chief Executive Officer, President and Director /S/ JOHN NICHOLSON John Nicholson Senior Vice President and Chief Financial Officer * This certification accompanies the Annual Report on Form 10-K, to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing. NEKTAR MANAGEMENT TEAM CORPORATE INFORMATION Howard W. Robin President and Chief Executive Ofﬁ cer Bharatt M. Chowrira, Ph.D., J.D. Senior Vice President and Chief Operating Ofﬁ cer Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Scientiﬁ c Ofﬁ cer Rinko Ghosh Senior Vice President and Chief Business Ofﬁ cer Gil M. Labrucherie Senior Vice President, General Counsel and Secretary Lorianne K. Masuoka, M.D. Senior Vice President and Chief Medical Ofﬁ cer John Nicholson Senior Vice President and Chief Financial Ofﬁ cer Timothy A. Riley, Ph.D. Senior Vice President, Global Research Dorian Rinella Senior Vice President, Human Resources and Facilities Jillian B. Thomsen Senior Vice President, Finance and Chief Accounting Ofﬁ cer Corporate Headquarters Nektar Therapeutics 201 Industrial Road San Carlos, CA 94070-6256 Telephone (650) 631-3100 Facsimile (650) 631-3150 Annual Report on Form 10-K Copies of Nektar’s Annual Report on Form10-K, exclusive of exhibits, are available without charge upon written request to: Investor Relations 201 Industrial Road San Carlos, CA 94070-6256 Or via email to: investors@nektar.com; online copies can also be obtained at www.nektar.com under “Investor Relations.” Annual Meeting The Annual Meeting of Stockholders will be held on June 29, 2010, 2:00-3:00 p.m. (PDT) Hotel Soﬁ tel - San Francisco Bay 223 Twin Dolphin Drive Redwood City, California 94065 NEKTAR BOARD OF DIRECTORS Corporate Counsel Robert B. Chess Chairman of the Board, Nektar Therapeutics and Chairman, OPX Biotechnologies, Inc. R. Scott Greer Managing Director, Numenor Ventures, LLC Joseph J. Krivulka Founder and President, Triax Pharmaceuticals Christopher A. Kuebler Former Chairman, Covance Inc. Lutz Lingnau Former Executive Board Member, Schering AG Howard W. Robin President and Chief Executive Ofﬁ cer, Nektar Therapeutics Susan Wang Former CFO, Solectron Roy A. Whitﬁ eld Former Chairman, Incyte Genomics, Inc. Dennis Winger Former Senior Vice President and CFO, Applera Corporation O’Melveny & Myers LLP, Menlo Park, CA Independent Auditors Ernst & Young LLP, Palo Alto, CA Transfer Agent and Stockholder Services Mellon Investor Services, LLC 525 Market Street, Suite 3500 San Francisco, CA 94105 Telephone (877) 290-2261 The preceding discussion in this annual report contains forward- looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Nektar cautions that these forward-looking statements are subject to signiﬁ cant risks and uncertainties that may cause results to differ from those indicated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Part 1 of the Form 10-K included herein and ﬁ led with the Securities and Exchange Commission for the ﬁ scal year ended December 31, 2009 under the heading “Risk Factors.” Nektar undertakes no obligation to update forward- looking statements, whether as a result of new information, future events or otherwise. i s e t a c o s s A n g s e D y r w o H i : i n g s e D Nektar Therapeutics 201 Industrial Road San Carlos, CA 94070 USA +1 650.631.3100 Global Headquarters www.nektar.com NASDAQ: NKTR

Continue reading text version or see original annual report in PDF format above